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ABSTRACT 
 
CD4+ memory T cells are depleted in mucosal tissues post human immunodeficiency 
virus (HIV) and simian immunodeficiency virus (SIV) infection without restoration to pre-
infection levels during progressive course of disease.  Bone marrow (BM) as a hematopoietic 
organ has been investigated for hematologic and morphologic changes during HIV infection.  
However, BM as a primary lymphoid tissue during HIV infection has been poorly characterized.  
We proposed BM was also a site of CD4+ T cell depletion driven by increased apoptosis during 
progressive HIV disease.  We chose to investigate bone marrow changes using the premier non-
human primate Rhesus macaque SIV model for the study HIV infection.   
We observed hematologic abnormalities of anemia, thrombocytopenia, neutropenia and 
eosinophilia during SIV infection mimicked HIV infection as did morphologic increased BM 
cellularity, loss of iron marrow storage, and increased marrow fibrosis as infection advanced to 
AIDS.  The increased BM cellularity was characterized by increased erythroid, myeloid 
including dendritic cells, and lymphoid lineages in the later stages of infection.  In fact, numbers 
of BM CD3+ T lymphocytes increased in absolute numbers and proliferation percentage during 
progressive SIV infection mainly composed of CD8+ T cells and fewer CD4+ T cells.  Naïve 
and memory CD8+ T cells and CD4+ T cells were maintained in BM during SIV infection.  Low 
numbers of SIV infected BM cells were observed including CD3+ T cells, macrophages, and 
other hematopoietic cells with detection of both viral RNA and DNA by polymerase chain 
reaction.  However, less than 0.2% of CD3+ BM T cells were apoptotic determined by activated 
caspase 3 though overall BM cells tended to have increased rates of apoptosis in later stages of 
SIV.  Our data revealed BM T cells were not depleted but maintained to increased during SIV 
disease without an increase in apoptosis.  Future studies into mechanisms of bone marrow 
xxix 
 
lymphocyte maintenance may reveal homeostatic mechanisms potentially disrupted in mucosal 
tissues during HIV and SIV infection. 
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CHAPTER 1: INTRODUCTION AND SIGNIFICANCE 
 
RATIONALE AND SIGNIFICANCE 
 
HIV is a worldwide epidemic in the 21st century.   The HIV epidemic has been 
characterized as the „worst‟ epidemic in the history of humankind (Volberding 2003).  Numerous 
global resources have been extended into education, treatment, and prevention of HIV disease 
and acquired immune deficiency syndrome (AIDS), yet new infections continue in adult and 
pediatric populations.  The complex mechanisms of chronic immune stimulation accompanied by 
immune dysregulation during progressive HIV infection and ongoing replication still elude the 
scientific community after many years of stellar research.  How the bone marrow is woven into 
the intricate and detailed pathogenesis of HIV remains unexplored in HIV infection.  This body 
of research was to investigate the bone marrow as a lymphoid organ during progressive SIV 
infection for a model of changes in bone marrow of HIV infected patients.  It is unclear how HIV 
disease works in this body compartment.   
The bone marrow (BM) or marrow is a primary lymphoid organ and lymphocyte 
compartment or tissue of the body (Jain 1986; Paraskevas 2004; Tizard 2004).  Primary 
lymphoid organs develop early in the fetus, produce immature lymphocytes, and allow 
maturation of lymphocytes independent of antigen stimulation (Jain 1986; Paraskevas 2004; 
Tizard 2004).  Early T cell lymphoid progenitors leave the bone marrow and migrate to the 
thymus for differentiation into CD4+ and CD8+ lymphocytes whereas early B cell lymphoid 
progenitors remain in the bone marrow to differentiate into immature naïve B lymphocytes (Jain 
1986; Paraskevas 2004; Tizard 2004).   
It is estimated that billions of lymphocytes migrate through the bone marrow daily even 
though it is only fed by the blood vascular circulation and not the lymphoid circulation(Wei 
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2006).  Homeostatic mechanisms exist within the bone marrow to protect levels of CD4 and CD8 
resident lymphocytes.  Basal homeostatic proliferation (BHP) is an inherent function of T 
memory cells to self-renew under non-antigenic conditions (Nugeyre 2003).  Homeostatic bone 
marrow regulation is mostly controlled by the colony stimulating factors (Doweiko 1993).      
PURPOSE OF THE STUDY 
 
The objective of this research was to investigate the role of the bone marrow as a primary 
and extra-thymic lymphoid tissue in the replenishment of CD4+ lymphocytes during HIV 
infection.  CD4+ lymphocyte depletion in HIV occurs predominantly in mucosal lymphoid 
tissues during HIV and SIV infection but particularly in early and late stages, corresponding with 
high viremia (Veazey 2000b).  During infection, mucosal and peripheral depletion of activated 
memory CD4+ lymphocytes is ongoing without return to pre-infection levels (Veazey 2000).  
The bone marrow may contribute to the repression of CD4+ lymphocytes during HIV infection; 
however, the CD4+ lymphocyte pool in the bone marrow lymphoid compartment has been 
poorly characterized. 
Examination and comparison of the bone marrow as a lymphoid compartment could 
determine the extent of CD4+ lymphocyte depletion that is attributed to lack of production, 
turnover, and lymphocyte homing, as compared to rates of destruction in secondary lymphoid 
tissues such as lymph nodes, gut, and blood during progressive infection.  Additionally, 
examining bone marrow during progressive disease could determine and define possible 
disruptions of bone marrow homeostasis in relation to CD4+ lymphocyte depletion in this 
compartment. 
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SPECIFIC AIMS 
 
Hypothesis 
 
The hypothesis is ongoing apoptosis of CD4+ lymphocytes within the BM lymphocyte 
compartment during progressive SIV, despite low numbers of SIV infected cells in the bone 
marrow, contributes to BM exhaustion of CD4+ lymphocytes due to loss of BM homeostasis.  
The following represents a logical analytical approach for addressing our hypothesis and for 
describing the changes that occur in this compartment throughout SIV infection.   
Research Model 
 
All research was conducted at the Tulane National Primate Research Center (TNPRC) 
using Rhesus macaques (RM) for the animal model of HIV disease.  All animals were housed 
and treated according to the Animal Welfare Act and Guide for the Care and Use of Laboratory 
Animals, Institute of Laboratory Resources National Research Council.  All protocols and 
research procedures were approved by the Tulane Institutional Animal Care and Use Committee.  
TNPRC is accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care.  Four experimental database(s) (ED) of research subjects were utilized as defined in 
Appendix II as ED I-EDIV.    
Specific Aim 1 (Chapter 3) 
 
The objective was to validate the SIV model for study of bone marrow changes during 
HIV infection.  Marrow derived hematopoietic cells circulate in blood.  Hematologic values are 
interpreted by reported laboratory parameters from the complete blood count (CBC) as below or 
above the reference interval or reference range values for evidence of hematologic abnormalities. 
First, the occurrence of hematologic abnormalities during progressive, non-treated SIV infection 
in the Rhesus macaque was determined and compared to reported hematologic abnormalities 
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during HIV infection for confirmation of similarities.  Second, the impact of SIV disease on 
circulating cells was established to confirm the effect of SIV on bone marrow derived 
hematopoietic cells without confounding effects of intervention by therapeutic drugs or 
vaccinations, inadequate diet, or co-infections.   
Specific Aim 2 (Chapter 4) 
 
The objective was to validate the SIV model for occurrences of BM disruption or loss of 
homeostasis in HIV infection.  The occurrence of morphologic and histologic changes during 
progressive, non-treated SIV infection in the Rhesus macaque was determined and compared to 
reported abnormalities during HIV infection for confirmation of similarities. Marrow cellularity, 
marrow iron storage, and marrow fibrosis were evaluated for alteration during periods of SIV 
infection. 
Specific Aim 3 (Chapter 5 and Chapter 6) 
 
The objective was to determine the shifts of hematopoietic lineage populations, 
lymphocyte populations, and dendritic cell populations in BM during progressive, non-treated 
SIV infection in the Rhesus macaque.  Flow cytometry analysis of bone marrow was performed 
to identify percentage shifts of hematopoietic cells during periods of SIV infection. 
Specific Aim 4 (Chapter 7) 
 
The objective was to determine the number and phenotype of SIV infected cells in the 
BM during progressive, non-treated SIV infection in the Rhesus macaque for comparison with 
changes in tissue lymphocyte populations and plasma viral loads.  In situ hybridization and 
polymerase chain reaction were performed to reveal SIV infected cells in marrow. 
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Specific Aim 5 (Chapter 8) 
 
The objective was to determine changes in naïve, memory, and activated CD4
+
 
lymphocyte numbers in the BM lymphocyte compartment during progressive, non-treated SIV 
infection in the Rhesus macaque to identify the degree of CD4
+
 lymphocyte bone marrow 
exhaustion.  Flow cytometry and morphometric analyses were performed on marrow tissue and 
blood to calculate absolute numbers of lymphocytes during various periods of SIV infection. 
Specific Aim 6 (Chapter 9) 
 
The objective was to determine percentages of apoptotic and proliferating CD4
+
 BM 
lymphocytes during progressive, non-treated SIV infection in the Rhesus macaque.  Apoptosis 
was defined by flow cytometry and immunohistochemistry and correlated with the changes in 
the CD3+ lymphocyte bone marrow compartment and levels of pro-apoptotic cytokines,  as a 
mechanism for CD4+ bone marrow lymphocyte loss. 
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CHAPTER 2:  BACKGROUND AND LITERATURE REVIEW 
 
RETROVIRUSES 
 
Equine infectious anemia, feline immunodeficiency virus, SIV, and HIV are lentiviruses 
in the Retroviridae family of retroviruses (Goff 2001).  Lentiviruses have a bar or cone shaped 
nuclear core which is distinct among the retroviruses (Apetrei 2004).  The HIV virus and life 
cycle are detailed in Figure 2.1 (National Institute of Allergy and Infectious Disease). 
A.                                                               B. 
    
 
Figure 2.1. HIV virus 
Schematic representation of the HIV and SIV virus particle (A.) (HIV virus from National 
Institute of Allergy and Infectious Disease 
http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/Pages/structure.aspx.).  
Schematic representation of the HIV and SIV retrovirus life cycle (B.) (HIV life cycle from 
National Institute of Allergy and Infectious Disease 
http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/Pages/hivReplicationCycle.as
px.).   
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SIV AND HIV INFECTION AND DISEASE 
 
A concise review of the discovery of HIV and SIV has been previously reported (Gardner 
1993; Lifson 1988).   Three viral inoculations were used in our study of SIV and are their origin 
are briefly detailed here. 
SIVmac251 is a wildtype strain of SIV that originated from the RM with the same name 
at the New England Regional Primate Research Center.  Mm78-72 had retorbital lymphoma and 
tissue from this monkey was inoculated into macaque Mm 251-79 (Gardner 1996; Letvin 1985).  
Mm251-79 developed AIDS and the simian T-lymphotrophic virus type III (later reclassified as 
SIV) was isolated from this RM (Letvin 1985).  STLV III isolated from Mm 251-79 was grown 
in cultures of human T cells (Daniel 1985; Letvin 1985).  RM inoculated with STLV III virus 
isolated from Mm251-179 progressed to AIDS (Letvin 1985). 
SIVB670 is a wildtype strain of SIV that originated from the RM with the same name at 
the Delta Regional Primate Research Center (now call the TNPRC).  Lymph node tissue taken at 
necropsy from Macaque B670 was the source of SIV/DeltaB670 or SIVB670 (Baskin 1986; 
Gardner 1996; Murphey-Corb 1986).   Macaque B670 was inoculated with lymphoma cells 
isolated from macaque 8664 (Baskin 1986; Murphey-Corb 1986).  Macaque 8664 had been 
inoculated with Mycobacterium leprae isolated from Sooty mangabey A022 (Baskin 1986; 
Murphey-Corb 1986).  Macaques inoculated with SIVB670 progressed to AIDS (Murphey-Corb 
1986) 
SIVmac239 is a molecular clone that originated from the RM with the same name at the 
New England Regional Primate Research Center  Mm239-82 was inoculated with cell-free 
plasma from Mm61-82 and died 85 days post-inoculation (Daniel 1985).  STLV III was 
recovered from the blood of Mm239-82 (Daniel 1985).  Mm61-82 was inoculate with pooled 
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blood samples from 3 of 7 macaques that had been inoculated with lymphoma tissue from 
Mm251-79 (Daniel 1985).  All inoculated animals had signs of immunodeficiency at necropsy 
(Daniel 1985).   
SIV is a premier model for the study of HIV (Gardner 1993).  Mucosal memory CD4+ T 
cell depletion is the hallmark of acute SIV infection in RM (Lay 2009; Veazey 2000; Walker 
2004).  Although an increase in proliferating CD4+CCR5+ cells may be observed in progressive 
SIV disease in blood, mucosal CD4+CD195+ cells are never replenished in patients that progress 
to disease, likely because they are unable to compete with continued loss of this cell population 
(Walker 2004).  With continual depletion of CD4+ memory cells in the absence of proliferation, 
the body is unprotected against opportunistic invaders (Walker 2004).  Modeling of acute SIV 
infection in RM and sooty mangabeys revealed lymphoid compartments with highest numbers of 
the cell populations susceptible to infection along with the highest viral production rate of each 
infected cell will drive peak viral load (Lay 2009).   
T LYMPHOCYTES IN LYMPHOID ORGANS 
 
The primary lymphoid tissues are bone marrow and thymus (Feuerer 2003; Pabst 2007), 
since a functioning bone marrow and thymus are needed for T cell lymphopoiesis.  Bone marrow 
serves as a secondary lymphoid tissue in addition to its role as primary lymphoid tissue.  Naïve T 
cells transferred into host mice were found one day after transfer in bone marrow, spleen, and 
lymph nodes but not thymus (Feuerer 2003).  Bone marrow DC were observed to act as antigen 
presenting cells to naïve BM CD4+ and CD8+ T lymphocytes and induce T cell proliferation and 
differentiation in mice (Feuerer 2003).  Other secondary lymphoid tissues are lymph nodes, 
spleen, tonsils, and intestinal Peyer‟s patches (Pabst 2007).   
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Mouse studies indicate that uncommitted lymphocyte/myeloid precursors leave the bone 
marrow and enter the thymus for T cell/NK cell development (Spits 2002).  The daily output by 
the thymus of T cells in the RM is estimated to be 2-3X10
8
 cells which is higher than compared 
in the humans estimated to be 10
8
 cells (Borghans 2005).  With age, thymic involution occurs 
where thymic tissue is replaced with fat, and decreases in function, but thymopoiesis still occurs 
(Spits 2002).  Volume and size of the thymus compared to body weight is relatively stable with 
age (Pabst 2007).  Thymic output appears to be related to the bone marrow pool of thymic 
precursors and functional thymic parenchyma (Nikolich-Zugich 2007).   
The T cell pool is fairly consistent in „normal‟ individuals under the control of 
homeostatic regulation considering age as a factor (Surh 2005).  Single positive T cells are 
released from the thymus as „naïve‟ or non-antigen stimulated (Lackner 2007; Tizard 2004).  
Naïve T cells circulate in the blood and to secondary lymphoid sites (Obhrai 2006; Tizard 2004).  
Once naive T cells are activated, differentiation into effector T cells occurs with the ability to 
enter non-lymphoid tissues (Obhrai 2006; Tizard 2004).  Many effector T cells undergo 
apoptosis but remaining long-lived central memory cells can be found within lymphoid and non-
lymphoid tissues (Obhrai 2006).   
Naïve T cells that encounter antigen become short-lived effector memory T cells and 
long-lived central memory T cells ( Paraskevas 2004; Lackner 2007).  Naïve T cells home to 
lymphocyte compartments or lymphoid tissues (Paraskevas 2004).  Memory proliferation in 
response to antigen allows daughter cells to expand and differentiate into “secondary” effector 
cell populations ( Paraskevas 2004; Kaech 2002).  Activated T cells undergo programmed cell 
death after immune stimulation.  During the contraction stage or death stage, large numbers 
(>90%) of effector T cells made after contact with antigen are eliminated (Douek 2003; Kaech 
11 
 
2002).  The effector T cells that survive the death stage move into the long-lived memory T cell 
stage (Douek 2003; Kaech 2002).  Effector memory cells lose lymph node homing capabilities 
but are able to produce greater levels cytokines for Th responses (Lanzavecchia 2002).  In 
contrast, central memory cells retain lymph node homing capabilities but produce perforin and 
lesser levels of restricted cytokines for immune response (Lanzavecchia 2002).  CD4+ T cells 
can follow a linear progression from naïve cell to effector memory to central memory cells, but 
central memory cells may also be generated from earlier activated T cells (Obhrai 2006; Sallusto 
2004).  Homeostasis of memory cells occurs by slow division of long-lived memory cells for 
maintenance of the clonal cell line (Lanzavecchia 2002; Sallusto 2004).  Memory homeostatic or 
“self-renewal” proliferation occurs but is mechanistically different from antigenic “pluripotent” 
memory proliferation (Kaech 2002).   
T CELLS AND BONE MARROW 
 
Athymic and nude mice are T cell deficient with normocellular BM, an arrest of 
granulocytic immature myeloid cells, lymphopenia, low numbers of marrow erythroblasts, and 
normal concentrations of blood monocytes and platelets (Monteiro 2005).  In studies of T cell 
deficient mice by Montiero et al., reconstitution of these mice with fetal thymic grafts or CD4+ T 
cells allowed maturation of the granulocytic cells and restoration of circulating and bone marrow 
lymphocytes, though erythroid precursors were not affected, which was attributed to the presence 
of activated CD4+ BM cells (Monteiro 2005).  However, Montiero et al. did not find CD8+ T 
cells to restore granulocytes and lymphocytes to T cell deficient mice (Monteiro 2005).  
Montiero et al. suggested CD4+ T cell depletion during HIV may lead to neutropenia and 
disruption of hematopoiesis in bone marrow (Monteiro 2005).  Di Rosa et al. proposed BM has a 
role in maintenance of naïve and memory T cells and that BM may have a role in restoring BM 
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function in periods of loss of BM steady state (Di Rosa 2009).  Development of hematopoietic 
cells is under the influence of a complex microenvironment involving interactions of multitudes 
of growth factors, cytokines, chemokines, stromal cells and non-stromal cells, and stromal 
support. 
 
HEMATOPOIESIS 
 
Hematopoiesis is the development of cells found in blood and tissue from a pluripotent 
hematopoietic stem cell within the bone marrow (BM) environment (Bondurant 2004; Gasper 
2000; Huang 2007; Scott 2008a; Travlos 2006).  The bone marrow environment is identified 
within the medullary cavity of long bones and axial bones (Travlos 2006).  Hematopoiesis is 
maintained in flat bones as mammals age (Gasper 2000).  The medullary cavity consists of blood 
vessels, stromal tissue, and multiple lineages of cells (Scott 2008b).  BM mesenchymal stem 
cells are approximately 0.01-0.0001% of total BM nucleated cells (Dazzi 2006).  Adipose tissue 
is part of the normal stroma or supportive BM tissue (Scott 2008b).  Large amounts of adipose 
tissue in BM imparts a „yellow‟ color and is referred to „yellow marrow‟ in contrast to „red 
marrow‟ where BM is composed of mostly hematopoietic tissue (Scott 2008b; Stasney 1936).  
As hematopoiesis increases density of cells, adipose tissue decreases by resorption to allow the 
space occupying mass of cells (Gurkan 2008).  Hematopoiesis occurs within defined areas of the 
medullary cavity described as niches.  The niche comprises supportive cells and signals to 
support HSC populations and provide necessary signals for differentiation and maturation 
(Wagers 2005). 
One niche of bone marrow is the osteoblastic, bony, or endosteal niche of bone marrow 
(Calvi 2003; Huang 2007; Jung 2005; Sacchetti 2007; Wagers 2005).  Osteoblasts are found 
within and upon bone endosteum or lining of bony surfaces (Travlos 2006).  Osteoblasts are 
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mesenchymal bone marrow cells that regulate bone production.  Another important osteoblast 
function is to provide support for hematopoietic stem cells (HSC) by increasing numbers of long 
term hematopoietic stem cells (LT-HSC) as proven in transgenic mice (Calvi 2003; Huang 2007; 
Zhang 2003).   Increased numbers of LT-HSCs in mice were observed at 76% within the marrow 
cavity and 24% at the bone surface with the majority in the cancellous or trabecular bone surface 
including the epiphysis and metaphysis, and the remaining dispersed at the endosteal surface of 
the diaphysis or long bone (Travlos 2006; Zhang 2003). 
Another niche of bone marrow is the vascular niche of sinusoidal endothelium (Huang 
2007; Kiel 2005).  Components of the vascular niche including endothelial and other associated 
mesenchymal cells support HSC differentiation (Huang 2007; Kiel 2005; Wagers 2005).  In long 
bone, a specific vascular system is present (Dazzi 2006; Gurkan 2008; Travlos 2006; Zhang 
2003).  A nutrient artery enters the long bone feeding the central artery.  The central artery 
branches into radial arteries toward the inner lining of the bone (endosteum) where it forms 
sinuses and sinusoids.  The sinuses and sinusoids are drained into the central vein or central sinus 
which is located in the center of the bone.  The central vein exits bone by the nutrient vein.  
Blood flow is from the center nutrient artery toward the peripheral bone into sinuses then back 
into the central vein again.  The majority of blood vessels are distributed closer to the endosteal 
bone.  Hematopoiesis occurs mostly in the vascular rich regions of bone marrow.  Even though 
bone marrow has an intricate network of vessels, this organ is not drained by lymphatic vessels 
despite BM being a primary lymphoid organ (Di Rosa 2005; Travlos 2006). 
Long term culture hematopoietic stem cells (HSC) can self renew and gives rise to short 
term culture hematopoietic stem cells (ST-HSC) that cannot further self renew or differentiate 
into stem cells (Huang 2007; Wagers 2005).   The ST-HSC are pluripotent stem cells that under 
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direct intracellular and extracellular signals differentiate into a common myeloid progenitor 
(CMP) or common lymphoid progenitor (CLP) (Figure 2.2).  The CMP is influenced by the 
cytokine colony forming unit-granulocyte, erythroid, megakaryocyte, monocyte (CFU-GEMM) 
while the CLP is directed by the cytokine colony forming unit-lymphoid (CFU-L).  Precursor 
cells include the following groups: mitotically active dividing cells, immature and mature post-
mitotic cells, and storage pools of cells (Gasper 2000). 
The CLP cells further differentiates into B lymphocyte, T lymphocyte, natural killer (NK) 
cell, and dendritic cell progenitors.  B lymphocyte progenitors remain in the bone marrow and 
become immature B cells, then migrate to other lymphoid organs of spleen or lymph node to 
develop into active or memory B cells including plasma cells.  T lymphocyte progenitors leave 
the bone marrow to enter the thymus as early thymic progenitors for differentiation into CD4+ T 
cells, CD8+ T cells, T regulatory CD4+CD25+ T cells, and γδ T cells.   
The CMP further differentiates into myeloid cells including erythrocytes, 
megakaryocytes, monocytes, neutrophil, eosinophils, and basophils in bone marrow.  Monocytes 
differentiate into macrophages within tissue.  Mast cell precursors leave the bone marrow and 
differentiate into mature mast cells in tissue.  DC, from myeloid progenitors, differentiate in the 
tissue.  Erythroid lineage is referred to with the prefix „rubri‟ in veterinary medicine instead of 
„erythro‟ or „normo‟ in humans (Scott 2008b).  Erthropoiesis occurs in erythroblastic islands 
while megakaryocytopoiesis occurs near endothelium, and granulocytopoiesis occurs in less 
defined areas (Travlos 2006).  Evaluation of bone marrow can be performed by multiple methods 
and has been reviewed (Bolliger 2004; Cotelingam 2003; Grindem 2002; Huser 1970; Travlos 
2006).  Bone marrow aspiration or cytology, bone marrow biopsy or histopathology, and flow 
cytometry may be utilized to obtain information about the status of hematopoiesis.  In  
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Figure 2.2. Bone marrow hematopoiesis 
Schematic representation of bone marrow hematopoiesis as defined in the text. (Bondurant 2004; 
Gasper 2000; Scott 2008a; Travlos 2006). 
BFU-E    burst forming unit-erythroid 
BFU-Meg   burst forming unit-megakaryocyte 
BFU-Meg/E   burst forming unit-megakaryocyte/erythroid 
CFU-B   colony forming unit-B lymphocyte 
CFU-Baso colony forming unit-basophil 
CFU-E colony forming unit-erythroid 
CFU-Eo colony forming unit-eosinophil 
CFU-G colony forming unit-granulocyte 
CFU-GEMM  colony forming unit-granulocyte, erythroid, megakaryocyte, 
monocyte  
CFU-GM colony forming unit-granulocyte, macrophage  
CFU-L colony forming unit-lymphoid 
CFU-M colony forming unit-macrophage 
CFU-Mast colony forming unit-mast cell 
CFU-Meg colony forming unit-megakaryocyte 
CFU-MK colony forming unit-megakaryocyte 
CFU-T colony forming unit-T lymphocyte 
DCLD    Dendritic Cell-Lymphoid Derived 
DCMD   Dendritic Cell-Myeloid Derived 
HSC    hematopoietic stem cells 
NK    natural killer cell 
 
Figure on next page. 
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conjunction with direct evaluation of bone marrow, the peripheral blood should also be examined 
to define changes noted in BM hematopoiesis.   
Bone marrow histopathology can define the architecture of tissue and megakaryocyte 
numbers but cell identification is more difficult (Scott 2008b).  The myeloid 
(granulocytic/monocytic lineage) to erythroid lineage (M:E) ratio is a quantitative, calculated, 
yet only semi-quantitative or subjective assessment of the granulocytic/monocytic myeloid 
lineage to erythroid lineage.  The M of the M:E ratio refers to non-erythroid myeloid cells 
including granulocytic and monocytic lineages and occasionally megakaryocytic lineages (Scott 
2008b).  Therefore, the M:E is a misnomer since the erythroid lineage is also of myeloid descent 
and is not included in the „M‟ aspect (Scott 2008b).  The M:E ratio may or may not encompass 
numbers of megakaryocytes, also myeloid cells, present of which the megakaryocytes can be 
easily identified by their characteristic large size and multi-lobed nuclei (Travlos 2006).  Neither 
does the M:E ratio account for mast cells and macrophages, of myeloid lineage, nor lymphoid 
cells as expected by the name myeloid (Scott 2008b).  Thus much more careful and less 
subjective assessments of cells and phenotype is necessary to assess the impact of an infection or 
other condition in bone marrow. 
APOPTOSIS PATHWAY 
 
Mechanisms of failure of bone marrow to support orderly and effective hematopoiesis in 
HIV infection are not know, but could be from either  direct viral destruction, bystander 
apoptosis, pronounced bystander apoptosis from T 
lymphocytes/monocytes/macrophages/megakaryocytes, a suppressive cytokine milieu, and/or 
loss of stromal cell structure (Isgro 2005).   Our hypothesis is immature BM CD4+ T 
lymphocytes are lost through apoptosis during progressive SIV disease.   
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Caspases are involved in apoptosis by an endoplasmic reticulum (ER) disruption 
pathway, ligand-mediated or death domain pathway, and a mitochondrial pathway (Elmore 2007; 
Gupta 2007).  Activated caspase 3 is a late pathway effector or „executioner‟ caspase involved in 
all three pathways (Figure 2.3) (Elmore 2007; Gupta 2007).  Activation of caspase 3 leads to 
degradation of DNA and cytoskeletal proteins leading to formation of apoptotic bodies (Elmore 
2007). 
Endoplasmic reticulum mediated apoptosis is induced by alterations to protein processing 
or the ER calcium pool (Gupta 2007).  Protein processing in the ER includes post-translational  
changes, folding, and sorting, and a disruption of normal processing may induce apoptosis 
(Gupta 2007).  Calcium dysregulation within the ER can lead to and induce apoptosis (Gupta 
2007).  The highest amount of intracellular calcium is within the ER where concentrations are 
10,000 fold-lower than cytosolic ER concentrations (Gupta 2007).  Also, disturbances leading to 
shift of the ER calcium pool (higher or lower) may induce apoptosis (Gupta 2007).  ER 
disruption can directly activate the caspase system involved in apoptosis (Dong 2006). Though 
controversial, in humans, caspase 12 appears to be the first activated caspase (Dong 2006). The 
Bcl2 family appears to be involved in ER disruption induced apoptosis (Szegezdi 2006).   
Additionally, stress imposed upon the ER can sends signals to the mitochondria and may trigger 
mitochondrial apoptosis (Szegezdi 2006).   Caspases involved in ER disruption induced 
apoptosis include 3,4,6,7,8,9, and 12 (Szegezdi 2006).  Gupta and Gollapudi observed in 
thapsigargi-induced apoptosis that activation of the ER disruption pathway through increased 
calcium, CD8+ T cells were induced into apoptosis.  Naïve CD8+ T cells and CD8+ central 
memory T cells were more sensitive to apoptosis than CD8+ effector memory T cells by ER 
stress activation (Gupta 2007).  
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TNF-α ligand binding and CD95 ligand binding both may induce ligand-mediated or 
death receptor pathways (Gupta 2007).  TNF-α may bind TNF receptors (TNFR) which activate 
the adapter protein TNFR-associated death domains (TRADD) which in turn activate Fas-
associated death domains (FADD) which in turn activates caspase 8 (Gupta 2007; Hurtrel 2005).  
TRADD may activate other adapter proteins, TNFR-associated factor 2 and receptor interactive 
protein (RIP) that lead to stimulation of MAP kinase (apoptosis inducer or inhibitor) and NF-κB 
(apoptosis inhibitor) that in turn upregulate transcription factors to inhibit or stimulate apoptosis 
(Gupta 2007).  Gupta and Gollapudi observed in TNF-α induced apoptosis with activation of the 
death domain pathway, T cells responded differently.  Naïve CD8+ T cells and CD8+ central 
memory T cells were observed to undergo apoptosis while CD8+ effector memory T cells were 
observed to be resistant to apoptosis by death domain activation (Gupta 2007).  
Mitochondrial mediated apoptosis is induced by changes to either the outer mitochondrial 
membrane (OMM) or inner mitochondrial membrane (IMM) (Gupta 2007).  Stress to the cell 
leading to breach of the OMM allows leakage of cytochrome c, apoptosis-inducing factor, some 
pro-caspases, and other molecules from the intermembrane space (Gupta 2007).  The OMM 
contains anion channels that are voltage dependent along with Bcl-2 found on the IMM which 
are involved in maintenance of the mitochondrial membrane potential(Gupta 2007). Cytochrome 
c when free in the cytoplasm can bind an adapter protein apoptotic protease-activating factor -1 
(Apaf-1) (Gupta 2007).  Pro-caspase 9 is activated without cleavage in the presence of 
ATP/dATP (Gupta 2007).  Gupta and Gollapudi observed in H2O2 induced apoptosis with 
activation of the mitochondrial pathway, T cells responded differently.  Naïve CD4+ and CD8+ 
T cells and CD4+ and CD8+ central memory T cells were observed to undergo apoptosis while 
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CD4+ and CD8+ effector memory T cells were observed to be resistant to apoptosis by H2O2 
stress (Gupta 2007). 
 
 
Figure 2.3. Apoptosis pathway 
Schematic representation of apoptosis pathways as described in text.  All pathways have a 
common sequence of initiation of effector caspases (Gupta 2007).  (With permission see 
Appendix V).
1
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 Gupta S and Gollapudi S (2007). "Susceptibility of naive and subsets of memory T cells to apoptosis via multiple signaling 
pathways." Autoimmun Rev 6(7): 476-481. 
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CHAPTER 3:  HEMATOLOGIC ABNORMALITIES DURING 
PROGRESSIVE SIV INFECTION MIRROR HIV DISEASE 
 
INTRODUCTION 
 
Hematologic abnormalities including anemia, lymphopenia, thrombocytopenia, 
neutropenia, and leukopenia have been reported in HIV infection and AIDS (Castella 1985; 
Morris 1982; Moyle 2002; Spivak 1984).  However, there is considerable debate whether these 
abnormalities are caused by HIV infection alone, concurrent opportunistic infections, anti-
retroviral therapy (ART), intravenous (IV) drug usage, or other lifestyle factors.   
Early studies usually involved patients with advanced HIV disease, often using 
opportunistic infections as diagnostic criteria, so the hematologic changes were often attributed 
to the opportunistic infection such as Pneumocystis pneumonia.  Furthermore, early studies were 
often confounded by the use of anti-microbials and later studies by ART.  For example 
azidothymidine (AZT) trials started in 1986 in the USA, and this and other drugs were eventually 
shown to have significant side effects including anemia and other hematologic abnormalities 
(Fischl 1987).  An increased risk of anemia in HIV patients naïve for antiviral therapy was 
observed in African Americans (Sullivan 1998).  Also, older patients, African Americans, and 
males are more likely to become thrombocytopenic during HIV disease (Sloand 1992).  HIV 
patients infected by heterosexual relations were reported to be at higher risk to develop 
thrombocytopenia compared to homosexuals, bisexual, IV drug users, transfusion recipients, or 
hemophiliacs (Sloand 1992).  Neutropenia is observed often in HIV patients on drug therapy or 
in late stages of AIDS (Street 1996; Coyle 1997). Thus, studies of hematologic abnormalities in 
HIV infected patients are difficult to interpret and it is not known whether pathogenesis involves 
direct viral destruction of hematopoietic cells and/or precursors or secondary effects from 
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immune dysfunction (i.e. autoimmune hemolytic anemia) caused by the virus, drugs, or 
concurrent infections (Coyle 1997; Curkendall 2007; Olayemi 2008; Treacy 1987; Zon 1987).  
The objective of the study was to determine the frequency of hematologic abnormalities 
in SIV infected macaques during various periods of infection under well-controlled conditions 
for comparison with HIV infected patients.  We hypothesized hematologic changes during 
progressive non-interventional SIV infection of RM in well-controlled studies would be similar 
to those of untreated HIV infected patients and represent changes due to SIV infection alone 
without impact of confounding factors.  Close approximations in prevalence of hematologic 
abnormalities between SIV and HIV would validate the SIV model for bone marrow studies in 
HIV infection and AIDS.  Currently, SIV infected RM are the premier animal model for studying 
HIV infection in humans, as SIV-induced disease recapitulates essentially all features of HIV 
infection and AIDS in the macaque model.    
MATERIAL AND METHODS 
 
Database Selection 
 
A retrospective longitudinal evaluation of SIV pathogenesis complete blood count (CBC) 
data collected from Indian RM inoculated with SIV viral strains between January 1986 and 
December 2006 was conducted at TNPRC.  Criteria for inclusion included the following:  >1.75 
years old at time of inoculation; a single inoculation with SIVB670, SIVmac239, or SIVmac251; 
slow progression to AIDS (≥260 days post-inoculation or DPI); and serial CBC data collected 
from 0 DPI until humane sacrifice.  Further, all animals were devoid of SIV-related experimental 
therapy or vaccination throughout the study.  AIDS criteria were defined based on the 1993 
Centers for Disease Control (CDC) guidelines and limited to opportunistic infections (OI), 
encephalitis, and/or multi-organ lymphoma confirmed by histopathologic examination at 
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necropsy.  Data collected from age-matched Indian RM served as the controls. Controls included 
RM beginning research protocols for the first time and macaques were naïve to experimental 
inoculation or therapy.   RM inclusive in the study were referred to as experimental database 
(ED) I and further defined in this chapter and Appendix II. 
Hematologic Data and Definitions 
 
Hematologic data and definitions are described in Appendix I.   
Statistical Analysis 
 
Hematologic data from pre-inoculation to humane sacrifice for SIV inoculated RM was 
organized for evaluation and statistical analyses according to viral inoculation or period of 
infection.  Viral inoculation group(s) was identified by individual inoculum with one of three 
wildtype strains: SIVB670, SIVmac239, or SIVmac251.  Period of infection was assigned by 
DPI due to inconsistent sampling among SIV infected RM as uninfected or pre-inoculation (0 
DPI or Period 1), early (1-42 DPI or Period 2), chronic (43-120 DPI or Period 3), and slowly 
progressive to AIDS (AIDS or >120 DPI until sacrifice or Period 4).   Control hematologic data 
analysis consisted of a one-time CBC sample. 
Differences of hematologic values between the control macaques and infected RM were 
statistically compared using the Mann Whitney non-parametric unpaired t test in GraphPad 
Prism 5 (GraphPad Software; San Diego, CA).  Correlation of CBC data was compared using 
non-parametric Spearman correlation coefficients in GraphPad Prism 5 (GraphPad Software).   
Prevalence rate was defined as the percentage of total macaques with a hematologic 
abnormality.  Incidence rate was defined as the percentage of total macaques observed with the 
first event of a hematologic abnormality within a defined period.  Statistical differences in 
prevalence between the control and infected subjects arranged by inoculum groups or periods 
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were compared using the Tukey Kramer one way analysis of variance (ANOVA) test in 
GraphInstat 3 (GraphPad Software).   Statistical differences in prevalence and incidence between 
infected subjects arranged by inoculum groups or periods were compared using the Tukey 
ANOVA test in GraphInStat 3 (GraphPad Software). Graphs represent the mean of the data 
evaluated.   
The SAS® (Version 9.1.3) statistical package was used to analyze the CBC data values 
of SIV inoculated subjects by repeated measures analysis of variance (MANOVA) in a split-plot 
arrange of treatments.  Effects on the main plot included sex, group*sex, and animal within 
group*sex.  Subplot factors included period and the interactions of period, group and sex.  Since 
any factor which included sex was non-significant in the initial analysis, sex was absorbed as an 
effect and the models were rerun.  Where overall significance was found, post hoc pairwise 
comparisons of means were conducted with Tukey‟s HSD test for main effects and t tests of 
least-squares means for interaction effects.    
Graphs represent the means and error bars represent the standard error of the mean 
(SEM).  Statistical analyses were considered significant at p value (p) ≤0.05. 
RESULTS 
 
Experimental Database I  
 
Retrospective analysis of the TNPRC animal database revealed 61 Indian RM inoculated 
with a single dose of SIVmac239, 129 Indian RM inoculated with a single dose of SIVmac251, 
and 427 Indian RM inoculated with a single dose of SIVB670 during the twenty year time 
period.  However, only a subset of animals met the stringent inclusion criteria that excluded 
animals younger than 1.75 years at inoculation, those vaccinated/immunized/ and/or challenged 
with other viruses, treated for SIV or other diseases, treated with ART or other anti-microbials, 
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or rapid progressors.  Finally, only macaques that had serial CBC data collected at all defined 
periods of infection were included.  Thus only data from five SIVmac239 infected, six 
SIVmac251 infected, and ten SIVB670 infected RM were included in this study as the infected 
cohort (Appendix II).  Thirty-one control macaques comprised the uninfected cohort (Appendix 
II).   
Hematologic Differences Between Control and SIV Infected Rhesus macaques 
 
CBC data and prevalence rates were compared between control and SIV infected 
macaques to detect hematologic changes present during untreated progressive SIV infection 
(Figure 3.1 and Table 3.1 respectively).  Change in prevalence for hematologic abnormalities 
between SIV infected and control RM was similar to differences observed by evaluation of CBC 
data.  Hemoglobin and hematocrit (HCT) values were significantly decreased in SIV infected 
RM paralleled by significant increase in anemia prevalence compared to control macaques.  SIV 
macaques had a significantly lower mean cell hemoglobin concentration (MCHC) however 
hypochromia prevalence was not significant compared to non-infected macaques.  Platelet counts 
were depressed in SIV macaques with increased significance for thrombocytopenia (TCP) 
prevalence compared to controls.  Significant increases in prevalence for neutropenia and 
neutrophilia was detected in SIV macaques with overall significantly lower neutrophil counts 
compared to controls.  SIV macaques were observed with significantly low lymphocyte counts 
and increased prevalence of lymphopenia compared to non-infected subjects.  Increased 
prevalence for monocytosis (p<0.001) and monocytopenia was present in SIV subjects though a 
difference in monocyte count was not present compared to controls.  Eosinophilia prevalence 
was significantly increased with a trend for increased eosinophil count compared to control  
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Figure 3.1. Hematologic values of control and SIV infected macaques 
Comparison of CBC values between data from control macaques and data from SIV infected 
macaques.  MCV is mean cell volume.  MCHC is mean cell hemoglobin concentration.  
Significant differences by Mann Whitney t tests (*p<0.0001 and **p<0.001) are shown.  Values 
indicate mean + SEM. 
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Table 3.1. Prevalence Rate of Hematologic Abnormalities in Control and SIV Infected 
Rhesus macaques 
 
Hematologic Abnormality Control Subjects (%) SIV Infected Subjects (%) 
Lymphopenia 23 100** 
Anemia 3 90** 
Eosinophilia 13 90** 
Neutropenia 0 90** 
Neutrophilia 10 76** 
Thrombocytopenia 3 67** 
Monocytopenia 3 62 
Monocytosis 3 48** 
Basophilia 0 24**** 
Microcytosis 6 5 
Lymphocytosis 0 5 
Hypochromia 0 6 
Macrocytosis 0 0 
**Significance p≤0.001 when compared to control cohort by ANOVA analysis 
****Significance p≤0.05 when compared to control cohort by ANOVA analysis 
 
subjects.  Basophilia was noted with significantly increased prevalence in SIV subjects and 
significantly higher absolute numbers in controls when comparisons were applied. 
Classification of SIV infected subjects by strain of inoculum revealed differences when 
compared to controls for prevalence of hematologic abnormalities (Table 3.2).  All hematologic 
changes were present in SIVB670 macaques.  A significant difference was observed between the 
control group and each SIV inoculum group for prevalence of anemia, neutropenia, 
lymphopenia, eosinophilia, and basophilia. SIVB670 and SIVmac251 macaques displayed 
significance for TCP and neutrophilia compared to controls.  Monocytopenia was significant for 
SIVmac239 and SIVB670 compared to control macaques.  Both SIVmac groups were significant 
for monocytosis compared to non-infected macaques.  Basophilia was only statistically different 
for SIVB670 macaques.   
Classification of SIV infected subjects by time period revealed differences when 
compared to the controls for prevalence of hematologic abnormalities (Table 3.3).  All time 
periods showed significant differences compared to controls for prevalence of neutropenia.  Post-
inoculation periods significantly differed compared to control macaques for both lymphopenia 
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and eosinophilia prevalence.  Early and AIDS periods showed significant prevalence differences 
compared to non-infected controls for anemia. Interestingly, only the AIDS period showed a 
significantly increased prevalence of thrombocytopenia, neutrophilia, and monocytosis when 
compared to control macaques.  Lymphocytosis and monocytopenia prevalence rates were too 
low to be statistically analyzed.   
Table 3.2. Significance by p Value Comparing Prevalence Rates of Hematologic 
Abnormalities for Control and SIV Infected Rhesus macaques by Inoculum 
 
Hematologic Abnormality SIVmac239 SIVmac251 SIVB670 
Anemia <0.001 <0.001 <0.001 
Thrombocytopenia NS <0.001 <0.001 
Neutropenia <0.001 <0.001 <0.001 
Neutrophilia NS <0.01 <0.001 
Lymphopenia <0.001 <0.001 <0.001 
Lymphocytosis NS NS NS 
Monocytopenia <0.001 NS <0.001 
Monocytosis <0.01 <0.001 NS 
Eosinophilia <0.01 <0.001 <0.001 
Basophilia NS NS <0.01 
NS = not significant 
Table 3.3. Significance by p Value Comparing Prevalence Rates of Hematologic 
Abnormalities for Control and SIV Infected Rhesus macaques by Period 
 
Hematologic Abnormality Period 1 Period 2 Period 3 Period 4 
Anemia NSa <0.001 NS <0.001 
Thrombocytopenia NS NS NS <0.001 
Neutropenia <0.001 <0.001 <0.001 <0.001 
Neutrophilia NS NS NS <0.001 
Lymphopenia NS <0.001 <0.01 <0.001 
Lymphocytosis NAb NA NA NA 
Monocytopenia NA NA NA NA 
Monocytosis NS NS NS <0.001 
Eosinophilia NS <0.001 <0.001 <0.001 
Basophilia NS NS NS NS 
a) NS =  not significant; b) NA = not analyzed  
Prevalence and Incidence of Hematologic Values in SIV Infected Rhesus macaques 
 
CBC data of SIV infected RM were evaluated for differences by group and period (Table 
3.4).  Significance in group effect, period effect, and group by period effect was noted for  
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hematocrit, platelet count, neutrophil count, and lymphocyte count.  The monocyte count was 
significant for a group effect and period effect.  Only significance for a group effect was detected 
for eosinophil and basophil count. 
Table 3.4. Significance by p Value Comparing CBC Data of SIV Infected Rhesus macaque 
by Group and Period 
 
CBC Value Group Effect Period Effect Group*Period Effect 
Hematocrit  <0.0001 <0.0001 <0.0001 
Platelet Count <0.0001 <0.0001 0.0311 
Neutrophil count <0.0001 <0.0001 0.0066 
Lymphocyte count <0.0001 0.0053 0.0382 
Monocyte count <0.0001 0.0004 NS 
Eosinophil count 0.0233 NS NS 
Basophil count 0.0435 NS NS 
NS = not significant 
Incidence rates for hematology changes in SIV infected macaques were calculated to 
detect the first time a specific hematologic abnormality occurred within a time period by viral 
inoculum (Table 3.5).   Evaluation of incidence rates aided in the determination of recurrence of 
a hematologic event.  Several changes in circulating cells were noted during SIV, although 
incidence rates were detected most commonly for anemia, TCP, neutropenia, neutrophilia, 
lymphopenia, and eosinophilia.   
Prevalence rates for hematologic abnormalities during SIV infection were determined by 
period for each viral strain (Table 3.6).  Prevalence rates for neutropenia and lymphopenia were 
noted during all periods for all viral strains.  Anemia and eosinophilia prevalence rates were the 
next most common followed by prevalence rates for TCP and neutrophilia. 
Hematologic Abnormalities During Progressive SIV Infection 
 
Anemia 
 
Anemia was frequently observed in early and AIDS periods of SIV infected RM for all 
inoculums (Figure 3.2).  Overall, the anemia was mild, normocytic and normochromic, yet  
34 
 
Table 3.5. Incidence Rate of Hematologic Abnormalities for SIV infected RM 
 
  SIVmac239 (%) SIVmac251 (%) SIVB670 (%) 
 Hematologic 
Abnormality Total 
0 
DPI
a
 
1-42 
DPI 
43-120 
DPI 
>120 
DPI Total 
0 
DPI 
1-42 
DPI 
43-120 
DPI 
>120 
DPI Total 
0 
DPI 
1-42 
DPI 
43-120 
DPI 
>120 
DPI 
Anemia 100 20 60 0 20 83 0 50 0 33 90 14 52 5 19 
TCPb 40 0 0 0 40 84 0 17 0 67 67 0 10 14 43 
Neutropenia 100 40 40 20 0 84 17 50 17 0 90 38 38 14 0 
Neutrophilia 60 0 0 20 40 83 33 0 0 50 77 10 5 5 57 
Lymphopenia 100 60 40 0 0 100 33 50 0 17 100 28 43 10 19 
Lymphocytosis 0 0 0 0 0 0 0 0 0 0 5 0 0 0 5 
Monocytopenia 80 20 0 0 60 0 0 0 0 0 62 38 5 0 19 
Monocytosis 60 0 0 20 40 66 0 0 33 33 47 0 0 14 33 
Eosinophilia 80 0 40 20 20 100 0 100 0 0 91 10 57 10 14 
Basophilia 0 0 0 0 0 17 0 0 0 17 40 0 10 5 10 
a) DPI = days post-inoculation; b) TCP = thrombocytopenia 
Table 3.6. Prevalence Rate of Hematologic Abnormalities for SIV infected RM 
 
  SIVmac239 (%) SIVmac251 (%) SIVB670 (%) 
 Hematologic 
Abnormality Total 
0 
DPI
a
 
1-42 
DPI 
43-120 
DPI 
>120 
DPI Total 
0 
DPI 
1-42 
DPI 
43-120 
DPI 
>120 
DPI Total 
0 
DPI 
1-42 
DPI 
43-120 
DPI 
>120 
DPI 
Anemia 100 20 60 0 80 83 0 50 0 83 90 20 70 60 90 
TCPb 40 0 0 0 40 83 0 17 0 67 70 0 10 40 60 
Neutropenia 100 40 80 80 80 83 17 67 83 67 90 50 80 80 70 
Neutrophilia 60 0 0 20 40 83 33 0 0 83 80 0 10 10 80 
Lymphopenia 100 60 100 60 100 100 33 83 67 100 100 10 40 70 100 
Lymphocytosis 0 0 0 0 0 0 0 0 0 0 10 0 0 0 10 
Monocytopenia 80 20 0 0 60 0 0 0 0 0 90 70 80 80 90 
Monocytosis 60 0 0 20 60 67 0 0 33 50 30 0 0 0 30 
Eosinophilia 80 0 40 60 80 100 0 100 67 83 90 20 40 60 90 
Basophilia 0 0 0 0 0 17 0 0 0 17 40 0 20 10 20 
a) DPI = days post-inoculation; b) TCP = thrombocytopenia 
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highly prevalent in infected animals.  Reticulocyte counts were not available to ascertain 
regenerative capacity of the anemia, but several causes for anemia were ruled out including 
hemolysis, renal disease, endocrine disease, bone marrow infiltrative disease, and 
myelodysplasia.  The occurrence of a mild normocytic and normochromic anemia was 
suggestive of a non-regenerative process such as anemia of chronic inflammatory disease or 
early iron-deficiency anemia (Glader 2004; Means 2004).  
A.                                B. 
     
 
Figure 3.2. Prevalence and incidence of anemia during SIV infection 
Prevalence rates (A.) and incidence rates (B.) for anemia by period for each viral inoculum.  
Significance between periods within groups represented by horizontal lines by ANOVA 
(p<0.05).  
 
Anemia was often recurrent but was rarely persistent in SIV infected RM.  The early 
period had the highest rate of incidence for anemia (at least 50%) compared to later time periods. 
Only one subject inoculated with B670 was persistently anemic after inoculation. A mild anemia 
was detected in animals chronically infected with SIVmac251 and SIVmac239 but varied from 
mild to severe in SIVB670 subjects as infection progressed.  Severe yet transient and recurrent 
anemia was detected in two subjects chronically infected with SIVB670.   
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Anemia was not apparent in all periods of infection, but when observed was mostly in the 
AIDS, with lower prevalence in the early period and much less in the chronic period.  All except 
one subject in each inoculation group displayed anemia in the AIDS stage.  Interestingly, 
subjects inoculated with SIVmac239 and SIVmac251 did not manifest anemia in the chronic 
phase, while a 60% prevalence of anemia was present in the chronic period of SIVB670 
inoculated RM.   
Thrombocytopenia 
 
Incidence of thrombocytopenia increased toward progression to AIDS but the degree of 
thrombocytopenia did not parallel this finding (Figure 3.3).   Thrombocytopenia in SIV infected 
RM was moderately prevalent, while rarely recurrent as it was observed in only three SIVB670 
inoculated subjects, including one subject displaying persistent and variably mild to severe 
thrombocytopenia in chronic and AIDS periods.  In the early period of infection, one subject in 
the SIVmac251 and one subject in the SIVB670 group were observed with mild 
thrombocytopenia.  Subjects infected with SIVB670 were more likely to demonstrate 
thrombocytopenia as SIV infection progressed compared to macaques with SIVmac239 and 
SIVmac251.   
Thrombocytopenia during the chronic period was only detected in group SIVB670 at 
40% prevalence while absent in the SIVmac239 and SIVmac251 groups, similar to prevalence 
for anemia.  During the AIDS stage, all three inoculum groups had thrombocytopenic subjects 
with prevalence of 40% of SIVmac239 inoculated subjects, 67% of SIVmac251 inoculated 
subjects, and 60% of SIVB670 inoculated subjects.   
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A.                               B. 
    
 
Figure 3.3. Prevalence and incidence of thrombocytopenia during SIV   
Prevalence rates (A.) and incidence rates (B.) for thrombocytopenia by period for each viral 
inoculum.  Significance between periods within groups represented by horizontal lines by 
ANOVA (p<0.05). 
 
 
Neutropenia 
 
Neutropenia was another frequent finding in SIV-infected macaques, as 90% of infected 
subjects were found to have neutropenia at some period of infection (Figure 3.4).  Incidence of 
neutropenia was greater than 50% for all time periods and fairly consistent between time periods 
and inoculum groups but tended to decline with progression of disease.  Again, however, 
although highly prevalent, neutropenia was usually transient, yet often recurrent, although mostly 
mild to occasionally moderate.  All subjects in the SIVmac239 group displayed neutropenia at 
some stage of infection, and all but one each in both SIVmac251 and SIVB670 groups displayed 
neutropenia.  Neutropenia was always mild in SIVmac251-infected subjects, but often moderate 
in SIVmac239 and SIVB670 infected subjects.   
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     A.                               B. 
     
Figure 3.4. Prevalence and incidence of neutropenia during SIV infection 
Prevalence rates (A.) and incidence rates (B.) for neutropenia by period for each viral inoculum.  
Significance between periods within groups represented by horizontal lines by ANOVA 
(p<0.05). 
 
 
Lymphopenia 
 
Total prevalence of lymphopenia was highest of all hematologic variances over time by 
inoculum but incidence varied (Figure 3.5). Essentially every animal experienced lymphopenia 
at least during some stage of SIV infection.  Lymphopenia was present in all inoculum groups at 
all time periods with at least 40% prevalence ending with 100% prevalence in the progressive 
phase.  Inoculated RM had lymphopenia that was often mild, occasionally moderate, rarely 
severe, and also rarely persistent in only two subjects infected with SIVmac239 during 
progressive infection.   
Eosinophilia 
 
Prevalence of eosinophilia was high in SIV infected macaques (Figure 3.6).  
Nevertheless, eosinophilia was mild and often recurrent in SIV infected RM but never persistent.  
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    At least two subjects from all infected time periods for all inoculums groups displayed 
eosinophilia.  
DISCUSSION 
 
Although several hematologic anomalies were occasionally observed in individual 
control animals, virtually all SIV-infected animals displayed anemia, thrombocytopenia, 
neutropenia, neutrophilia, lymphopenia, or eosinophilia at some stage of SIV infection.   CBC 
data, prevalence rates, and incidence rates were evaluated between SIV infected and uninfected 
macaques to identify differences and ascertain relevance of hematologic abnormalities during 
non-treated SIV infection.  Hematologic abnormalities were compared by period and viral group 
during SIV by prevalence and incidence to identify trends. 
Comparison of HCT, hemoglobin, MCV, and MCHC as hematologic parameters for 
classification of anemia were significantly lower in SIV infected macaques than controls with the 
exception of MCV.   HCT and hemoglobin values and prevalence for anemia were significantly 
different during SIV compared to controls interpreted as an important hematologic abnormality 
during SIV infection.  Anemia prevalence was highest in AIDS but incidence was highest in 
period 2 for all viral strains.  Of note, anemia was not present in SIVmac infected RM during 
period 3.  The SIV RM model simplifies the ability to rule out many causes for anemia such as 
drug, diet, and acute or chronic blood loss.  Reticulocyte count was not available to ascertain 
regeneration during anemic episodes but MCHC and MCV were evaluated to classify anemias. 
Initially, MCHC was significantly decreased in SIV infected macaques compared to 
controls but prevalence for hypochromia was low compared to controls and this finding was 
regarded as unimportant during SIV infection.  The lack of significant difference in MCV 
between RM infected and uninfected with SIV indicated this value was not important during SIV  
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.  A.                                                                      B. 
     
Figure 3.5. Prevalence and incidence of lymphopenia during SIV infection 
Prevalence rates (A.) and incidence rates (B.) for lymphopenia by period for each viral inoculum.  
Significance between periods within groups represented by horizontal lines by ANOVA 
(p<0.05). 
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A.                                                                     B. 
   
 
Figure 3.6. Prevalence and incidence of eosinophilia during SIV infection 
Prevalence rates (A.) and incidence rates (B.) for eosinophilia by period for each viral inoculum.  
Significance between periods within groups represented by horizontal lines by ANOVA 
(p<0.05). 
 
infection.  In fact, prevalence for macrocytosis was absent in both control and SIV infected 
macaques with low prevalence rate comparisons for microcytosis, thus MCV changes were 
considered inconsequent to SIV infection.  
 Platelet count and TCP were significantly different between controls and SIV infected 
macaques indicating thrombocytopenia was a relevant hematologic abnormality during SIV 
infection. TCP prevalence was low compared to other hematologic abnormalities and early time 
periods were less likely to manifest this anomaly with highest incidence and prevalence in AIDS 
for all three inoculums.  Similar to anemia, TCP was not observed in SIVmac infected RM 
during period 3. 
A significantly low neutrophil count in SIV infected macaques compared to controls was 
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SIV infected macaques compared to controls.  Multiple causes could not be discounted for 
neutrophilia such as epinephrine-mediated physiologic neutrophilia, corticosteroid-induce stress 
neutrophilia, and  inflammation (Smith Graham S. 2000).  Therefore neutrophilia was regarded 
as equivocal in this study for SIV disease.  Neutropenia, however, may be observed during 
periods of increased tissue demand/ destruction or due to reduced bone marrow production or 
acute inflammation.  Absence of neutropenia in controls and occurrence post- SIV infection in 
all viral groups supported neutropenia to be a common hematologic event during SIV.  Most 
infected RM had detectable neutropenia prior to AIDS.   
Lymphocyte count during SIV was significantly lower compared to controls observed as 
the highest prevalence for a hematologic abnormality during SIV infection.  Lymphopenia was a 
hallmark hematologic abnormality in all SIV periods for all viral inoculums whereas only one 
RM in AIDS inoculated with SIVB670 was detected with lymphocytosis (1 event from 557 
CBCs) indicating this event to be rare.   
The likelihood of circulating monocytes to be elevated or decreased during SIV infection 
was similar by prevalence rates (near 50%) resulting in minimal absolute count differences from 
controls.  We interpreted monocyte count shifts to be non-conclusive during SIV infection even 
though significant prevalence differences were noted for prevalence by group and period.   
Even though only an increased trend for eosinophilia in SIV infected macaques compared 
to controls was noted, the high prevalence of eosinophilia in SIV infected macaques compared to 
controls indicated a relevant change during progressive SIV infection.  Parasite data was 
evaluated to determine if parasitism alone could account for the eosinophilia. Rare parasite fecal 
direct smear and flotation results were available during progressive SIV infection, that included 
all AIDS diagnoses, with at least one RM evaluated per period.  Only two controls had fecal 
43 
 
evaluation on the day of CBC collection.  Intestinal parasites (roundworms and protozoa) were 
detected on all fecal analyses for two SIVmac239 infected RM, two SIVmac251 infected RM, 
and seven SIVB670 infected RM plus the two controls.   However, one SIVmac239 infected RM 
had only 3 of 4 fecal results positive for parasites and 1 fecal examination negative at 362 DPI.  
Parasitism could not account for the eosinophilia alone so this hematologic abnormality was 
considered pertinent to SIV. 
Basophil granulocytes represented <1% of total circulating cells indicating shifts would 
minimally impact total WBC and may be difficult to discern as a specific change in SIV disease.   
Basophil count and basophilia prevalence in SIV infected macaques was significantly lower than 
in controls.  Consequently, basophilia was considered an unremarkable event during SIV 
infection.   
Overall, prevalences in SIV infected RM from our study mirrored prevalences in HIV 
patients exclusive of AIDS related therapies.  Fairly consistent characterization of hematologic 
abnormalities were found in HIV cohorts with the note that anemia was determined by 
hemoglobin concentration that varied by sex and global location.  HIV patients naïve to ART, 
chemotherapy, radiation therapy, or anti-microbials by self-declaration and/or preceding 
enrollment in clinical trials were found with the following frequencies of hematologic 
abnormalities: anemia 10-95%; TCP 10-83%; lymphopenia 64%; neutropenia 17-40%; and 
eosinophilia 3%  (Adediran 2006; Alaei 2002; Babadoko 2008; Erhabor 2005; Malyangu 2000; 
Marroni 1995; Moore 1998; Mugisha 2008; Peltier 1991; Sa 2007; Sloand 1992; Walsh 1985).  
AIDS patients naïve to antiretroviral therapy displayed frequencies of 30-88% anemia, TCP 16-
66%, lymphopenia 31-83%, neutropenia 8-29%, eosinophilia 23% (Adewuyi 1999; Murphy 
1987; Spivak 1984; Zon 1987) which was similarly represented in our prevalence of SIV 
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infected RM with AIDS.  Lower values were noted for earlier stages of HIV disease as 6-40% 
anemia, TCP 0-20%, lymphopenia 15-30%, neutropenia 0-30%, eosinophilia 16-18% (Adewuyi 
1999; Murphy 1987; Zon 1987).  Comparative non-AIDS stages in the RM of this study revealed 
anemia, TCP, lymphopenia, neutropenia, and eosinophilia were all lower than in macaques in 
AIDS with the exception of neutropenia which revealed minimal differences.   
We observed significant differences between macaques infected with different strains of 
virus. The RM SIV model using three different strains allowed hematologic abnormalities in the 
AIDS population to be evaluated according to progression of infection.  SIVmac239 infected RM 
had the highest incidence and prevalence for lymphopenia and neutropenia.  SIVB670 inoculated 
RM had the highest incidence and prevalence for anemia and TCP.  SIVmac251 diseased RM 
had the highest incidence and prevalence for eosinophilia.  The choice to compare three SIV 
inoculum groups in this retrospective study was to mimic biological variability of HIV strains in 
the human population.  HIV-1 group M and SIVsm lineages share molecular methods of 
diversification (Apetrei 2005; Apetrei 2004).  Natural infections of Sooty mangabey monkeys 
with SIVsm housed at primate centers in the United States were the origin for SIVmac and 
SIVB670 viruses (Apetrei 2005).  However, SIVB670 and SIVmac251 represent distinct 
lineages (Apetrei 2005).  Therefore, SIVmac239, SIVmac251 and SIVB670 inoculated RM may 
reflect demographics of HIV infection in viral diversification, and thus affect hematologic 
abnormalities.  In our study of SIV infected RM, slow progressors devoid of therapeutic 
intervention defined explicitly the incidence and prevalence and observance of hematologic 
parameters during untreated HIV disease.   
The retrospective database investigation of natural SIV disease progression in Rhesus 
macaques revealed prevalence of hematologic abnormalities during progressive SIV infection in 
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Macaca mulatta that mirrored progressive HIV infection in Homo sapiens.  These results suggest 
that, like in HIV infection, lymphopenia, anemia, thrombocytopenia, and neutropenia are major 
complications of progressive SIV infection.  Advantages of the Rhesus macaque model for 
studies of HIV pathogenesis allow the researcher to control for variables including antiretroviral 
drug therapy, sexual preference/lifestyle, socio-economic strata, and recreational drug use, 
hemophilia, and blood transfusion, duration of infection, diet, and race.  However, in our study, 
SIV inoculum and stage of infection were significant determinants of several hematologic 
abnormalities suggesting the strain of virus and chronicity of disease may be important in the 
development of certain hematologic disorders in HIV infection.   
SUMMARY 
 
Studies of hematologic abnormalities in HIV infected patients are confounded by a 
multitude of factors such as unknown duration or strain of viral infection, sexual activity, drug 
usage, race, geography (i.e. endemic disease, availability of healthcare), chronic 
conditions/diseases including multiple infections, and diet (i.e. iron availability). A retrospective 
data analysis of SIV infected Rhesus macaques of Indian origin was performed at the Tulane 
National Primate Research Center to determine the prevalence of hematologic abnormalities 
without the effect of anti-retroviral therapy, lifestyle, diet, or race.  Hematologic data from RM 
inoculated with SIV and without antiviral therapy or vaccination from 1987-2006 was collected 
pre-inoculation and during development of AIDS were studied.  Anemia, thrombocytopenia, 
lymphopenia, eosinophilia, and neutropenia increased in prevalence with progression of SIV 
disease, but some variances were noted with different SIV strains and during different periods of 
progressive SIV infection.  Concordance of hematologic abnormalities during progressive SIV 
infection to similar changes in HIV disease suggest that, like in HIV infection of humans, 
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hematologic abnormalities are major complications of SIV infection and that such hematologic 
abnormalities are often attributed to SIV infection alone rather than intervening therapeutic 
regimens. Additionally, this study confirms the SIV Rhesus macaque model to study 
hematologic and bone marrow changes during HIV disease.  
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CHAPTER 4:  BONE MARROW CHANGES EARLY AND LATE 
DURING SIV INFECTION 
 
INTRODUCTION 
 
Detection of changes in erythrocytes, platelets, and leukocytes as anemia, 
thrombocytopenia, and neutropenia respectively during SIV and HIV infection reflect, likely, 
alterations in bone marrow hematopoiesis (Chapter 3).  Geller et al. in 1985 initially defined a 
BM pattern pathognomonic for AIDS, prior to identification of HIV as causative agent (Geller 
1985).  This pattern was defined as granulocytic left shift and hyperplasia, including eosinophils, 
and erythroid hypoplasia with an increased M:E ratio.  In addition, the hypercellular marrow 
included megakaryocytic hyperplasia, lymphocytic infiltration, and evidence of fibrosis.  Studies 
over time have determined the marrow to be more variable than Geller first observed and without 
a pathognomonic pattern.  However, BM studies of HIV infected patients are complicated by 
inconsistent defined stages of disease (e.g. AIDS related complex or ARC, symptomatic, “pre-
AIDS”), classifications of AIDS (e.g. total CD4+ count, opportunistic infection, neoplasia), 
erratic report for anti-microbial or ART, variable methods of BM collection (e.g. aspirate, 
biopsy, ante-mortem, post-mortem), and divergent morphologic characterization of BM which 
makes patterns of disease and comparisons difficult to interpret (Thiele 1992). 
The objective of this study was to examine bone marrow changes during progressive SIV 
infection in subjects devoid of ART or any pharmacoligic intervention, including vaccination, for 
comparison with HIV patients.  Our earlier study of SIV infection revealed hematologic 
abnormalities were present in primary pathogenesis studies uncomplicated by drug therapy, diet, 
lifestyle, and economic factors present in populations of HIV patients (Chapter 3).  We 
hypothesized bone marrow disruption from a steady state environment would be present during 
progressive stages of SIV disease identified by time post-infection and detection of clinical 
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disease, but variable for hematopoietic cell lineages, consistent with the observed hematologic 
abnormalities.  We also hypothesized bone marrow morphologic assessment during SIV would 
mirror HIV as did hematologic abnormalities.  Morphologic assessment of bone marrow tissue 
for changes in nucleated cells, iron storage, and fibrosis along with phenotype of hematopoietic 
stem cells was performed  to elucidate evidence of bone marrow dysregulation as foretold by the 
common occurrence of hematologic abnormalities.   
MATERIAL AND METHODS 
Experimental Database II 
 
Experimental database and definitions are described in Appendix II.   
Hematologic Data and Definitions 
 
Hematologic data and definitions are described in Appendix I.   
Plasma Viral Load 
 
Plasma viral loads and definitions are described in Appendix IV.   
 
Flow Cytometry Analysis 
 
Whole blood and BM tissue collection, flow cytometry analysis, and definitions are 
described in Appendix III.   
Flow cytometry was performed to identify CD34+ HSC in WB and BM.  CD34-PE 
(Clone 563) monoclonal antibody for surface staining from BD Biosciences (San Jose, CA) was 
utilized to detect HSC.  HSC were identified by CD34 versus (vs.) side scatter (SSC) plot gating 
in a parent gate (Figure 4.1).   
Bone Marrow Morphologic Assessment 
 
Five µm sections of paraffin-embedded formalin fixed bone marrow tissue were 
processed and special stains applied for examination of each tissue.  A blinded evaluation by one 
microscopist of random, non-touching fields using a Zeiss Axiostar Plus microscope (Zeiss; 
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Thornwood, NY) was performed.  Representative photographs of inspected fields at the 20X 
objective from Leica DMLb microscope (Leica; Bannockburn, IL) using Spot Insight color 
camera and Spot Imaging Software (Diagnostic Instruments; Sterling Heights, MI) were 
collected and scored. 
     A.                                          B.                                           C. 
                 
 
Figure 4.1. Identification of hematopoietic stem cells by flow cytometry gating 
Determination of CD34+ hematopoietic stem cells (HSC).  A. Lymphocyte gate of whole blood 
by FSC versus SSC plot.  B. Multilineage gate of bone marrow including lymphocytes by FSC 
versus SSC plot.  C. Gate of interest by CD34 versus SSC plot within the parent gate identified 
CD34+ HSC. 
 
Bone Marrow Cellularity and Bone Marrow Megakaryocyte Numbers 
 
Routine hematoxylin and eosin (H&E) stain was applied to marrow tissue. Each field was 
subjectively graded using the 10X objective or microscopic low power field (lpf) for mean 
percentage of bone marrow cellularity in relation to adipose tissue over 20 fields (Table 4.1 and 
Figure 4.2).  Conjointly, megakaryocytes were counted in the same fields to obtain the mean 
megakaryocyte number per lpf.   
Bone Marrow Nucleated Lineage Cell Ratio 
 
Periodic Acid Schiff (PAS) stain was applied to BM tissue.  A 300 nucleated cell 
differential count was performed to count populations of cells based on morphologic appearance 
and PAS staining.  Cells were counted as PAS positive myeloid lineage cells (granulocytic and 
monocytic lineage excluding lymphocytes and macrophages) or PAS negative erythroid lineage  
S
S
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S
S
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S
S
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52 
 
 
Table 4.1. Grade of Bone Marrow Cellularity 
 
Grade % Cellularity of Field 
0 0 
1 1-5 
2 6-24 
3 25 
4 26-49 
5 50 
6 51-74 
7 75 
8 76-89 
9 90-99 
10 100 
 
 
 
 
Figure 4.2. Images of bone marrow tissue cellularity by grade 
Photomicrographs of hematoxylin and eosin stained bone marrow tissue representing cellularity 
by grade or percentage of nucleated cells (Table 4.1).  A. Grade 1 or 1-5% cellularity (macaque 
R908).  B. Grade 2 or 6-25% cellularity (macaque L880).  C. Grade 8 or 76-89% cellularity 
(macaque AP53).  D. Grade 9 or 90-99% cellularity (macaque R544).  Field represents a 10X 
objective image (100X) on a Leica DMLb microscope (Leica; Bannockburn, IL) using Spot 
Insight color camera and Spot Imaging Software (Diagnostic Instruments; Sterling Heights, MI). 
 
 
D. 
 
C. 
A. B. 
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cells.  Plasma cells and cells of the megakaryocytic lineage were also excluded.  Sections were 
evaluated using the Olympus BX41 microscope (Olympus; Center Valley, PA) at 100X oil 
immersion objective with a minimum of 3 fields observed.  The M:E ratio was calculated. 
Bone Marrow Iron Store 
 
Gomori‟s iron stain was applied to marrow tissue sections. Marrow sections were 
subjectively graded for stainable iron in marrow particles at the 20X objective for the degree of 
iron staining over 7 fields as mean marrow iron stores per field (Table 4.2 and Figure 4.3) (Gale 
1963; Stuart-Smith 2005).   
Table 4.2. Grade of Bone Marrow Iron Storage  
 
 
 
 
 
 
 
 
Bone Marrow Lymphocyte Aggregates  
 
H&E stained marrow sections were graded using the 10X objective to determine the 
number of bone marrow lymphocyte aggregates (BMLA) in 10 lpfs as a measure of the degree of 
lymphocytic infiltration (Table 4.3).  Morphologic evaluation of the lymphocyte aggregates was 
performed. 
Bone Marrow Fibrosis 
 
Gordon and Sweet‟s reticulin stain for type III collagen in marrow stroma was applied to 
marrow tissue sections.  Sections were subjectively graded at the 20X magnification for the 
degree of intercellular reticulin staining over 7 fields as measure of marrow fibrosis per tissue 
(Table 4.4 and Figure 4.4) (Thiele 2005).   
 
Grade  Description 
0 Absent or not visible  
1 Small particles visible, normal minimal  
2 Large particles visible, normal adequate 
3 Dense clumps visible, moderate to high 
4 Large deposits visible, excessive 
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Figure 4.3. Images of bone marrow tissue iron content by grade 
Photomicrographs of Gomori‟s iron stained bone marrow tissue representing iron content (blue 
staining) by grade (Table 4.2).  A. Grade 0 or absent iron stores (macaque AV63).  B. Grade 1 or 
normal iron storage (macaque AJ79).  C. Grade 2 or mild iron storage (macaque AP53).  D. 
Grade 3 or moderate iron storage (macaque I553).  Field represents a 20X objective image 
(200X) on a Leica DMLb microscope (Leica; Bannockburn, IL) using Spot Insight color camera 
and Spot Imaging Software (Diagnostic Instruments; Sterling Heights, MI). 
 
 
Table 4.3. Grade of Bone Marrow Lymphoid Aggregates 
 
Grade  Description 
0 Absent 
1 Minimal to Mild, 1 follicle in 10 fields  
2 Moderate, 2-4 follicles in 10 fields 
3 Severe, > 5follicles in 10 fields 
 
 
Table 4.4. Grade of Bone Marrow Fibrosis  
 
 
 
  Grade Description 
0 Minimal , normal 
1 Mild 
2 Moderate with minimal bundles 
3 Excessive with moderate bundles 
A. B. 
C. D. 
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Figure 4.4. Images of bone marrow tissue fibrosis by grade 
Photomicrographs of Gordon and Sweet‟s stained bone marrow tissue representing fibrosis by 
grade as black staining (Table 4.4).  A. Grade 0 or minimal fibrosis, normal (macaque L750).  B. 
Grade 1 mild fibrosis (macaque BI58).  C. Grade 2 moderate fibrosis with minimal bundles 
(macaque L164).   D. Grade 3 or excessive fibrosis with moderate bundles (macaque CB74).  
Field represents a 20X objective image (200X) on a Leica DMLb microscope (Leica; 
Bannockburn, IL) using Spot Insight color camera and Spot Imaging Software (Diagnostic 
Instruments; Sterling Heights, MI). 
 
 
Statistical Analysis 
 
For data evaluation, controls were non-SIV infected macaques and SIV infected subjects 
were grouped into periods defined as early and chronic based on disease progression as chronic 
asymptomatic SIV disease (ASY), chronic advanced SIV disease (ASD), and AIDS (Appendix 
II).   Macaques developing AIDS were slow progressors at >260 DPI. 
Statistical analyses were performed using non-parametric tests.  Differences between the 
control group and each infected RM group for mean grade of BM morphologic assessments were 
A. B. 
C. D. 
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examined statistically using the one-sample t test (GraphPad Software; San Diego, CA) where 
the mean of the control RM served as the theoretical mean.  Mean prevalence CBC data were 
examined statistically between the control group and each infected RM group using the Kruskal-
Wallis one way analysis of variance (ANOVA) analysis (GraphPad Software).   Differences 
between the control group and each infected RM group for hematologic data and phenotypic 
assessment were examined statistically using the Mann Whitney t test in GraphPad Prism 
(GraphPad Software).  Correlations were compared using Spearman correlation coefficients 
(GraphPad Software).  The mean of the data was represented in graphic illustration by phase of 
infection with the standard error of the mean (SEM) presented by the error bars.  All 
comparisons were considered significant at p ≤0.05. 
RESULTS 
 
Bone Marrow Cellularity During SIV Infection 
 
One RM in the control group was not represented in BM morphologic analyses due to 
lack of detectable BM tissue in paraffin blocks (H741).  One control had a hypocellular marrow 
and decreased M:E ratio attributed to decreased myeloid cells and increased erythroid cells 
(R534).  A moderate correlation was detected between BM cellularity and BM M:E ratio 
(Spearman r =0.6032, p=0.0011). 
Early in SIV infection, marrow cellularity was minimally changed from the control 
group, with no significant change to the M:E ratio (Figure 4.5).  Macaques within the early 
period of SIV infection were 3/10 with a hypercellular marrow: 2 RM with unchanged M:E ratio 
(BI58, CB74) and 1 macaque as a decreased M:E ratio attributed to erythroid hyperplasia in 
response to anemia and myeloid hypoplasia (BN37).  Only 1/10 macaques during the same 
period had an increased M:E ratio attributed to increased granulocytic cells, normocellular  
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   A.                                                                     B.
 
Figure 4.5. Comparison of bone marrow cellularity and M:E ratio during SIV infection 
Evaluation of control and SIV infected subjects by period of infection for bone marrow 
cellularity and myeloid to erythroid (M:E) ratio.  A. Mean bone marrow cellularity by grade.  B. 
Mean bone marrow M:E ratio.  C.  Myeloid component of M:E ratio by percentage of cells in 
bone marrow.  D.  Erythroid component of M:E ratio by percentage of cells in bone marrow.  
Comparisons between control cohort and each period of infection for cellularity and M:E ratio 
were determined by one sample t test (***p<0.01).  Periods of SIV infection were early, chronic 
asymptomatic SIV disease (ASY), chronic advanced SIV disease (ASD), and AIDS.  Grey lines 
represent means + SEM. 
 
 
 
 
 
Bone Marrow Cellularity
C
O
N
TR
O
L
E
A
R
LY
A
S
Y
A
S
D
A
ID
S
0
2
4
6
8
10
G
ra
d
in
g
 S
c
a
le
Bone Marrow M:E  Ratio
C
O
N
TR
O
L
E
A
R
LY
A
S
Y
A
S
D
A
ID
S
0
1
2
3
4
%
Bone Marrow Myeloid of M:E Ratio
C
O
N
TR
O
L
EA
R
LY
AS
Y
AS
D
AI
D
S
0
20
40
60
80
100
%
 C
e
lls
Bone Marrow Erythroid of M:E Ratio
C
O
N
TR
O
L
EA
R
LY
AS
Y
AS
D
AI
D
S
0
20
40
60
80
100
%
 C
e
lls
C. 
D. 
58 
 
marrow, and neutropenia (BA17). One macaque had a hypocellular marrow and unchanged M:E 
ratio (BV13).  A trend for hematologic abnormalities was noted in this phase (Table 4.5).  Three 
macaques in this time period were not evaluated for cellularity or M:E ratio due to poor cellular 
preservation of marrow tissue sections (C419, L880, and T139).   
Table 4.5. Prevalence Rate of Hematologic Abnormalities by Phase of SIV Disease 
 
  Control (%) Early (%) 
Asymptomatic 
SIV Disease (%) 
Advanced SIV 
Disease (%) AIDS (%) 
Anemia 0 20 14 67**** 63 
Thrombocytopenia 0 0 14 83**** 25 
Neutropenia 0 50 71**** 33 13 
Neutrophilia 0 20 0 33 30 
Lymphopenia 50 60 71 67 100 
Eosinophilia 25 0 14 0 13 
****Significance p≤0.05 when compared to control cohort by ANOVA analysis  
 
 
The M:E ratio of BM remained unchanged until decrease during the asymptomatic (ASY) 
period that paralleled a decrease in marrow cellularity and peak neutropenia (p<0.05).  Only 1/7 
ASY period macaques had a hypercellular marrow with decreased M:E ratio attributed to 
increased erythroid cells (DE09).  One macaque in this period had a hypocellular marrow but the 
M:E ratio was not evaluated (DB53).  In the ASY period, 4/7 had a normocellular marrow.  This 
included 2/4 with low M:E ratio attributed to decreased myeloid cells and increased erythroid 
cells (BV74) and neutropenia (DI28);  1/4 with anemia, thrombocytopenia, neutropenia and 
decreased M:E ratio attributed increased erythroid cells (N998); and 1/4 with increased M:E 
ratio, increased myeloid series, decreased erythroid series, and neutropenia (CF35).  Additionally 
in the ASY phase, neutropenia prevalence peaked and TCP was observed which was also present 
in later stages of SIV.  One macaque was not evaluated for marrow cellularity or M:E ratio due 
to minimal BM tissue in the formalin block (R908).   
In the advanced SIV disease (ASD) period, cellularity of BM started to increase above 
non-infected levels as 50% macaques had a hypercellular BM: 2/3 with unchanged M:E ratios 
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and neutrophilia with anemia (AP53) and neutrophilia with TCP (BD78);  1/3 with increased 
M:E ratio attributed to increased granulocytic cells and decreased erythroid cells with anemia 
and TCP (BE64).  One macaque had an unchanged marrow cellularity with a decreased M:E 
ratio characterized by decreased granulocytic cells and increased erythroid cells and neutropenia 
(CD95).  One macaque had a hypocellular marrow with an unchanged M:E ratio and neutropenia 
(V205).  Concurrently in ASD, as neutropenia prevalence dropped, neutrophilia and 
thrombocytopenia (p<0.05), and anemia (p<0.05) increased to peak prevalence (Table 4.5).   
The apex of BM cellularity was in AIDS macaques with ~ 1.5X increase above the 
cellularity of controls (p<0.01).  None of the AIDS macaques had decreased marrow cellularity, 
as was observed in previous periods, though 1 had an unchanged marrow cellularity and anemia 
(BA25).  The M:E ratio of macaques in AIDS was similar to control macaques with only 1 
macaque detected with an increased M:E ratio characterized by an increase in granulocytic cells 
greater than the rise in erythroid cells (P045).  One macaque was not evaluated for BM 
cellularity or M:E ratio due to observation of BM amyloid (I553).  Two other macaques were not 
evaluated for M:E ratio due to poor PAS staining (R544, T798). 
Hematopoietic CD34+ Stem Cells in During SIV Infection 
 
CD34+ hematopoietic stem cells were detected in bone marrow and blood (Figure 4.6).  
Circulating stem cells were increased in the early period (p<0.001) (Figure 4.7).  In marrow, only 
the early and asymptomatic periods showed an increased trend of HSCs.  The highest marrow 
percentage of stem cells was noted in the ASY period as total BM cellularity was the most 
depressed.   Significant correlations were not detected between BM CD34 percentages and BM 
cellularity or BM M:E ratios. 
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Figure 4.6. Hematopoietic stem cell identification 
Phenotypic representation of CD34+ hematopoietic stem cell dot plots for the control cohort 
defined by flow cytometry gating (Figure 4.4).  Upper panel is whole blood (WB).  Lower panel 
is bone marrow (BM). 
 
 
 
Figure 4.7. Comparison of hematopoietic stem cells during SIV infection 
Percentage of CD34+ hematopoietic stem cells within the parent gate as shown in figure 4. 6 for 
blood (A.) or bone marrow (B.) in SIV infection.  Comparison of control cohort and each period 
during SIV infection by Mann Whitney t tests (***p<0.01).  Periods of SIV infection were early, 
chronic asymptomatic SIV disease (ASY), chronic advanced SIV disease (ASD), and AIDS.  
Grey lines represent means + SEM. 
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Bone Marrow Megakaryocytes During SIV Infection 
 
The mean of the platelet concentration was lower in the early phase compared to controls 
without evidence of TCP and megakaryocyte hyperplasia was noted in 2 macaques (BI58, BN37) 
(Figure 4.8).  Megakaryocytes were decreased in the ASY group, from the earlier phase, 
including 2 megakaryocytic hyperplastic and 1 hypoplastic macaques.  TCP was present in the 
ASY phase in 1 macaque.  During the ASD phase megakaryocytes were increased in BM 
(p<0.05), with an almost double compared to the control group.  TCP prevalence rates peaked at 
83% (p<0.001) in the ASD group, observed as 1/5 mildly TCP macaque with megakaryocyte 
hypoplasia (V205), and 4/5 were severely TCP.  The four macaques with TCP included 2/4 with 
adequate megakaryocytes (BD78, L164), 1/4 with low megakaryocytes (CD95), and 1/4 with 
increased megakaryocytes (BE64).  One macaque in the ASD group had BM megakaryocyte 
hyperplasia without TCP (AP53).  Nearly 3X as many megakaryocytes compared to controls 
were present in 5/6 AIDS macaques including 1/6 with mild TCP (BE65), 1/6 with moderate 
TCP (R544), and 3/6 with adequate platelet concentrations (AE55, BI33,  PO45, T798).   Only 1 
AIDS macaque was not observed with megakaryocyte hyperplasia (BA25).  BM megakaryocyte 
positively correlated with BM cellularity (Spearman r =0.8239, p<0.0001) but not platelet count.  
Megakaryocytes were not identified with dysplastic changes and always were intact with multi-
lobulated nuclei.   
Bone Marrow Iron Content During SIV Infection 
 
Iron content of marrow was adequate in controls without observance of anemia (Figure 
4.9).  Anemia of macaques post-infection was non-regenerative based on absence of a peripheral 
reticulocytosis.  Depleted iron content in 9/10 macaques (p<0.0001) in the early period, when a 
decreased hematocrit (p<0.05) was also noted.   During the early period, 2/9 macaques displayed  
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A.                                                                B. 
  
Figure 4.8. Comparison of megakaryocyte number and platelet count during SIV infection 
Evaluation of control and SIV infected subjects by period of infection for bone marrow 
megakaryocyte number and CBC platelet count.  A. Mean megakaryocyte count of bone marrow 
per low power field.  B. CBC platelet count with thrombocytopenia represented as values below 
blue horizontal line.  Comparisons between control cohort and each period of infection for 
megakaryocyte numbers was determined by one sample t test and platelet counts by Mann 
Whitney t test (****p<0.05).  Periods of SIV infection were early, chronic asymptomatic SIV 
disease (ASY), chronic advanced SIV disease (ASD), and AIDS.  Grey lines represent means + 
SEM. 
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A.                                                            B.                                                
 
 
Figure 4.9. Comparison of bone marrow iron content and hematocrit value during SIV 
infection 
Evaluation of control and SIV infected subjects by period of infection for grade of bone marrow 
iron content and CBC hematocrit value.  A. Subjective grade of bone marrow iron content.  B. 
Hematocrit value with anemia represented as values below blue horizontal line.  Comparisons 
between control cohort and each period of infection for iron content was determined by one 
sample t test and for hematocrit values by Mann Whitney t test (*p<0.0001, **p<0.001, and 
****p<0.05).  Periods of SIV infection were early, chronic asymptomatic SIV disease (ASY), 
chronic advanced SIV disease (ASD), and AIDS.  Grey lines represent means + SEM. 
 
 
a normocytic normochromic anemia consistent with AIRD (BI58, BN37).  In the ASY period, 
anemia prevalence decreased from 20% to 14%, as 1/7 macaques showed normocytic 
normochromic anemia and Grade 1 BM iron content (N998).  In the asymptomatic phase, 2/7 
macaques lacked anemia but had decreased BM iron stores (BV74, DI28).  Anemia prevalence 
tripled to 67% (p<0.05) in the ASD period with minimal changes in BM iron content from the 
ASY phase.  Infected macaques in ASD revealed 4/6 had Grade 0 BM iron content but only 2/4 
showed a normocytic normochromic anemia (CD95, L164) and 2/4 were not anemic (BD78, 
V205).  One macaque in this period had increased marrow iron content and microcytic 
hypochromic anemia (AP53) and one macaque had normal iron content with microcytic 
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normochromic anemia (BE64).  Anemia prevalence (63%) and BM iron storage did not change 
in AIDS with 3/8 having a normocytic normochromic anemia and decreased iron content (AE55,  
BE65, R544) and 2/8 macaques with a normocytic normochromic anemia and adequate iron 
storages suggestive of ACD (BA25, T798).  The remaining 3/8 macaques were not anemic, and 
1/8 had low BM iron (BI33); 1/8 with adequate BM iron (P045); and 1/8 had increased BM iron 
(I553).  Microscopically, erythroid dysplasia was not observed in the marrow of any macaques.   
Anemia was not associated with AIDS diagnosis.  A low correlation was noted between BM iron 
storage and BM M:E ratio (Spearman r =0.4663, p=0.0041).  A correlation was not present 
between bone marrow iron stores and BM cellularity, mean cell hemoglobin concentration 
(MCHC), mean cell volume (MCV), or HCT.           
Lymphoid Aggregates in Bone Marrow During SIV Infection 
 
Lymphocyte aggregates were observed in cellular areas of BM, but were not defined 
follicles with germinal centers, similar to described patterns of poorly defined aggregates in 
random distribution by Shenoy and Lin, and Delacrétaz et al. (Delacrétaz 1987; Shenoy 1986).   
    BMLA Grade 1 composed of mature small lymphocytes was considered a normal finding, 
therefore BMLA Grade 1 composed of variably sized lymphocytes or BMLA Grade 2 and higher 
were considered abnormal morphologic findings.   
BMLA were increased in number during the early period (p<0.05) with variable 
morphologic sizes (Table 4.6).  Highest grades of BMLA were observed in AIDS macaques also 
with different morphologic sizes.  Lymphoid neoplasia, plasma cells, and atypical lymphocytes 
were not observed in BMLA or bone marrow sections examined.  BMLA grades were not 
correlated with the absolute lymphocyte concentration in blood. 
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Table 4.6. Bone Marrow Lymphoid Aggregates (BMLA) during SIV infection 
 
Subject 
Identification 
Phase of SIV Disease,  
Histologic Diagnosis 
Age 
years, 
Necropsy 
BMLA 
Grade  
Lymphocyte 
Population, 
Size 
Histiocyte 
Population 
EH70 Uninfected 3 1 >95% Small <5% 
AV85 Early 8 2 >90% Small <10% 
BA17 Early 8 2 ~50% Variable ~50% 
BI58 Early 3 2 ~50% Variable ~50% 
BN37 Early 2 2 >95% Small <5% 
C419 Early 20 1 >90% Small <10% 
BV74 ASYa 5 1 >90% Small <10% 
CD95 ASDb, Right heart failure 8 2 >90% Small <10% 
L164 ASDc, Colitis 13 1 >90% Small <10% 
BE65 AIDS, Mycobacterium avium 6 1 ~50% Large ~50% 
R544  AIDS, Meningoencephalitis 9 3 >90% Small <10% 
T798 AIDS, Mycobacterium avium 9 2 ~90% Large ~10% 
a) ASY = asymptomatic SIV disease; b) ASY = asymptomatic SIV disease; c) ASD = advanced SIV disease  
 
 
Bone Marrow Fibrosis During SIV Infection 
 
Marrow fibrosis was not detected in non-infected RM or in the ASY period (Figure 4.10).  
Marrow fibrosis was noted in almost 50% of RM in other periods of SIV infection with peak in 
the early phase (p<0.05).  Reticulin staining of marrow was focally located and linear in 
appearance yet not associated with lymphoid follicles or blood vessels.   
DISCUSSION 
 
Our findings of increased BM cellularity in 26% of non-AIDS macaques, 50% ASD, and 
86% of AIDS macaques were higher than reports of 16% hypercellular marrow in HIV infected 
non-AIDS patients (Tripathi 2005), 31% symptomatic non-AIDS HIV patients (Namiki 1987; 
Sun 1989), and 18-50% HIV AIDS patients (Namiki 1987; Ricci 1995; Sun 1989; Tripathi 
2005).  Although conceivable, the SIV model could be an exaggeration of these changes, 
discrepancies in detection may occur due to lack of standardized categorization of infected 
subjects, or selection criteria in human studies, as described in the earlier chapter, may also make 
direct comparisons invalid.   
 
66 
 
 
Figure 4.10. Comparison of bone marrow fibrosis during SIV infection 
Evaluation of control and SIV infected subjects by period of infection for grade of bone marrow 
fibrosis.  Comparisons between control cohort and each period of infection for fibrosis was 
determined by one sample t test (****p<0.05).  Periods of SIV infection were early, chronic 
asymptomatic SIV disease (ASY), chronic advanced SIV disease (ASD), and AIDS.  Grey lines 
represent means + SEM. 
 
Here, we detected 42% of RM in the early phase of SIV infection with hypercellular BM 
consistent with findings of Mandell et al. of hypercellular bone marrow in 50% of early 
SIVmac239 infected RM (Mandell 1993).  Kitagawa et al. reported 46% of SIV infected RM 
with BM hypercellularity (Kitagawa 1991).  Baskin et al. reported 7/24 RM infected with 
hypercellular marrow in AIDS (Baskin 1988).  A few macaques in each group of our study were 
noted with a hypocellular BM except in the AIDS phase.  Delacrétaz identified megakaryo- and 
erythrodysplastic BM changes in HIV patients but noted these two conditions are easier to 
identify on plastic embedded specimens compared to detection of granulodysplastic changes 
(Delacrétaz 1987).  Myelodysplastic changes may be due to indirect or direct HIV infection, anti-
microbial or ART drugs, or secondary infections (Ryu 2001).  However, evidence of 
myelodysplasia was not identified in our study. 
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The BM morphologic M:E mean of the control group of macaques was 1.94+0.46 which 
was similar to reported reference intervals for RM at 0.86-1.91:1 (Huser 1970; Jain 1986; 
Stasney 1936; Switzer 1967).   In general we observed, a decreased M:E ratio due to BM cellular 
decline in granulocytic/monocytic lineage and an equal or greater cellular rise in erythroid 
lineage.  We observed an increased M:E ratio was attributed to increased BM 
granulocytic/monocytic cells and an equal or lesser relative drop in erythroid cells.  Post-
infection the lowest M:E ratio was 1.88 in the asymptomatic phase and the highest 2.076 in 
AIDS, all within the control study range means.  Nearly twice as many infected macaques (52%) 
were within the M:E control range than below (22%) or above the range (26%).  Similarly, 25% 
of SIV infected RM were noted with an increased M:E ratio (Kitagawa 1991).  Of note, in the 
ASY phase all macaques were outside the M:E control range with 4/5 below and 1/5 above and 
all AIDS macaques were within or above the control range M:E ratio.   Infected macaque M:E 
ratios were similar in distribution to M:E ratios of HIV patients with reports of normal 50-72 %, 
5-40% elevated, and 10-22% decreased (Castella 1985; Delacrétaz 1987; Ricci 1995). 
CD34+ circulating hematopoietic stem cells remained similar between control and SIV 
infected macaques in our study as supported by findings in HIV patients reported by Costantini 
et al (Costantini 2009; Marandin 1996).   Increases in BM CD34+ cells early in SIV infection 
were supported by findings in SIV infected RM by Hillyer et al (Hillyer 1993b).  Our finding of 
decreased marrow CD34+ HSC in later stages of SIV was supported by by SIV studies by 
Hillyer et al. and van Wely et al. but contrary to reports by Marandin et al. (De Luca 1993; 
Hillyer 1993b; Marandin 1996; van Wely 1993).    
Culture studies of BM CD34+ stem cells from HIV infected patients revealed decreased 
HSC in later stages with most effect noted in AIDS (Marandin 1996).  Steinberg et al. found 
68 
 
lower numbers of BM precursor cells when HIV was incubated with pure cultures of CD34+ BM 
HSC (Steinberg 1991).  In vitro growth of hematopoietic progenitor colonies was decreased from 
the BM mononuclear cells obtained in AIDS and symptomatic HIV patients (De Luca 1993; 
Leiderman 1987; Stella 1987), SIVmac infected RM (Watanabe 1990), and SHIV inoculated 
cynomolgus macaques within 21 DPI (Thiebot 2001).  Overnight incubation of HIV with human 
BM cells from non-HIV infected patients and depleted of accessory cells resulted in decreased in 
vitro growth of myeloid, erythroid, lymphoid, and CD34+ precursor cells (Steinberg 1991).  One 
theory proposed is that HIV progenitor cells may become infected with HIV but hematopoiesis is 
unlikely to be disturbed unless HIV antibodies suppress myelopoiesis (Donahue 1987; 
Leiderman 1987; Stella 1987).  CD34+ marrow HSC were shown to be infected wihtin HIV 
patients, in vivo (Carter 2010).   In vitro, CD34+ HSC sorted from bone marrow aspirates were 
incubated with HIV89.6 and 3 days later, infection of HSC was detected by Gag protein (Carter 
2010).  However, the lower percentage of HSC in SIV macaques in our study did not affect 
overall BM cellularity and megakaryocytes in AIDS macaques though prevalence of 
hematologic abnormalities increased over time.  In fact, BM cellularity was lowest in the ASY 
phase as percentage of HSC was highest.   
Mandell et al. reported 2/6 RM infected with SIVmac239, <14 DPI, displayed 
megakaryocytic hyperplasia (Mandell 1993) similar to our findings of 2/7 RM in the early phase 
of SIV infection.  Both the ASY and ASD phases of SIV infection were noted to have 2 
macaques with megakaryocyte hyperplasia and 1 macaque with megakaryocyte hypoplasia 
compared to the final phase with hyperplasia in 6/7 macaques. Higher numbers of 
megakaryocytes were noted in BM from HIV infected patients ranging from 33-78% (Castella 
1985; Khalil 1996; Ricci 1995; Shenoy 1986; Zucker-Franklin 1989) and 38% from SIV infected 
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RM (Kitagawa 1991). Megakaryocyte hypoplasia has been reported rarely in HIV patients 
(Castella 1985) and in 3 infected RM and 1 control RM in our study.  Denuded nuclei or 
hypolobulation and megakaryocytic emperipolesis have been observed in megakaryocytes of 
HIV patients (Gordon 1994; Karcher 1991; Khandekar 2005; Ricci 1995; Tripathi 2005; Zucker-
Franklin 1989) though not detected in our study.   
Correlations were not present between BM megakaryocytes, and platelet concentration, 
or mean platelet volume in our study.  Koenig et al. observed 92% of TCP HIV patients had low 
mean platelet volume and few non-TCP HIV patients had low mean platelet volume and 
theorized HIV had a direct effect on megakaryocytes to produce small platelets (Koenig 1991). 
Alternatively, Karcher and Frost identified a correlation between megakaryocyte hypoplasia and 
thrombocytopenia in HIV patients (Karcher 1991) and Castella et al. noted ~30% of HIV 
patients had adequate to increased megakaryocytes with concurrent TCP (Castella 1985).   
Megakaryocyte numbers were increased over the controls for all post-infection phases 
while blood platelet concentrations were decreased during the same time periods. With increased 
BM megakaryocytes, shown here, peripheral platelet counts would be expected.   Decreased 
megakaryocyte precursors have been reported in HIV patients with megakaryocyte hyperplasia 
indicating possible HIV effect on megakaryocytopoiesis possibly through ineffective production 
by direct infection or inhibitory cytokines (Cole 1998).   Thrombocytopenic HIV patients were 
observed with splenic sequestration of platelets, increased marrow megakaryocytes, ineffective 
marrow platelet production, shortened platelet life spans, and antiplatelet antibodies to 
glycoprotein IIIa (Cole 1998).  Autoantibody platelet production, elevated mean platelet volume 
or production of large platelets, absence of marrow megakaryocyte abnormalities, and 
appropriate marrow response to low platelet concentrations are hallmarks of immune mediated 
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TCP (Cole 1998; Harris 1990).  TCP may be due to marrow and peripheral mechanisms during 
HIV infection which could explain TCP and marrow findings of the SIV infected macaques in 
this study. 
A moderate positive correlation was found between BM cellularity and BM 
megakaryocyte numbers (Spearman correlation r=0.6439, p<0.0001) with both climaxing during 
AIDS.  A moderate positive correlation was noted between BM megakaryocytes and both BM 
fibrosis (Spearman correlation r=0.6439, p<0.0001) and iron storage (Spearman correlation 
r=0.6439, p<0.0001).  The megakaryocyte count showed a low positive correlation to the M:E 
ratio (Spearman correlation r=0.4459, p=0.0174) though peak in AIDS was absent.  Finally, 
megakaryocytes also positively correlated with BM lymphoid follicle hyperplasia though low 
(Spearman correlation r=0.3616, p=0.0387) without similarities in patterns.   
Anemia in SIV infected macaques was more severe in symptomatic versus asymptomatic 
macaques over controls in our study.  This was previously reported by Hillyer et al. findings of 
“well” versus “sick” SIV infected macaques (Hillyer 1993a).  Infected macaques in our study 
were not observed with histologic, CBC abnormalities, or erythrocyte morphologic changes 
supportive of hemolysis or bleeding or regenerative anemias.  Infected macaques displayed 
depleted BM iron stores at 53% and 13% displayed adequate to increased BM iron stores 
compared to HIV patients at 11-25% and 10-85% respectively (Castella 1985; Harris 1990; 
Karcher 1991; Khalil 1996; Sun 1989; Zhao 2004).    
Anemia of iron deficiency (AIRD) is characterized by absent BM iron stores and early in 
the condition is a normocytic normochromic anemia that progressively develops into a 
microcytic hypochromic anemia (Glader 2004).  Anemia of chronic inflammatory disease (ACD) 
is characterized by normal to increased BM iron stores and a normocytic normochromic anemia 
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(Glader 2004).  Anemia was absent in controls in this particular study, but detected in the early 
period and was consistent with AIRD by normocytic and normochromic profile and low marrow 
iron content.  During the ASY period, AIRD persisted but macaques also had normocytic 
normochromic anemia and Grade 1 BM iron content supportive of ACD, indicating mixed 
mechanisms for anemia were present, which may be related to stage of infection.  Non-
regenerative anemia, AIRD or ACD, was noted in our studies with occasional erythroid marrow 
hyperplasia and without marrow erythroid dysplasia.   Mixed mechanisms for anemia continued 
to be detected in the ASD and AIDS periods. 
Hillyer et al. observed regenerative anemias in infected macaques with diagnoses of 
autoimmune hemolytic anemias, increased to normal erythropoietin levels, BM erythroid 
hyperplasia, dyserythropoiesis, and decreased in vitro BFU-E colony formation (Hillyer 1993a).  
ACD is associated in humans with blunted erythropoietin levels (Khandekar 2005) which may 
not be the cause in SIV as Hillyer et al. found increased erythropoietin in SIV infected RM 
(Hillyer 1993a).  Multifactorial causes for anemia include destruction of erythrocytes, folic 
acid/B12 deficiencies, decreased BM erythroid stem cells, cytokine inhibition, iron deficiency, 
anti-microbial or ART drugs, or OI (Costantini 2009; de Monye 1999; Hillyer 1993a; Khandekar 
2005; Schneider 1985; Steinberg 1991; Thiebot 2001; Zhao 2004).  A retrospective study of BM 
iron content in 348 adult HIV patients revealed markedly increased grades were associated with 
low hemoglobin values, decreased survival time, BM dysplasia, and pneumocystis or 
mycobacterial infections (de Monye 1999).  Associations were not noted in our study with BM 
iron storage to CBC values, viral load, fibrosis, or AIDS diagnosis.  A study of AIDS patients 
observed high marrow iron content in HIV patients diagnosed with myocbacterial disease, 
Pneumocystis pneumonia, or candidiasis (de Monye 1999).  A positive correlation was noted 
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between BM iron storage and M:E ratio and based on our study,  hematocrit is not based on BM 
changes alone.  A negative low correlation was present between BM iron content and BMLA 
(Spearman correlation= -0.3418, p=0.0413). 
BMLA were detected during the early period (40%) as viral load crested then again in the 
final stage of AIDS (38%).   Our study results for BMLA were higher than 16% reported in SIV 
infected RM by Kitagawa et al. (Kitagawa 1991).  King et al. observed 3/16 SIV infected 
macaques in AIDS demonstrated lymphoid aggregates composed of small lymphocytes (King 
1983) compared to our 2/8 AIDS macaques Grade 1 or 2 BMLA composed of mostly large-sized 
lymphocytes, and 1/8 AIDS macaques with Grade 3 BMLA composed of small-sized 
lymphocytes.  In our study, both AIDS RM co-infected M. avium displayed BMLA accentuated 
with variable sized lymphocytes and histiocytes while AIDS RM co-infected with Pneumocystis 
spp did not have BMLA.  Personal communication from Dr. Peter Didier, TNPRC Anatomic 
Pathologist, noted he frequently found BMLA in AIDS RM diagnosed with M. avium (Didier 
2009).   
Our findings of lymphoid aggregates have been suggested by Karcher et al. as non-
specific HIV findings in BM caused by inflammation or immune stimulation, not OI or 
lymphoma (Karcher 1991).  BMLA composed of small mature lymphocytes have been reported 
in healthy younger humans while frequency increases with age (Castella 1985).  Geller et al. in 
1985 originally described the „AIDS pattern‟ of BM including defined clusters of large-sized 
lymphocytes (Geller 1985).  Further, Karcher et al. and others have documented most lymphoid 
aggregates of HIV patients by morphologic characteristics as poorly defined clusters of mostly 
small mature lymphocytes with few aggregates containing larger-sized lymphocytes occasionally 
with histiocytes (Castella 1985; Delacrétaz 1987; Harris 1990; Karcher 1991; Khalil 1996; 
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Shenoy 1986; Sun 1989; Zhao 2004).  Our study of SIV infected RM showed variable 
morphology with multiple lymphoid aggregates compared to small mature lymphocytes in single 
lymphoid aggregates per tissue.  Additionally, BM plasmacytosis was absent in our study though 
13-78% has been reported in HIV patients (Castella 1985; Delacrétaz 1987; Harris 1990; 
Karcher 1991; Khalil 1996; Shenoy 1986; Zhao 2004).  Finally, 0-37% BM lymphoma and 0-
15% BM Kaposi‟s sarcoma has been reported in HIV patients (Castella 1985; Delacrétaz 1987; 
Harris 1990; Karcher 1991; Khalil 1996; Shenoy 1986; Sun 1989; Zhao 2004) while these 
findings were not expected in our RM with prior reports of 0% and 0% respectively (Baskin 
2001). 
Myelofibrosis is increased connective tissue or collagen in bone marrow (Scott 2008).  
Myelofibrosis and disruption of stromal elements to support bone marrow homeostasis can lead 
to dysregulation of hematopoiesis (O'Malley 2005).  Marrow fibrosis may consist of reticulin 
fibrosis characterized by reticulin staining or collagen fibrosis characterized by collagen IV 
staining (Apaja-Sarkkinen 1986).  Reticulin staining exposes type III procollagen which is a 
component of the marrow extracellular matrix and identified by Gomori‟s reticulin stain (Apaja-
Sarkkinen 1986).  Fibrosis was present early (40%) and during symptomatic phases of SIV 
infection, 33% ASD and 37% AIDS, in macaques of this study.  Reticulin stain of BM from HIV 
patients ranged from 0-83% though the type of stain was not defined (Castella 1985; Delacrétaz 
1987; Harris 1990; Karcher 1991; Khalil 1996; Tripathi 2005).  Less than half of SIV infected 
macaques of our study displayed BM fibrosis in AIDS while O‟Malley at al. described 100% 
BM fibrosis in HIV AIDS patients by reticulin staining and minimal actin or collagen IV positive 
staining (O'Malley 2005).     
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BM fibrosis may be a non-specific HIV finding related more to inflammation or immune 
stimulation (Karcher 1991; O'Malley 2005), similar to lymphocyte aggregations in marrow of 
HIV infected patients.   However, here we demonstrated a low correlation between the 
occurrence of BMLA and fibrosis in marrow from SIV infected RM (Spearman correlation 
r=0.3662, p=0.0281).  Gelatinous transformation of marrow, another stromal abnormality of 
bone marrow, is defined by BM hypoplasia, BM adipose tissue atrophy, and extracellular 
gelatinous material (Alcian blue stain positive, PAS stain variable) seen in starving or cachectic 
people has been identified in 9-38% of HIV patients including reports of up to 100% AIDS 
patients (Delacrétaz 1987; Karcher 1991; Murugan 2007).  We observed 1 AIDS macaque with a 
hypercellular marrow and extracellular material Alcian blue stain positive attributed to amyloid 
(I553).   
Histiocytic infiltration of BM and evidence of phagocytosis have been reported in HIV 
patients but were not observed as the sole composition of aggregates or in increased numbers in 
this study (Harris 1990; Karcher 1991; Khalil 1996; Khandekar 2005; Sun 1989).  Granulomas 
were rarely indentified in BM of SIV infected macaques in this study but reported 12-35% in 
HIV patients often associated with the identification of fungi and acid fast bacteria by special 
stains (Castella 1985; Harris 1990; Khalil 1996; Shenoy 1986; Sun 1989; Zhao 2004). 
A common finding of marrow in HIV patients has been myelodysplasia (Karcher 1991).  
Myelodysplasia in HIV patients has been attributed to direct effect of marrow by HIV disease 
and drug therapy (Karcher 1991).   Criteria for diagnosis of myelodysplasia may be variable 
(Karcher 1991), but diagnosis is commonly made by microscopic evaluation of bone marrow 
aspirates that were not evaluated in this study.  Delacretaz et al. first reported myelodysplastic 
changes evident in de-calcified paraffin embedded formalin fixed bone marrow sections from 
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HIV infected patients (Delacrétaz 1987).  Future studies of bone marrow aspirates in SIV 
infected macaques may reliably detect myelodysplasia.   
Lymphopenia, anemia, thrombocytopenia, neutropenia, and neutrophilia occurred in RM 
following infection with SIV.  However, response of BM to increased or decreased peripheral 
cell changes could not be fully evaluated because all observations in this study observation were 
one-time evaluations.  CBC abnormalities during progressive SIV infection were consistent and 
supported the hypothesis that loss of bone marrow homeostasis contributes to the hematologic 
changes observed during progression to AIDS.  Hematologic abnormalities from this study were 
supported by the preceding serial CBC results of SIV infected RM (Chapter 3). 
Observed BM morphologic and phenotypic changes along with hematologic 
abnormalities during progressive SIV infection were characteristic of HIV disease and reports of 
HIV myelopathy.  Increased BM cellularity, myeloid and erythroid lineage shifts, fibrosis, iron 
depletion, and BMLA were observed morphologic changes during periods of SIV disease also 
reported in HIV patients.  Additionally, decline of BM HSC percentages in later stages of SIV 
were detected by phenotypic BM examination, and also consistent with HIV patients.  Our study 
verifies BM changes are evident during SIV infection and representative of progressive HIV 
disease.  Also, our study confirms SIV alone contributes to BM deviations from homeostasis 
regardless of therapeutic intervention, and that BM changes contribute to occurrence of 
hematologic abnormalities.   
SUMMARY 
 
Rhesus macaques inoculated with SIV without interventional drug or vaccine therapy 
were evaluated to fully assess changes in bone marrow from early to late stages of disease.  
Patterns of BM and hematologic changes were noted during progressive phases of SIV infection 
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defined by clinical signs and days post-inoculation.  SIV infected macaques in the early phase of 
infection with high viremia had BM changes including increased circulating and BM CD34+ 
hematopoietic stem cells, BM iron depletion, increased BM lymphoid aggregates, and BM 
fibrosis, though correlations with viral load were not detected.   Neutropenia prevalence spiked 
in the next asymptomatic SIV disease (ASY) period as BM cellularity dropped to lowest levels, 
characterized by loss of granulocytic/monocytic lineage cells and rise in erythroid lineage cells 
that lead to a depressed M:E ratio, while BM CD34+ hematopoietic stem cells peaked.  
However, in advanced SIV disease or AIDS, BM CD34+ cells were depressed and fibrosis was 
detected in almost 50% of macaques as BM cellularity started to rise and the M:E ratio returned 
to within control intervals.  In the ASD phase, anemia, thrombocytopenia, and neutrophilia 
prevalence climaxed.  Pan hyperplasia of BM with resultant hypercellularity including lymphoid 
aggregation was present consistently as were most hematologic abnormalities during AIDS.  In 
AIDS, the M:E ratio was characterized by a return of the myeloid series to control intervals and a 
loss of the erythroid lineage.  Observed BM abnormalities in SIV infected macaques were 
characteristic of reported changes and ranges in HIV patients and implicate SIV infection alone 
rather than therapeutics for observed bone marrow disturbances.  Finally, hematologic changes 
involved BM and peripheral mechanisms. 
Again, natural SIV disease progression in the macaque model emulates bone marrow 
changes and hematologic abnormalities well documented during HIV disease.  Deviation of bone 
marrow from the steady state was present during early and later stages of SIV disease in 
macaques.  Examination of phenotypic population changes in bone marrow during early and late 
SIV infection is described in subsequent chapters to confirm and expand these morphologic 
observations. 
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CHAPTER 5: ERYTHROID, LYMPHOCYTIC, AND 
MONOCYTIC LINEAGES ARE MAINTAINED IN THE 
CHRONIC PERIOD OF SIV INFECTION 
 
INTRODUCTION 
 
SIV infection in Rhesus macaques is a well-established research animal model for study 
of HIV and AIDS.   The RM SIV model correlates well to HIV-1 human infection (Lee 2004).  
The SIV RM model mimics HIV hematologic abnormalities and bone marrow changes during all 
phases of infection as demonstrated in Chapters 3 and 4.   
Bone marrow changes during SIV infection have been primarily characterized by 
morphologic and microscopic (Chapter 4).  Our prior study of marrow morphologic changes 
during SIV infection revealed pan hyperplasia in the early and later stages of disease 
characterized by overall BM hypercellularity with a stable myeloid (granulocytic/monocytic) to 
erythroid ratio despite lineage shifts.  Phenotypic analysis of bone marrow is another method of 
assessment for lineages and M:E ratio as performed by flow cytometry to determine the precise 
measurements of cell size, complexity, and immunophenotype of cells.  Immunophenotypic 
analysis of marrow may provide additional information about observed changes in hematopoietic 
lineages during SIV disease. 
 The objective of this study was to define the immunophenotype of hematopoietic cells in 
the Rhesus macaque and further analyze the shifts of bone marrow erythroid, granulocytic, 
lymphoid, and monocytic hematopoietic lineages during progressive SIV infection as previously 
documented in Chapter 4.  We hypothesized phenotypic shifts in bone marrow hematopoietic 
cells during HIV infection would mirror morphologic hypercellularity for granulocytic, 
monocytic and erythroid lineages as SIV disease progresses.  Additionally, we hypothesized that 
marrow pan hypercellularity could include lymphoid lineages which would be deteted by 
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phenotypic analysis.  Blood was analyzed to determine if changes in blood paralleled those in 
marrow.  Flow cytometry was utilized to determine phenotype of hematopoietic cells in marrow 
and blood by based on forward scatter (FSC), side scatter (SSC), CD45, and CD14 staining 
intensity.   
MATERIAL AND METHODS 
 
Experimental Database III 
 
Experimental database and definitions are described in Appendix II.   
Hematologic Data and Definitions 
 
Hematologic data and definitions are described in Appendix I. 
Flow Cytometry Analysis 
 
Whole blood and BM tissue collection, flow cytometry preparation, flow cytometry 
acquisition, flow cytometry analysis, and definitions are described in Appendix III.   
Flow cytometry was performed using monoclonal antibodies: CD45-FITC (clone MB4-
6D6; Miltenyi; Auburn, CA), CD34-PE (clone 563; BD Biosciences; San Jose, CA), and CD14-
PE (clone M5E2; BD Biosciences).   
Immunophenotype of Bone Marrow and Whole Blood  
 
Hematopoietic cells were defined by phenotypic analyses of populations within the FSC 
vs. SSC plot, CD45 vs. SSC plot, and CD45 vs. CD14 plot as previously described for humans 
and/or RM in blood and humans in marrow based on cell size, complexity, and staining 
(Bjornsson 2008; Lafont 2000; Loken 1990; Reimann 1994; Shah 1988; Stelzer 1993; van 
Lochem 2004; Walker 2004; Zamir 2005).  FSC vs. SSC plot analysis defined four distinct 
populations for marrow and blood that were further defined by CD45 and CD14 staining.  FSC 
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vs. SSC plot analysis is defined in Figure 5.1 for marrow and Figure 5.2 for blood.  CD45 vs. 
SSC plot analysis is presented and defined in Figure 5.3 for marrow and Figure 5.4 for blood.   
             
Figure 5.1. Phenotypes of bone marrow populations by forward versus side scatter 
characteristics 
R1 is the marrow debris gate or „debris gate‟ composed unlysed erythrocytes, platelets, 
fragmented cells, debris and rarely intact cells.  This gate mainly consists of debris with 
low FSC and low SSC properties. 
R2 is the marrow multilineage gate or „MLN gate‟ composed of lineage negative immature 
hematopoietic stem cells (LNIHC), immature hematopoietic stem cells, erythroid lineage 
cells, lymphoid lineage (lymphoblasts, T cells, B cells, NK cells) cells, and basophils.  
This gate contains cells with low FSC and low SSC cells. 
R3 is the marrow immature myeloid/monocyte gate or „monocyte gate‟ composed of CD34+ 
hematopoietic stem cells, immature myeloid cells, and monocytes.  This gate contains 
cells with low to moderate FSC and moderate SSC cells. 
R4 is the marrow „granulocyte gate‟ composed of non-dividing (post-mitotic) granulocytes 
(predominantly neutrophils and fewer eosinophils without basophils).  Cells in this gate 
have moderate to high FSC, and high SSC, the latter based on their high internal 
complexity and laser scatter effect, due to their multilobed nuclei. 
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Figure 5.2. Phenotypes of whole blood populations by forward versus side scatter 
characteristics  
R5 is the blood debris gate or „debris gate‟ composed of unlysed erythrocytes, platelets, 
fragmented cells, debris and rarely intact cells.  
R6 is the blood lymphocyte gate or „lymphocyte gate‟ composed of lymphocytes (predominant 
population), mature basophils, and if present, metarubricytes (nucleated erythrocytes).   
R7 is the blood monocyte gate or „monocyte gate‟ composed of monocytes.  
R8 is the blood granulocyte gate or „granulocyte gate‟ composed of neutrophils (predominant 
population) and eosinophils.   
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A.                                                                                            B.                                     
 
Figure 5.3. Phenotype of bone marrow by CD45 staining 
Forward scatter versus side scatter plot of CD45 populations as indicated by color and region 
(legend in center) (A.).  Populations of marrow hematopoietic cells by gate as indicated by CD45 
versus SSC plot (B.). 
R9 or „CD45 marrow erythroid gate‟ contained cells with low side angle scatter and low forward 
light scatter staining CD45
Neg 
and smallest and least complex of cells.   Debris, erythroid 
series cells, platelets, and mesenchymal cells are found in this gate. 
R10 or „CD45 marrow blast gate‟ contained cells with low side angle scatter and low forward 
light scatter staining CD45
Dim to moderate
 and less complex mature lymphocytes.  Immature 
B lymphocytes (lymphoblasts), myeloid blasts, CD34+ stem cells, and basophils are 
found in this gate. 
R11 or „CD45 marrow lymphocyte gate‟ contained cells with low side angle scatter and low 
forward light scatter staining CD45
Bright
.  B lymphocytes, T lymphocytes, NK cells, and 
few CD34+ cells are found in this gate. 
R12 or „CD45 marrow monocyte gate‟ contained cells with moderate side angle scatter and 
moderate forward angle scatter staining CD45
Mod 
and bigger than mature lymphocytes.  
The monocytic lineage and CD34+ cells are found in this gate. 
R13 or „CD45 myeloid gate‟ contained cells with moderate side angle scatter and low forward 
light scatter staining CD45
Dim
 and similar size to mature monocytes but lower CD45 
expression.  Immature myeloid cells and CD34+ cells are found in this gate. 
R14-R16 or „CD45 granulocyte gates‟ contained cells with variable scatter and staining.  R14 
gated cells exhibited high side angle scatter and moderate light angle scatter staining 
CD45
Dim
.  R15 gated cells exhibited high side angle scatter and moderate light angle 
scatter staining CD45
Mod
.  R16 gated cells exhibited high side angle scatter and high 
forward light scatter staining CD45
Mod
.  Large myeloid cells consisting of immature and 
mature granulocytic cells are found in these gates. 
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Figure 5.4. Phenotype of whole blood by CD45 staining 
Forward scatter versus side scatter plot of CD45 populations (A.).  Populations of blood cells by 
gates in the CD45 versus SSC plot (B.).   
R17 is the „CD45 debris gate‟ characterized by CD45Neg staining and low SSC composed of 
unlysed erythrocytes, platelets, fragmented cells, debris and rare intact cells.  
R18 is the „CD45 lymphocyte gate‟ characterized by CD45Bright staining and low SSC consisting 
of lymphocytes (predominant population) and basophils.   
R19 is the „CD45 monocyte gate‟ characterized by CD45Moderate tobright staining and moderate 
SSC containing monocytes.   
R20 and R21 or „CD45 granulocyte gates‟ characterized by CD45 variable staining and high 
SSC.  R20 is characterized by CD45
Dim to moderate 
staining.
  
 R21 characterized by CD45
Mod
 
to
 
bright 
staining. Neutrophils (predominantly), eosinophils, and few larger monocytes are 
found in these gates.   
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Figure 5.5. Phenotype of bone marrow by CD45 and CD14 staining 
Forward scatter versus side scatter plot of CD45 and CD14 populations (A.).  Populations of 
blood cells by gates in the CD45 versus CD14 plot (B.).   
R22 or „debris gate‟ contains events with low side angle and low forward light scatter, CD45 and 
CD14 negative, and moslty platelets, fragmented cells, and debris. 
R23 or „erythroid gate‟ contains cells with low side angle and low forward light scatter 
expressing CD45
Neg
 
to dim
 and CD14
Neg
 mostly erythroid lineage cells and stem cells.   
R24 or „CD14Neg blast gate‟ contains cells with low side angle scatter and low forward light 
scatter expressing CD45
Mod
 and CD14
Neg
 less complex than mature lymphocytes.  
Immature B lymphocytes (lymphoblasts), myeloid blasts, CD34+ stem cells, and 
basophils are found in this gate. 
R25 or „CD45 marrow lymphocyte gate‟ contained cells with low side angle scatter and low 
forward light scatter expressing CD45
Bright
  and CD14
Neg
.  B lymphocytes, T 
lymphocytes, NK cells, and few CD34+ cells are found in this gate. 
R26 or „marrow monocyte gate‟ contained cells with moderate side angle scatter and moderate 
forward angle scatter expressing CD45
Bright
 CD14
Bright
 and bigger than mature 
lymphocytes.  Monocytic lineage cells and CD34+ cells are found in this gate. 
R27 or „myeloid gate‟ contained cells with variable side angle scatter and variable forward light 
scatter expressing CD45
Dim
 and CD14
Dim
.  CD34+ stem cells and immature myeloid cells 
comprised this gate. 
R28-30 or „marrow granulocyte gates‟ contained cells with variable scatter and staining.  R28 
cells exhibited high side angle scatter and high forward light scatter expressing CD45
Dim 
to mod
 and CD14
Mod
.  R29 cells exhibited variable side angle scatter and variable forward 
light scatter expressing CD45
Bright
 and CD14
Dim
.  R30 cells exhibited variable side angle 
scatter and variable forward light scatter expressing CD45
Neg
 and CD14
Neg
.  Immature 
and mature granulocytes (exclusive of basophils) are found in these gates. 
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    A.                                                                                      B.
Figure 5.6. Phenotype of whole blood by CD45 and CD14 staining 
Forward scatter versus side scatter plot of CD45 and CD14 populations (A.).  Populations of 
blood cells by gates in the CD45 versus CD14 plot (B.).   
R31 or „debris gate‟ contained events with low side and forward angle scatter staining CD45Neg 
and CD14
Neg 
composed of unlysed erythrocytes, platelets, fragmented cells, and debris.  
R32 or „CD45CD14 lymphocyte gate‟ contained cells with low side angle and low forward light 
scatter staining CD45
Bright
 and CD14
Neg
.  Cells consist of lymphocytes and few CD34+ 
cells. 
R33 and R35-38 or „CD45CD14 marrow granulocyte gates‟ contained cells with variable 
staining and scatter.  R33 contained cells with low side angle and forward light scatter 
staining CD45
Dim
 and CD14
Neg
.  R35 contained cells with low side angle and forward 
light scatter staining CD45
Mod
 and CD14
Neg
.  R36 contained cells with high side angle 
scatter and moderate to high forward light scatter staining CD45
Dim
 
to
 
mod 
and CD14
Mod to 
bright
.   R37 contained cells with variable side angle and forward light scatter staining 
CD45
Bright
 and CD14
Mod
.  R38 or „eosinophil gate‟ contained cells wit side angle and 
variable to high forward light scatter staining CD45
Mod
 and CD14
 Mod
.  Cells here consist 
of immature and mature granulocytes. 
R34 or „CD45CD14 monocyte gate‟ contained cells with moderate side angle scatter and 
moderate forward light scatter staining CD45
Mod
 
to
 
bright
 and CD14
Mod to
 
bright
.  Cells consist 
of mature monocytes and few CD34+ cells. 
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CD45 vs. CD14 plot analysis is defined in Figure 5.5 for marrow and Figure 5.6 for blood.  
CD45 and CD14 staining was defined as negative (Neg), dim, moderate (Mod), or bright based 
on intensity.  
Statistical Analysis 
 
For data evaluation, controls were non-SIV infected macaques and SIV infected subjects 
were grouped into periods defined as early and chronic (Appendix II).  Macaques developing 
AIDS were fast and slow progressors. 
Percentages of immunophenotypic populations for control and SIV infected macaques 
were compared using the Mann Whitney non-parametric unpaired t test,  and correlations were 
determined using non-parametric Spearman correlation coefficients (GraphPad Software; San 
Diego, CA).   
Graphs represent the means and SEM.  Significant differences were defined as  p≤0.05. 
 
RESULTS 
 
Bone Marrow Multilineage Populations and Whole Blood Lymphocyte Populations During 
SIV infection 
 
The MLN gate represented ~30% nucleated cells in bone marrow of control macaques 
(Figure 5.7A).  The MLN gate consisted of the erthroid (R9 and R23), blast (R10 and R24), and 
the lymphocyte (R10 and R24) gates.  In control macaques, the erythroid gates (Figure 5.7C) 
represented the highest population (~17%) followed by the lymphocyte (~8%) (Figure 5.7B) and 
the blast (~6%) gates (Figure 5.7D).  Early during SIV infection the MLN gate decreased 
characterized by a significant drop in all three subsets of the population.  During chronic SIV 
infection, the MLN gate rebounded characterized by a rise in the erythroid and lymphocyte gates 
but continued significant loss of the blast gates by CD45 staining. 
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Figure 5.7. Bone marrow multilineage populations 
The multilineage gate of bone marrow (R2 gate) consisted of the three subsets: erythroid gate, 
lymphocyte gate, and blast gate.  A. The multilineage gate of bone marrow (R2 gate).  B. The 
marrow erythroid gates were defined as the R9 gate in CD45 versus SSC plot and the R23 gate in 
CD45 versus CD14 plot.  C. The marrow lymphocyte gates were defined as the R11 gate in 
CD45 versus SSC plot and the R25 gate of CD45 versus CD14 plot.  D. The marrow blast gates 
were defined as the R10 gate in CD45 versus SSC plot and the R24 gate of CD45 versus CD14 
plot.  Comparison of controls to macaques in early and chronic periods of SIV infection by Mann 
Whitney t tests (****p<0.05).  Percentages of cells in respective gates are shown as mean + 
SEM. 
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Lymphocytes in BM (R11 gate) were negatively correlated to viral load (Spearman r = 
 -0.5559, p= 0.0254), however other subsets of the MLN population were not during SIV 
infection.  The BM R9 erythroid gate was positively correlated to the BM R23 gate (Spearman r 
=0.6826, p=0.0002).  The marrow R11 lymphocyte gate was strongly positively correlated  to the 
marrow R25 lymphocyte gate (Spearman r =0.9544, p<0.0001).  The R10 marrow blast was 
positively correlated to the R24 marrow blast gate (Spearman r =0.7938, p<0.0001).   
Whole blood lymphocytes were ~15% of circulating cells in control macaques by 
phenotypic analysis (Figure 5.8).  Blood lymphocytes were reported by CBC analysis (Figure 
5.8A and 5.8B), the lymphocyte gate in FSC vs. SSC plot (R6) (Figure 5.8C), the lymphocyte 
gate in CD45 vs. SSC plot (R18) (Figure 5.8D), and the lymphocyte gate in CD45 vs. CD14 plot 
(R32) (Figure 5.8D).  During SIV infection, CBC concentrations of lymphocytes plummeted 
(p<0.05) while phenotypic percentages slightly increased post-infection.  Viral load was not 
correlated to any of the defined blood lymphocyte populations.  Strong positive correlations were 
detected between the defined populations of blood lymphocytes: R6 (FSC vs. SSC plot) 
compared to R18 (CD45 vs. SSC plot) gated populations (Spearman r =0.9269, p<0.0001);  R6 
(FSC vs. SSC plot) compared to R32 (CD45 vs. CD14 plot) gated populations (Spearman r 
=0.8319, p<0.0001); and  R18 (CD45 vs. SSC plot) compared to  R32 (CD45 vs. CD14 plot) 
gated populations (Spearman r =0.8628, p<0.0001).    
Bone Marrow and Blood Monocyte Populations During SIV Infection 
 
Monocyte populations represented 4-6% of nucleated cells in BM and WB for controls 
(Figure 5.9 and Figure 5.10).  Percentages of marrow monocytes were detected by FSC vs. SSC 
plot (R3 in Figure 5.9A) and CD45 vs. SSC plot (R12 in Figure 5.9B).  Blood monocytes were 
reported by CBC analysis (Figure 5.10A and 5.10B), the monocyte gate in FSC vs. SSC plot (R7  
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A.                                  B.                                 C.                                   D. 
 
Figure 5.8. Whole blood lymphocyte populations  
Whole blood lymphocytes by CBC data and phenotype.  A. Percent lymphocytes from CBC 
data.  B. Absolute lymphocyte count from CBC data.   C. Lymphocyte gate (R6) in FSC versus 
SSC plot.  D. Lymphocyte gate by phenotype: R18 is the lymphocyte gate in CD45 versus SSC 
plot; R32 is the lymphocyte gate in CD45 versus CD14 plot.  Comparison of controls to 
macaques in early and chronic SIV infection by Mann Whitney t tests (***p<0.01 and 
****p<0.05).  Percentages of cells in respective gates are shown as mean + SEM. 
 
      A.                                                                  B.   
 
Figure 5.9. Bone marrow monocyte populations 
The marrow monocyte populations were defined by two gates:  (A.) R3 gate in FSC versus SSC 
plot; and (B.) R12 gate in CD45 versus SSC plot.  Comparison of controls to macaques in early 
and chronic SIV infection by Mann Whitney t tests (no significant differences).  Percentages of 
cells in respective gates are shown as mean + SEM. 
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 A.                                  B.                                 C.                                    D. 
 
Figure 5.10. Whole blood monocyte populations 
Whole blood monocytes by CBC data and phenotype.  A. Percent monocytes from CBC data.  B. 
Absolute monocyte count from CBC data.   C. Monocyte gate in FSC versus SSC plot (R7).  D. 
Monocyte gate by CD45 versus SSC plot (R19).  Comparison of controls to macaques in early 
and chronic SIV infection by Mann Whitney t tests (***p<0.01).  Percentages of cells in 
respective gates are shown as mean + SEM. 
 
 
in Figure 5.10C), and the monocyte gate in CD45 vs. SSC plot (R19 in Figure 5.10D). Post-
infection, percentages of monocytes were minimally increased from  control macaques in BM 
and WB.  Early post-infection, circulating monocytes increased in percentage but decreased in 
absolute number while marrow cells were unchanged.  Later in infection, marrow and blood 
monocytes maintained percentages, but remained depressed in circulating absolute numbers.  
Viral load did not correlate with changes in monocytes in WB or BM. 
The marrow monocyte gate in the FSC vs. SSC plot (R3) positively correlated with the 
monocyte gate in the CD45 vs. SSC plot (R12) (Spearman r =0.6632, p=0.0004).  The whole 
blood monocyte gate in the FSC vs. SSC plot (R7 gate) positively correlated with the monocyte 
gate in the CD45 vs. SSC plot (R19 gate) (Spearman r =0.7836, p<0.0001).    
Bone Marrow and Blood Granulocyte Populations During SIV Infection 
 
Granulocyte populations were  ~40-50% of BM and WB cells in control macaques 
(Figure 5.11 and Figure 5.12).  Post-infection, percentages of marrow granulocytes decreased 
significantly in the chronic period (p<0.05).   
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The marrow granulocyte gate (R4) was characterized by subsets of populations (Figure 
5.11).  Percentages of marrow granulocyte subsets were based on scatter and CD45 intensity as 
the following (Figure 5.11B) including those with:  highest percentage of granulocytes, and 
moderate sized and CD45
Dim
 (R14 gate); moderate sized and CD45
Mod
 (R15 gate); lowest 
percentage of granulocytes and  largest cells and CD45
Mod
 (R16 gate).  The CD45
Mod
 marrow 
granulocytes increased in the early period of SIV infection as the CD45
Dim
 marrow granulocytes 
declined.  During the chronic period of SIV infection, losses of all subsets of marrow 
granulocytes was detected.  Bone marrow granulocyte populations did not correlated with viral 
loads. 
     A.                                                                      B.   
 
 
Figure 5.11. Bone marrow granulocyte populations 
The marrow monocyte populations were defined by two gates:  (A.) R4 gate in FSC versus SSC 
plot; and (B.) R14- R16 gates in CD45 versus SSC plot.  Comparison of controls to macaques in 
early and chronic SIV infection by Mann Whitney t tests (no significant differences).  
Percentages of cells in respective gates are shown as mean + SEM. 
 
Percentages of blood granulocytes were detected by CBC analysis (Figure 5.12A and 
5.12B), the granulocyte gate in FSC vs. SSC plot (R8 in Figure 5.11C), and the granulocyte gates 
in CD45 vs. SSC plot (R20 and R21 in Figure 5.11D). The ratio of WB R20 (CD45
Mod
) to R21 
(CD45
Bright
) granulocytes was increased in the early phase characterized by parallel losses in both 
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gates with the loss of R21 in greater proportion.  The WB ratio decreased in the chronic phase 
compared to control macaques defined by a drop in R20 population (granulopenia) and rise in 
R21 population (granulocytosis).  Absolute numbers of total granulocytes, neutrophils and 
eosinophils, from CBC data declined in the early phase (p=0.0006) then rose minimally but were 
still low in the chronic phase.   
The blood granulocyte gate (R8) in FSC vs. SSC plot positively correlated to the  sum of 
the granulocytes gates (R20 and R21) in CD45 vs. SSC plot (Spearman r =0.9348, p<0.0001).  
Correlations were not detected between phenotypic gates and CBC data for granulocytes by 
percentage or absolute numbers.  Viral load negatively correlated with CBC absolute 
concentrations of granulocytes (Spearman r = -0.6425, p=0.0073) yet positively correlated to 
CBC percentages of granulocytes (Spearman r =0.5214, p=0.0384).   
    A.                                  B.                                   C.                                   D. 
 
Figure 5.12. Whole blood granulocyte populations  
Whole blood granulocytes by CBC data and phenotype.  A. Sum of neutrophil and eosinophil 
granulocyte percents from CBC data.  B. Absolute neutrophil and eosinophil granulocyte counts 
from CBC data.   C. Granulocyte gate in FSC versus SSC plot (R8).  D. Granulocyte gates by 
CD45 versus SSC plot (R20 and R21).  Comparison of controls to macaques in early and chronic 
SIV infection by Mann Whitney t tests (***p<0.01).  Percentages of cells in respective gates are 
shown as mean + SEM. 
 
 
Bone Marrow Phenotypic Lineage Ratio During SIV Infection 
 
A  phenotypic lineage ratio (GM:MLN) was determined in bone marrow.  The GM:MLN 
ratio was defined as the sum of the marrow granulocyte and monocyte populations or myeloid 
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lineage (GM) compared to the MLN population composed of the marrow erythroid and 
lymphoid lineages and immature stem cells (Figure 5.10).  The control macaque GM:MLN ratio 
was 1.79+0.36 which continually declined post-infection.  The drop of the GM:MLN ratio below 
control values in the early phase was due to a concurrent drop in both granulocyte and MLN 
populations and minimal change in the monocyte populations.  The drop in cells within MLN 
population (15%) was higher than the drop in the granulocyte population (10%) from the control 
macaque level.  Within the chronic phase, again the monocyte population was minimally 
changed while the granulocyte population dropped (29%) from the control macaque level and the 
MNL population rose (20%) to levels near the control macaque level.  
 
 
Figure 5.13. Bone marrow lineage phenotype ratio 
The GM:MLN ratio defined as the sum of the marrow granulocyte (R4 gate) and monocyte 
populations (R3 gate) or myeloid lineage (GM) compared to the multilineage MLN gate (R2) 
population composed of the marrow erythroid and lymphoid lineages and immature stem cells.  
Comparison of controls to macaques in early and chronic SIV infection by Mann Whitney t tests 
(no significant differences).  Grey lines represent means + SEM. 
 
 
DISCUSSION 
 
Phenotypic analysis of BM and WB cells defined populations based on size and 
complexity by the FSC vs. SSC plot.  The main phenotypic populations were defined as the 
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following:  debris, lymphocyte or MLN, monocyte, and granulocyte.  Debris usually consists of 
non-lysed erythrocytes, ghost erythrocytes, particles, cell fragments, and platelets and platelets 
(Loken 1990).   CD45 staining and CD14 staining helped eliminate nonmyeloid cells or debris 
from marrow populations as the marrow MLN gate occassionally overlapped the debris gate.   
Early during SIV infection, percentages of marrow erythroid and lymphocytic lineages, 
immature hematopoietic cells, and granulocytes were low.  Even though total marrow 
granulocytes were low, the CD45
Mod
 and moderately-sized granulocytes were increased.  BM 
monocytes were unchanged in the early period.  In WB, phenotypic percentages and absolute 
numbers of circulating granulocytes plus absolute numbers of mononuclear cells (lymphocytes 
and monocytes) were similarly decreased.   
The depressed trend in BM continued for percentages of blast cells in the chronic phase 
but the percentages of erythroid lineage and lymphocytic lineage rebounded in the chronic phase.  
Percentages of BM granulocytes did not rebound even as the percentage of monocyte cells was 
unchanged.  Circulating lymphocytes remained depressed as did the other mononuclear cells, 
monocytes.  Viral load negatively correlated with lymphocyte populations in BM and the sum of 
absolute numbers of total granulocytes from CBC data.  Viral load positively correlated with 
percentages of granulocytes from CBC data. 
The phenotypic study GM:MLN mean ratio was 1.79+0.03 for control macaques while 
the  morphologic M:E mean ratio was 1.94 for controls in our earlier study (Chapter 4).  
Phenotypically, the marrow GM:MLN ratio dropped early in infection due to decrease in the 
majority of hematopoietic cell populations, erythroid and lymphoid lineages plus immature cells 
and granulocytes yet monocytes were unchanged.  Morphologically, the marrow M:E ratio 
dropped in the early period of infection due to loss of myeloid cells and concurent increase in 
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erythroid cells.  A continued drop in the BM ratio was noted by phenotypic analysis due to 
increase in percentages of erythroid and lymphoid lineages and monocytes with a sustained loss 
of granulocytic cells.   During chronic SIV infection, the M:E ratio increased to levels noted in 
non-infected RM characterized by a gradual rise in myeloid cells and loss in erythroid cells. 
The GM and M component of the BM ratios were similarly defined in the phenotypic and 
morphologic studies respectively.  Of note, the GM population included macrophages and other 
mononuclear cells possibly excluded by morphologic appearance.  Additionally, the second part 
of the ratio included lymphocytes, debris, and immature cells for the phenotypic definition but 
not the morphologic definition.  The GM:MLN ratio included a higher percentage of non-
myeloid cells thus decreasing the ratio compared to the M:E morphologic ratio. Consistent with 
marrow ratios was a loss of granulocytic lineage. 
Loss of granulocytic cells may be attributed to precursor cells.  Reports in HIV and SIV 
for decreased precursors of the granulocytic series have been documented and may account for 
changes noted in our study.  Committed precursors of the granulocytic lineage occur as colony 
forming unit-granulocyte, macrophage (CFU-GM).  Long term bone marrow cultures from 
healthy patients infected with HIV showed decreased CFU-GM (Marandin 1995) which was also 
found in cultures of bone marrow from HIV infected patients (Tomishima 2003).  Chronically 
infected SIVmac251 RM were reported to have persistently low CFU-GM without change to 
colony forming unit-macrophage (CFU-M) (Thiebot 2005).   
One discrepancy from our prior observations was noted in immature hematopoietic cells.  
In Chapter 4 we defined early increases in percentages of BM CD34+ hematopoietic stem cells 
then decline as SIV infection progressed.  In our current study we observed overall loss in the 
MLN marrow gate early during infection then rise as the infection progressed characterized by a 
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rise in the erythroid and lymphocyte gates and loss in the blast gate.  The same CD34 
manufacturer, clone, and fluorochrome was used in both studies.  The CD34+ stem cells may be 
found in each subset of the MLN marrow gate as lineage negative or lineage differentiated.  The 
percentage of CD34+ cells was <0.5% and poorly reflective of the total MLN population.  
Further analysis of the stem cells is needed to confirm the trend as LNIHC or lineage 
differentiated CD34+ cells.    
Overall, the phenotypic analysis was comparable to the morphologic analysis in control 
macaques.  The phenotypic trend paralleled the morphologic trend when compared between the 
early and chronic phases respectively with maintenance of the erythroid and lymphoid lineages, 
loss of granulocytic lineages, and maintenance of monocytic lineages.  Additionally the observed 
hematologic abnormalities of this study are supported by findings in our prior discoveries 
described in Chapter 3 and Chapter 4.   
SUMMARY 
 
Phenotypic analysis of SIV infected Rhesus macaques defined lineages of hematopoietic 
cells in bone marrow by CD45 and CD14 staining.  The BM erythroid lineage and lineage 
negative immature hematopoietic cells declined early during infection then increased in later 
phases.  Granulocytes cells and immature hematopoietic cells in BM remained low during 
progressive infection.  During infection, the BM monocytic lineage and immature myeloid cells 
were minimally increased.  BM lymphocytes were low in the early phase then rose to levels 
observed in control macaques in the chronic phase.  Trends observed phenotypically in bone 
marrow were similar to morphologic trends in bone marrow identified for lineages and the 
myeloid to erythroid lineage ratio as loss of granulocytes during infection.  Viral load was 
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negatively correlated to the percentage of BM mature lymphocytes.  Hematologic abnormalities 
were consistent with prior findings of lymphopenia, monocytopenia, and neutropenia.   
Our study confirms phenotypic analysis of bone marrow recapitulates morphologic 
observations.  Immunophenotype of lymphocytes and dendritic cells, cells essential for antigen 
presenting function, will be subsequently determined to identify which subsets shifted during 
SIV infection with respect to BM and WB gated populations. 
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CHAPTER 6: T LYMPHOCYTES ARE MAINTAINED IN BONE 
MARROW AS B LYMPHOCYTES AND NK CELLS DECLINE 
DURING SIV INFECTION 
 
INTRODUCTION 
 
Phenotying by flow cytometry and morphologic analysis of bone marrow revealed 
decreases in cells within the MLN gate early in SIV infection with return to control macaque 
levels in chronic infection while monocytes were minimally impacted and granulocytes declined 
in our studies (Chapter 4 and Chapter 5).  Moreover, phenotypic changes were observed to 
reflect morphologic changes during progressive SIV disease (Chapter 4 and 5).  However, prior 
phenotypic analysis studies of hematopoietic bone marrow cells during SIV infection have been 
difficult to interpret based on sample preparation (e.g. density gradient, culture purification, 
aspirate sample, etc.) and gating protocols (single versus multi-color flow cytometry, sorting, 
starting populations, etc.).   
The objective of this study was to define, establish, and compare BM and WB 
immunophenotypes of  lymphocytes and antigen presenting cells based on lineage gating 
established in Chapter 5 and to determine shifts in populations during SIV infection.  It is 
estimated that billions of lymphocytes migrate through the bone marrow daily even though it is 
only fed by the blood vascular circulation and not the lymphoid circulation (Wei 2006).  
Immature B cells leave BM and mature in peripheral lymphoid tissues (Baumgarth 2004).  Long-
lived plasma cells and memory CD8 T cells may be found in the bone marrow (Wei 2006).  
Mouse studies indicate that uncommitted lymphocyte/myeloid precursors leave the bone marrow 
and enter the thymus for T cell/NK cell development (Spits 2002). Natural killer cells have been 
reported to develop in the bone marrow of adults and children by Blom et al. (Blom 2006).  
Myeloid dendritic cells (mDC) and plasmacytoid dendritic cells (pDC) are hematopoietic derived 
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cells that form direct-cell-to-cell contact with T lymphocytes as antigen presenting cells (APC) 
(Coates 2003).  If environmental conditions are appropriate, pDC can act as APC for naïve T 
cells but are less efficient than mDC at phagocytosis of antigenic material (McKenna 2005).  
Both plasmacytoid and myeloid dendritic cells can aid memory T cell activation (McKenna 
2005).  Human pDC have been shown in vitro to recruit and activate NK cells (McKenna 2005).  
Disruption of percentages of lymphocytes and dendritic cells in bone marrow during SIV 
infection would confirm another dysfunction in bone marrow and may help explain the 
pathogensis of HIV infection. 
We hypothesized lymphocyte populations of T cells, plasma cells, B cells, and NK cells 
would be low during early SIV infection but rise during chronic infection compared to control 
macaque levels in bone marrow based on data showing maintenance of marrow lymphocytes 
(Chapter 5).  Further, we hypothesized populations of dendritic cells would be maintained during 
SIV infection in bone marrow due to data showing maintenance of the BM monocytoid gate 
(Chapter 5).  Flow cytometry was utilized to determine immunophenotype of multiple 
populations in bone marrow and whole blood.  We compared gating schemes of FSCvs.SSC and 
CD45 versus SSC for select populations to determine correlation between different identification 
schemes of populations based on flow gating observations from Chapter 5. 
MATERIAL AND METHODS 
 
Experimental Database III 
 
Experimental database and definitions are described in Appendix II.   
Hematologic Data and Definitions 
 
Hematologic data and definitions are described in Appendix I. 
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Flow Cytometry Analysis 
 
Whole blood and BM tissue collection, flow cytometry preparation, flow cytometry 
acquisition, flow cytometry analysis, and definitions are described in Appendix III.  
Immunophenotype of hematopoietic cells was performed for select populations of cells based on 
specific panels and Boolean gating for flow cytometry analysis (Table 6.1).  
Lymphocyte Grandparent Gates for T Lymphocytes, B Lymphocytes, and NK Cells 
 
The bone marrow grandparent gate was defined as the marrow multilineage gate, which 
includes lymphocytes, in the FSC vs. SSC plot (R2 in Figure 5.1) and the marrow lymphocyte 
gate in CD45 vs. SSC plot (R11 in Figure 5.3).  The whole blood grandparent gate was defined 
as the lymphocyte gate in the FSC vs. SSC plot (R6 in Figure 5.2) and the lymphocyte gate in the 
CD45 vs. SSC plot (R18 in Figure 5.4). 
Immature Lymphocyte Grandparent Gates for Plasma Cells and Immature B Lymphocytes  
 
The bone marrow grandparent gate was defined as the marrow multilineage gate, which 
includes lymphocytes, in the FSC vs. SSC plot (R2 in Figure 5.1) and the marrow lymphocyte 
gate in CD45 vs. SSC plot (R11 in Figure 5.3) and the marrow blast gate in CD45 vs. SSC plot 
(R10 in Figure 5.3).  The whole blood grandparent gate was defined as the lymphocyte gate in 
the FSC vs. SSC plot (R6 in Figure 5.2) and the lymphocyte gate in the CD45 vs. SSC plot (R18 
in Figure 5.4) and the debris gate in the CD45 vs. SSC plot (R17 gate in Figure 5.4). 
Monocyte Grandparent Gates for Dendritic Cells 
 
The bone marrow grandparent gate was defined as the marrow monocyte gate in the FSC 
vs. SSC plot (R3 in Figure 5.1) and the marrow monocyte gate in CD45 vs. SSC plot (R12 in 
Figure 5.3).  The whole blood grandparent gate was defined as the monocyte gate in the FSC vs. 
SSC plot (R7 in Figure 5.2) and the monocyte gate in the CD45 vs. SSC plot (R19 in Figure 5.4).    
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Table 6.1. Multi-Color Flow Cytometry Panels by Antibody, Clone, and Manufacturer 
 
Flow Cytometric 
Phenotype FITC
a
 PE
b
 
PE- 
Texas 
Red
c
 PE-Cy5
d
 
PerCP-
Cy5.5
e
 PE-Cy7
f
 APC
g
 
APC-
Cy7
h
 
Pacific 
Blue
i
 QDOT655 
Hematopoietic Cell 
Panel 
 CD45 
MB4-6D6 
Miltenyi 
 CD34  
563 
BD   
CD184 
12G5 
BD   
HLA-DR 
L243 
BD 
 CD90 
5E10 
BD 
 
CD14 
M5E2 
BD   
T Lymphocyte 
Panel 
 CD7 
M-T701 
BD 
 CD34 
563 
BD 
 CD8  
3B5 
Caltag 
CD2 
RPA-2.10 
BD   
CD3 
SP34-2 
BD 
 CD45 
MB4-6D6 
Miltenyi  
 CD20  
L27 
BD 
CD14 
M5E2 
BD 
 CD4 
T4/19Thy5D
7 
NIH 
B Lymphocyte 
Panel 
IgG 
G18-145 
BD 
CD38 
OKT10 
NIH 
 CD8  
3B5 
Caltag 
IgM 
G20-127 
BD 
CD28 
L293 
BD 
HLA-DR 
L243 
BD 
 CD45 
MB4-6D6 
Miltenyi 
CD20  
L27 
BD 
CD3 
SP34-2 
BD   
Plasma Cells and  
Immature B 
Lymphocyte Panel 
 CD138 
MI15 
BD 
CD38 
OKT10 
NIH 
 CD8  
3B5 
Caltag 
IgG 
G18-145 
BD 
CD28 
L293 
BD 
HLA-DR 
L243 
BD 
CD45 
MB4-6D6 
Miltenyi 
CD20  
L27 
BD  
CD3 
SP34-2 
BD   
Natural Killer Cell 
Panel 
 CD3 
SP34-2 
BD 
 CD335 or 
NKp46  
BAB281 
Beckman 
 CD8  
3B5 
Caltag     
HLA-DR 
L243 
BD 
 CD45 
MB4-6D6 
Miltenyi  
CD20  
L27 
BD   
 CD4 
T4/19Thy5D
7 
NIH 
Dendritic Cell Panel 
 CD3 
SP34-2 
BD 
 CD11c 
S-HCL-3 
BD  
 CD8  
3B5 
Caltag 
 CD123 
9F5 
BD    
HLA-DR 
L243 
BD 
 CD45 
MB4-6D6 
Miltenyi 
CD20  
L27 
BD 
 CD14 
M5E2 
BD   
Fluorescein isothiocyanate (FITC); b) Phycoerythrin (PE); c)  Phycoerythrin Texas Red (PE-Tx RED or PE-TxR); d) Phycoerythrin Cyanine 5 (PE-Cy5); e) Peridinin Chlorophyll 
Protein Cyanine 5.5 (PerCP-Cy5.5); f) Phycoerythrin Cyanine 7 (PE-Cy7); g)  Allophycocyanin (APC); h) Allophycocyanin Cyanine 7 (APC-Cy7); i) Pacific Blue (PacBlue or 
PacBl), Peridinin Chlorophyll Protein (PerCP); and j) Quantom dots 655 (QDOT 655) 
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Hematopoietic Cell Panel 
 
The hematopoietic cell panel was a specific panel to identify and classify populations 
within whole blood and bone marrow.  Forward scatter versus side scatter plot analysis (Figure 
5.1 and Figure 5.2), CD45 vs. SSC plot analysis (Figure 5.3 and Figure 5.4), and CD45 versus 
CD14 plot analysis (Figure 5.5 and Figure 5.6) revealed several gates for bone marrow and 
whole blood respectively as defined in Chapter 5.  
T Lymphocyte Panel 
 
T cells are characterized by expression of the T cell receptor CD3 (Shah 1988; 
Szczepanski 2006).  CD3+ T lymphocytes were determined by gates in bone marrow and whole 
blood (Figure 6.1).  Populations of T lymphocytes were examined by expression of early 
maturation markers (Figure 6.1B).   
B Lymphocyte Panel 
 
Mature B lymphocytes have been characterized as CD20+ in bone marrow and whole 
blood (Baumgarth 2004; Loken 1987; Shah 1988; Szczepanski 2006).  CD20+ B lymphocytes 
were determined by gates in bone marrow and whole blood (Figure 6.2).   
A.                                    B.                                                                  
 
Figure 6.1. Identification of T lymphocytes 
Phenotypic determination of T lymphocytes.  A. The parent gate identified CD3+CD20- T 
lymphocytes by CD3 versus CD20 plot from the lymphocyte grandparent gates.  B. Early 
maturation markers in the CD2 versus CD7 plot of CD3+ T lymphocytes identified four 
populations of cells as Q1 CD3+CD20- CD2-CD7+ cells, Q2 as CD3+CD20- CD2+CD7+ cells, 
Q3 as CD3+CD20- CD2+CD7- cells, and Q4 as CD3+CD20- CD2-CD7- cells from the parent 
gate.  
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2
0
 
C
D
7
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A.                                B.                                 C.                                 D. 
                                               
 
Figure 6.2. Identification of B lymphocytes 
Phenotypic determination of B lymphocytes.  A. The parent gate identified CD20+CD3- B 
lymphocytes by CD20 versus CD3 plot from the lymphocyte grandparent gates.  B. CD20+CD3- 
CD38+ B lymphocytes were identified from the parent gate. C.-D. Multiple gating strategies 
identified CD20+CD3- B lymphocytes by antibody of interest versus SSC plot from the parent 
gate.  C. CD20+CD3- IgM+ B lymphocytes.  D. CD20+CD3- IgG+ B lymphocytes. 
 
 
Plasma Cells and Immature B Lymphocyte Panel 
 
Plasma cells and immature B cells have been identified based on CD38 and CD138 
staining (Medina 2003; Morice 2007; Nowakowski 2005; Rawstron 2002; Sims 2005; Smock 
2007).  Plasma cells and immature B lymphocytes were determined by gates in bone marrow and 
whole blood (Figure 6.3).     
A.                                       B. 
 
Figure 6.3. Identification of plasma cells and immature B lymphocytes 
Phenotypic determination of plasma cells and immature B lymphocytes.  A. The parent gate 
identified CD3-CD20- lymphocyte cells by CD3 versus CD20 plot from the immature 
lymphocyte grandparent gates.  B. CD38 versus CD138 plot of CD3-CD20- cells identified  
immature B lymphocytes in Q1 or CD3-CD20-CD38-CD138+ cells and plasma cells in Q2 or 
CD3-CD20-CD38+CD138+ cells.   
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Natural Killer Lymphocyte Panel 
 
Natural killer (NK) cells express natural cytotoxicity receptors including NKp46 or 
CD335 found on human and Rhesus macaque NK cells (Andersen 2004; Szczepanski 2006; 
Warren 2005).   Additionally, NKp46 is expressed on active and resting NK cells (Noessner 
2007; Warren 2005).   NK cells were determined by gates in bone marrow and whole blood 
(Figure 6.4).     
      A.                                         B.                                      C.      
 
 
Figure 6.4. Identification of natural killer cells 
Phenotypic determination of natural killer (NK) cells.  A. The parent gate identified CD3-CD20- 
cells by CD20 versus CD3 plot from the lymphocyte grandparent gates.  B. CD8+CD3- CD20- 
cells were identified from the parent gate.  C. NK cells identified as CD335+CD8+CD3-CD20- 
from the prior gate. 
 
 
Dendritic Cell Panel         
 
Dendritic cells display the FSC scatter of monocytes and the SSC scatter of lymphocytes 
found within a mononuclear gate (Upham 2000).  Phenotypic analysis by flow cytometry of 
dendritic cells identified mononuclear cells absent of mature T cell markers and mature B cell 
markers, also absent or dim fluorescence for mature granulocytic or monocytic markers (lineage 
negative) and positive for HLA-DR with either CD11c or CD123 fluorescence (Figure 4.19) 
(Della Bella 2008; Martin-Martin 2009; Szabolcs 2003; Upham 2000).  Dendritic cells are 
classified as CD11c+CD123- or mDC and pDC or CD11c-CD123+.    Dendritic cells were 
determined by gates from the dendritic cell panel for bone marrow and whole blood (Figure 6.5).   
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     A.                                       B.                                     C.                                                       
 
 
Figure 6.5. Identification of dendritic cells 
Phenotypic determination of dendritic (DC) cells.  A. The parent gate identified HLA-
DR
Bright
CD14- cells by HLA-DR versus CD14 plot from the monocyte grandparent gates.  B. 
HLA-DR
Bright
CD14-CD3- CD20- cells were identified from the parent gate.  C. HLA-
DR
Bright
CD14-CD3-CD20- CD123-CD11c+ myeloid dendritic cells (mDC) and HLA-
DR
Bright
CD14-CD3-CD20- CD123+CD11c- plasmacytoid dendritic cells (pDC) by CD123 
versus CD11c plot.   
 
 
Plasma Viral Load 
 
Plasma viral loads and definitions are described in Appendix IV.   
Statistical Analysis 
 
For data evaluation, controls were non-SIV infected macaques and SIV infected subjects 
were grouped into periods defined as early and chronic (Appendix II).  Macaques developing 
AIDS were fast and slow progressors. 
Marrow and blood T lymphocyte, B lymphocyte, plasma cell, immature B cell, NK cell, 
and dendritic cells gating strategies were compared between FSC vs. SSC and CD45 vs. SSC 
plots.  Percentages of immunophenotypic populations for control and SIV infected macaques 
were compared using the Mann Whitney non-parametric unpaired t test,  and correlations were 
determined using non-parametric Spearman correlation coefficients (GraphPad Software; San 
Diego, CA).   
Graphs represent the means and SEM.  Significant differences were defined as  p≤0.05. 
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RESULTS 
 
Percentages of CD3+ T Lymphocytes During SIV Infection 
 
T lymphocytes were defined as CD3+ cells.  T lymphocytes were maintained in BM 
during SIV but steadily lost in blood over time (Figure 6.6). BM CD3+ T lymphocytes were 
highly represented in the CD45
Bright
 gate (R11) but only represented a minor population in the 
marrow lymphocyte gate for control macaques, thus the gating strategies did not correlate (Table 
6.6).  In BM, >70% of CD3+ T lymphocytes were CD45
Bright 
with the remainder of CD3+ T 
lymphocytes detected in CD45
DimToNegative
 and low SSC gate (R10).  Circulating lymphocytes 
were predominantly CD3+ T lymphocytes in control macaques by both gating strategies 
confirmed by moderate correlation for comparison of gates (Table 6.3).  In WB, >97% of CD3+ 
T lymphocytes were CD45
Bright
.   
CD7, a marker of CD3+ T lymphocytes, is expressed early during maturation in pre-
thymic lymphocytes and maintained on the cell (Bodey 1994).  CD2 is another early maturation 
marker expressed in post-thymic lymphocytes also maintained on the cell (Bodey 1994).  BM of 
controls contained mostly CD3+CD2-CD7- T lymphocytes by FSC vs. SSC plot but 
CD3+CD2+CD7+ T lymphocytes by CD45 vs. SSC plot (Figure 6.7).  CD3+CD2-CD7+ T 
lymphocytes were decreased in BM post-infection.  CD3+CD2+CD7+ and CD3+CD2-CD7- T 
lymphocytes were minimally decreased early in SIV disease then in the chronic phase 
approached control levels.  Early in infection CD2+CD7- lymphocytes were increased then 
returned to control levels.  Most circulating CD3+ T cells co-expressed CD2 and CD7~60% with 
fewer cells that expressed only CD2 (15% ) in control macaques (Figure 6.8).  CD3+CD2-CD7+ 
lymphocytes were maintained in WB while CD2+CD7+ lymphocytes were lost and early in 
infection CD2+CD7- lymphocytes were increased then returned to control macaque levels.   
CD3+CD2-CD7- T lymphocytes increased post-infection. 
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Figure 6.6. Bone marrow and whole blood percentages of T lymphocytes during SIV 
infection 
Percentages of cells expressing CD3 in bone marrow (BM) and whole blood (WB) populations 
by T lymphocyte gating strategy as described in text for A-B. bone marrow and C-D. whole 
blood.  Comparison of control cohort to early and chronic periods during SIV infection by Mann 
Whitney t tests (***p<0.01 and ****p<0.05).  Percentages are shown as mean + SEM. 
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Figure 6.7. Expression of early markers on T lymphocytes in bone marrow during SIV 
infection  
Percentages of CD2 and CD7 on CD3+ T lymphocytes by early T lymphocyte gating strategy as 
described in text.  Lymphocytes in the A-D multilineage gate in FSC versus SSC plot and E-F 
marrow lymphocyte gate in CD45 versus SSC plot.  Comparison of control cohort to early and 
chronic periods during SIV infection by Mann Whitney t tests (****p<0.05).  Percentages are 
shown as mean + SEM. 
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Figure 6.8. Expression of early markers on T lymphocytes in whole blood during SIV 
infection  
Percentages of expression of CD2 and CD7 on CD3+ T lymphocytes by early T lymphocyte 
gating strategy as described in text.  Lymphocytes in the A-D lymphocyte gate in FSC versus 
SSC plot and E-F CD45 lymphocyte gate in CD45 versus SSC plot.  Comparison of control 
cohort to early and chronic periods during SIV infection by Mann Whitney t tests (***p<0.01 
and ****p<0.05).  Percentages are shown as mean + SEM. 
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Viral loads positively correlated with BM and WB CD3+ T lymphocytes gated by CD45 
(Spearman r =0.5294, p=0.0350) and (Spearman r =0.6122, p=0.0117) respectively.  Moreover, 
viral loads negatively correlated with BM CD3+CD2-CD7- T lymphocytes (Spearman r = -
0.5559, p=0.0254).  BM CD3+CD2+7+ T lymphocytes and CD3+CD2+CD7- comparisons 
between FSC vs. SSC and CD45 vs. SSC gating strategies  positively correlated (Table 6.2) 
while all WB phenotypes positively correlated (Table 6.3).   
 
 
Table 6.2. Correlation of CD3+ T Lymphocyte Gated Populations Comparison Between 
FSC versus SSC Plot (R2 gate) and CD45 versus SSC Plot (R11 gate) for Bone Marrow 
 
Bone Marrow Phenotype Spearman r Coefficient p value 
CD3+ T Lymphocyte 0.1643 NS 
CD3+CD2-CD7+ T Lymphocyte 0.3000 NS 
CD3+CD2+CD7+ T Lymphocyte 0.6478 0.0006 
CD3+CD2+CD7-  T Lymphocyte 0.7139 <0.0001 
CD3+CD2-CD7-  T Lymphocyte -0.0761 NS 
NS = no significance 
 
 
Table 6.3. Correlation of CD3+ T Lymphocyte Gated Populations Comparison Between 
FSC versus SSC Plot (R6 gate) and CD45 versus SSC Plot (R18 gate) for Whole Blood 
 
Whole Blood Phenotype Spearman r Coefficient p value 
CD3+ T Lymphocyte 0.5788 0.0038 
CD3+CD2-CD7+ T Lymphocyte 0.7369 0.0002 
CD3+CD2+CD7+ T Lymphocyte 0.6207 0.0021 
CD3+CD2+CD7-  T Lymphocyte 0.7967 <0.0001 
CD3+CD2-CD7-  T Lymphocyte 0.5426 0.0091 
NS = no significance 
 
 
Percentages of CD20+ B Lymphocytes During SIV Infection 
 
B lymphocytes were defined as CD20+ cells.  BM CD20+ B lymphocytes represented 
higher percentages of lymphocytes in bone marrow (~30%) than WB (~20%).  Further, 50% of 
BM CD20+ B cells co-expressed CD38, 20% co-expressed IgM, and less than 10% co-expressed 
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IgG in control macaques (Figure 6.9, Figure 6.10, and Figure 6.11).  Expression of CD45 
intensity on CD20+ B lymphocytes was 33% CD45
Dim
, 33% CD45
Moderate
, and 33% CD45
Bright
 in 
BM while >97% of circulating cells were CD45
Bright
.  B lymphocytes in BM were depressed post 
infection with apparently equal losses for total B cells as well as CD38+, IgM+ and IgG+ 
expressing B cells and in the chronic phase for IgG+ B cells.  WB B lymphocytes early in 
infecttion approached the control level (increased) mainly due to a  rise in IgM+ B cells in the 
chronic phase.  IgG+ B cells were consistently depleted post-infection in blood.  Correlations 
with viral load were not observed for B lymphocytes.  Gating of B lymphocytes by the FSC vs. 
SSC or CD45 vs. SSC lymphocyte populations were moderately to highly correlated for all 
populations (Table 6.4 and Table 6.5).   
Percentages of Plasma Cells and Immature B Lymphocytes During SIV Infection 
 
Plasma cells were defined as CD3-CD20-CD38+CD138+ cells and immature B cells 
were defined as CD3-CD20-CD38+CD138- cells.  Plasma cells and immature B lymphocytes 
were less than 1% of the lymphocyte population at 10 fold higher in WB than BM with 
predominance in the CD45
DimToNegative 
gate for control macaques R17 and R10 respectively 
(Figure 6.12 and Figure 6.13).  Immature B cells were present only in BM of the CD45
Bright
 gate 
(R11) and barely detectable in the WB gate (R18).  Plasma cells decreased post-infection in WB 
and BM with greatest depression in the chronic phase.  A rise of CD45
Bright
 plasma cells was 
noted in the early phase in BM.  Immature B cells increased post-infection with apex in the early 
phase.  Plasma cells and immature B cells were not correlated to viral loads.  Bone marrow was 
highly correlated while whole blood gating was moderately correlated for gating strategies 
between FSC vs. SSC and the sum of both CD45 vs. SSC populations (Table 6.6 and Tabel 6.7).   
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Figure 6.9. Bone marrow and whole blood percentages of B lymphocytes during SIV 
infection 
Percentages of cells expressing CD20 in bone marrow (BM) and whole blood (WB) populations 
by B lymphocyte gating strategy as described in text for A-B. bone marrow and C-D. whole 
blood.  Comparison of control cohort to early and chronic periods during SIV infection by Mann 
Whitney t tests (****p<0.05).  Percentages are shown as mean + SEM. 
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Figure 6.10. Expression of CD38 and antibody markers on B lymphocytes in bone marrow 
during SIV infection  
Percentages of CD38 and antibody markers by CD20+ B lymphocytes by B lymphocyte gating 
strategy as described in text.  Lymphocytes in the A-D multilineage gate in FSC versus SSC plot 
and E-F marrow lymphocyte gate in CD45 versus SSC plot.  A.  CD20+CD38+ lymphocytes.  
B.  CD20+IgM+ lymphocytes.  C.  CD20+IgG+ lymphocytes.  D.  CD45
Bright
CD20+CD38+ 
lymphocytes.  E.  CD45
Bright
 CD20+IgM+ lymphocytes.  F.  CD45
Bright
 CD20+IgG+ 
lymphocytes.  Comparison of control cohort to early and chronic periods during SIV infection by 
Mann Whitney t tests (***p<0.01 and ****p<0.05).  Percentages are shown as mean + SEM. 
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Figure 6.11. Expression of CD38 and antibody markers on B lymphocytes in whole blood 
during SIV infection  
Percentages of expression of CD38 and antibody markers on CD20+ B lymphocytes by B 
lymphocyte gating strategy as described in text.  Lymphocytes in the A-C lymphocyte gate in 
FSC versus SSC plot and E-F CD45 lymphocyte gate in CD45 versus SSC plot.  Comparison of 
control cohort to early and chronic periods during SIV infection by Mann Whitney t tests 
(****p<0.05).  Percentages are shown as mean + SEM. 
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Table 6.4.Correlation of CD20+ B Lymphocyte Gated Populations Comparison Between 
FSC versus SSC Plot (R2 gate) and CD45 versus SSC Plot (R11 gate) for Bone Marrow 
 
Bone Marrow Phenotype Spearman r Coefficient p value 
CD20+ B Lymphocyte 0.7549 0.0001 
CD20+CD38+ B Lymphocyte 0.6541 0.0018 
CD20+IgM+ B Lymphocyte 0.7865 <0.0001 
CD20+IgG-  B Lymphocyte 0.9402 <0.0001 
 
 
Table 6.5. Correlation of CD20+ B Lymphocyte Gated Populations Comparison Between 
FSC versus SSC Plot (R6 gate) and CD45 versus SSC Plot (R18 gate) for Whole Blood 
 
Whole Blood Phenotype Spearman r Coefficient p value 
CD20+ B Lymphocyte 0.6586 0.0016 
CD20+CD38+ B Lymphocyte 0.6586 0.0016 
CD20+IgM+ B Lymphocyte 0.6213 0.0035 
CD20+IgG-  B Lymphocyte 0.832 <0.0001 
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Figure 6.12. Bone marrow and whole blood percentages of plasma cells during SIV 
infection 
Percentages of CD3-CD20- cells expressing CD38 and CD138 in A-C bone marrow (BM) and 
D-F whole blood (WB) populations by plasma cell gating strategy as described in text.  
Comparison of control cohort to early and chronic periods during SIV infection by Mann 
Whitney t tests (****p<0.05).  Percentages are shown as mean + SEM. 
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Figure 6.13. Bone marrow and whole blood percentages of immature B lymphocytes during 
SIV infection 
Percentages of CD3-CD20- cells expressing CD38 and CD138 in A-C bone marrow (BM) and 
D-F whole blood (WB) populations by immature B lymphocyte gating strategy as described in 
text.  Comparison of control cohort to early and chronic periods during SIV infection by Mann 
Whitney t tests (****p<0.05).  Percentages are shown as mean + SEM. 
 
 
Table 6.6.Correlation of Plasma Cell and Immature B Lymphocyte Gated Populations 
Comparison Between FSC versus SSC Plot (R2 gate) and CD45 versus SSC Plots (R10 + 
R11 gates) for Bone Marrow 
 
Bone Marrow Phenotype Spearman r Coefficient p value 
CD3-CD20-CD38+CD138+ Plasma Cell 0.8700 <0.0001 
CD3-CD20-CD38-CD138+ Immature B Lymphocyte 0.7957 <0.0001 
 
 
Table 6.7. Correlation of Plasma Cell and Immature B Lymphocyte Gated Populations 
Comparison Between FSC versus SSC Plot (R6 gate) and CD45 versus SSC Plots (R17 + 
R18 gates) for Whole Blood 
 
Whole Blood Phenotype Spearman r Coefficient p value 
CD3-CD20-CD38+CD138+ Plasma Cell 0.5789 0.0075 
CD3-CD20-CD38-CD138+ Immature B Lymphocyte 0.5285 0.0166 
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Percentages of Natural Killer Cells During SIV Infection 
 
NK cells were defined as CD3-CD20-CD8+CD335+ cells.  Natural killer cells were less 
than 6% of the lymphocyte population for BM and WB with BM populations 2X higher than WB 
in controls (Figure 6.14).  Higher percentages of NK cells were CD45
Bright
 .  NK cells were 
decreased post-infection in BM.  WB NK cells varied by gating strategy but overall were spared. 
NK cells did not correlate with plasma viral loads.  Nk gating strategies did not correlate 
between gating strategies for BM or WB (Table 6.8 and Table 6.9).   
 
Figure 6.14. Bone marrow and whole blood percentages of natural killer cells during SIV 
infection 
Percentages of CD3-CD20-CD8+ cells expressing CD335 in A-B  bone marrow (BM) and C-D 
whole blood (WB) populations by natural killer gating strategy as described in text.  Comparison 
of control cohort to early and chronic periods during SIV infection by Mann Whitney t tests 
(****p<0.05).  Percentages are shown as mean + SEM. 
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Table 6.8. Correlation of Natural Killer Cell Gated Populations Comparison Between FSC 
versus SSC Plot (R2 gate) and CD45 versus SSC Plot (R11 gate) for Bone Marrow 
 
Bone Marrow Phenotype Spearman r Coefficient p value 
CD3-CD20-CD8+CD335+ Natural Killer Cell 0.4341 NS 
NS = not significant 
 
Table 6.9. Correlation of Natural Killer Cell Gated Populations Comparison Between FSC 
versus SSC Plot (R6 gate) and CD45 versus SSC Plots (R18 gate) for Whole Blood 
 
Whole Blood Phenotype Spearman r Coefficient p value 
CD3-CD20-CD38+CD335+ Natural Killer Cell -0.1001 NS 
NS = not significant 
 
 
Percentages of Dendritic Cells During SIV Infection 
 
Dendritic cells were defined as HLA-DR
Bright
CD14-CD3-CD20- and additionally for 
mDC CD11cCD123 or pDC CD11cCD123.  Dendritic cells were minor populations within 
blood and marrow monocyte populations that consisted of predominantly mDC and fewer pDC 
in control macaques (Figure 6.10).  For infected RM, mDC were below the control population 
level for BM and WB.  Depletion of pDC in chronic infection by CD45 gating was detected but 
increased by FSC gating, however both gating strategies showed a rise in the early phase in BM 
and WB.  Correlations for gating of dendritic cells were present for BM and WB comparing FSC 
vs. SSC lymphoid and lymphocyte gating to CD45 vs. SSC R12 and R19 gating respectively 
(Table 6.10 and Table 6.11).  Viral loads did not correlate with dendritic cells. 
DISCUSSION 
 
Phenotypic analyses of lymphocyte and dendritic cell subsets were analyzed during SIV 
infection.  Immunophenotyping in the previous chapter (Chapter 5) and findings within the 
current chapter established percentages of BM lymphocytes.  In control macaques, the BM FSC 
lymphoid gate was defined by CD45 and CD14 plots as ~20% CD3+ T lymphocytes, ~20% 
CD20+ B lymphocytes, ~20% erythroid lineage including lineage negative immature  
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Figure 6.15. Bone marrow and whole blood percentages of dendritic cells during SIV 
infection 
Percentages of HLA-DR
Bright
CD14-CD3-CD20- cells expressing CD11c and CD123 in bone 
marrow (BM) and whole blood (WB) populations by dendritic cell gating strategy as described 
in text.  A-B  Dendritic cells in marrow monocyte gate.  C-D CD45
Moderate
 dendritic cells in 
marrow.  E-F Dendritic cells in blood monocyte gate.  G-H CD45
Moderate to
 
bright
 dendritic cells in 
blood.  Comparison of control cohort to early and chronic periods during SIV infection by Mann 
Whitney t tests (no difference).  Percentages are shown as mean + SEM. 
 
 
Table 6.10. Correlation of Dendritic Cell Gated Populations Comparison Between FSC 
versus SSC Plot (R3 gate) and CD45 versus SSC Plot (R12 gate) for Bone Marrow 
 
Bone Marrow Phenotype Spearman r Coefficient p value 
HLA-DRBrightCD14-CD3-CD20-CD11c+CD123-  
Myeloid Dendritic Cell 0.8923 <0.0001 
HLA-DRBrightCD14-CD3-CD20-CD11c-CD123+  
Plasmacytoid Dendritic Cell 0.8724 <0.0001 
 
 
Table 6.11. Correlation of Dendritic Cell Gated Populations Comparison Between FSC 
versus SSC Plot (R7 gate) and CD45 versus SSC Plot (R19 gate) for Whole Blood 
 
Whole Blood Phenotype Spearman r Coefficient p value 
HLA-DRBrightCD14-CD3-CD20-CD11c+CD123-  
Myeloid Dendritic Cell 0.6269 0.0031 
HLA-DRBrightCD14-CD3-CD20-CD11c-CD123+  
Plasmacytoid Dendritic Cell 0.4676 0.0376 
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hematopoietic cells, ~5% immature hematopoietic cells, ~2 % NK cells, ~2% immature myeloid 
cells, and <1% plasma cells and immature B cells.  CD45
Bright
 BM mature lymphocytes were 
~6% of nucleated cells composed of ~70% CD3+ T lymphocytes, ~30% CD20+ B lymphocytes, 
<2% NK cells, and <1% plasma cells and immature B cells.   
Good correlations for gating by FSC vs. SSC compared to CD45 vs. SSC were found for 
monocytes and lymphocytes, similar to findings in Chapter 5.  CD3+ T cells represented about 
1/5 of cells in the multilineage population of controls with moderate to bright expression of 
CD45.  In blood, lymphocytes were predominantly CD3+ and CD45
Bright
 in controls similar to 
BM findings in the CD45
Bright
 gate.  However, careful attention must be paid to gating schemes 
for identification of BM T cells as CD3+ T have variable staining intensity for CD45.  
Circulating cells can be gated through CD45 or FSC gates.  WB T cells and WB B cells were 
>95% CD45Bright with high correlations present between gating strategies indicating CD45 is 
not necessary to identify circulating T and B lymphocytes.   
Multilineage gating of BM revealed CD3+ cells were predominantly CD2-CD7, a highly 
unexpected finding.  However, this in not completely unanticipated because CD2 and CD7 are 
maturation markers we hypothesized would discriminate immature CD3+ T cells or precursors.  
In blood or scondary lymphoid tissues, CD3+ cells would be expected to express both CD7 and 
CD2 as the T cell receptor is rearranged and surface expression of CD3 manifests during thymic 
development after expression of CD7 and before expression of CD2.  Findings of decreased 
expression of early maturation markers were poorly described in the literature especially for 
bone marrow.  Possible explanations would be down-regulation in the BM compartment, binding 
of CD2 and CD7 by antibodies or other ligands, de novo lymphocyte production in bone marrow, 
or undefined recirculation patterns.   
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Control macaques had similar percentages in BM and WB respectively by different 
gating strategies, with good correlations for total B cells and subsets.  IgM B cells were found in 
higher percentages in BM while IgG B cells were found in higher percentages in circulation for 
control macaques.  Plasma cells and immature B cells were found in higher percentages in the 
CD45
DimToModerate
 gate versus the CD45
Bright
 gate for BM and WB in control macaques.  For 
control macaques, most NK cells were CD45
Bright
.  
In Chapter 5 we showed that during SIV infection, BM monocytes were maintained yet 
there was a loss of BM granulocytes and early loss of BM lymphocytes while circulating 
lymphocytes declined.  This study showed CD3+ T cells were maintained in BM during SIV 
infection and circulating T cells were lost in the chronic phase.  Loss of circulating T cells or 
lymphopenia has been a defining feature of HIV, AIDS, and SIV (C.D.C. 1982; Henrickson 
1983; Veazey 1998).  BM CD45
Bright
 gating of T cells revealed mature lymphocytes were 
CD2+CD7+ similar to circulating T cells.   
In WB the percentage of CD3+CD2+CD7+ cells represented the major circulating 
population but these varied for BM by gating strategy in control macaques.  CD3+CD2-CD7- T 
lymphocytes increased by percentage in circulation post-infection while maintained in BM.  
CD3+CD2+CD7+ T cells were maintained in BM by percentage but 
CD45
Bright
CD3+CD2+CD7+ mature T cells decreased post-infection in BM and WB.  BM and 
WB CD3+CD2+CD7- immature T cell percentages peaked early in SIV infection then fell in 
chronic infection.  BM and WB CD3+CD2-CD7- T cells increased early in infection but later 
decreased in BM.   
B lymphocytes decreased post-infection in BM and WB including CD38+ activated B 
cells.  IgM secreting mature B cells were maintained in WB but declined in BM by percentage 
post-infection.  IgG secreting mature B cells were low in BM and WB with depletion of IgG B 
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cells in the chronic phase of BM.  Early in SIV infection RM revealed loss of circulating B cells 
including loss of IgG and IgM secreting cells with decreased function (Kuhrt 2010; Peruchon 
2009).  Replenishment of circulating B cells has been reported to be slower for IgM than IgG B 
cells without return to pre-infection levels (Kuhrt 2010).  One theory for B cell loss is depletion 
or re-distribution into other lymphoid compartments (Kuhrt 2010).  Our study observed loss of B 
cells in BM, ruling out sequestration or increased production in this lymphoid compartment. 
Post-infection plasma cells were depressed in BM and WB; however CD45
Bright
 gating 
revealed an increase in the early phase. Immature B lymphocytes in BM and WB increased 
during the early phase then dropped to near control macaque levels in the chronic phase.  In HIV 
patients, plasma cells were decreased early and late during infection without restoration post-
ART therapy (Bussmann 2010). 
NK cells in BM and WB were low in the early phase then depressed in the chronic phase.  
CD45
Bright
 NK cells were increased in the early phase.  Early in SIV infection circulating NK 
cells were decreased in the RM and in chronic infection (Pereira 2008; Peruchon 2009).  Possible 
theories for loss of NK cells include overstimulation, necrosis, increased apoptosis or switching 
of NK cell receptors (Pereira 2008). 
Circulating mDC were low post-infection in BM and WB.  pDC were increased post-
infection in blood but this was only noted in the early phase of infection in BM. HIV-1 acute and 
chronic infected patients showed losses of pDC and mDC (Brown K. N. 2007; McKenna 2005).  
Losses of DC in HIV patients was reported from blood and lymph nodes suggesting a loss and 
not a redistribution during infection (Brown K. N. 2007).  HIV infected DC have been reported 
to ineffectively work as APCs because they cannot appropriately stimulate T cells (McKenna 
2005). 
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Although the lymphocytes in SIV infection were maintained by both phenotypic and 
morphologic analyses, only the T cells were maintained while B cells, plasma cells, and NK cells 
declined for bone marrow and whole blood.  Monocytes were also maintained during SIV 
infection though we found losses of mDC without losses of pDC in bone marrow and whole 
blood.    Our study found lower numbers of DC in bone marrow and whole blood with 
maintenance of T cells in bone marrow but loss in whole blood.  Transfection of HIV by „escort‟ 
cells was recently shown by in vitro culture experiments using a CXCR4/CCR5 HIV-1 virus 
with „host‟ human cells that monocyte-derived dendritic cells and not peripheral blood 
mononuclear cells enhanced virus infection (Sealy 2009).  Maintenance of T cells in bone 
marrow with loss of DC suggests DC may be more likely to be infected in bone marrow 
compared to circulating cells.   
SUMMARY 
 
During SIV infection, BM percentages of CD3+ T cells were maintained as 
CD3+CD2+CD7+ T cells, B cells, plasma cells, NK cells, monocytoid dendritic cells and 
plasmacytoid dendritic cells, only in the early phase, declined.  Concurrently during SIV 
infection, circulating percentages of T cells, CD3+CD2+CD7+ T cells, B cells, plasma cells, NK 
cells, and monocytoid dendritic cells declined while plasmacytoid dendritic cells increased.  
Findings were representative of reports in HIV and SIV.  Antigen presenting cells and 
lymphocytes showed corollary declines during infection in whole blood while bone marrow 
lymphocytes were maintained.  Findings suggest infected cells of bone marrow may be 
mononuclear DC cells and less likely CD3+ T cells which will be examined in the following 
chapter.  Finally, immunophenotyping revealed T cells, NK cells, plasma cells, and immature B 
cells were variable for CD45 staining in bone marrow indicating gating schemes should be 
clearly identified for reporting of these populations during SIV infection.   
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CHAPTER 7: VIRAL COPIES OF SIV ARE READILY 
PRESENT IN BONE MARROW YET FEW MONONUCLEAR 
HEMATOPOIEITIC BONE MARROW CELLS ARE OBSERVED 
TO BE INFECTED IN THE COURSE OF SIV DISEASE 
 
INTRODUCTION 
 
As early as 3 days post-infection, bone marrow hyperplasia, consisting of myeloid 
hyperplasia with a left shift that increases the myeloid: erythroid ratio and megakaryocyte 
hyperplasia are evident (Mandell 1993).  RM studies of bone marrow hematopoietic cells have 
found virus in bone marrow as early as  2 weeks post SIV  infection by in vivo and in vitro 
techniques (Watanabe 1990).  These early bone marrow changes may be the result of direct viral 
infection of T cells and macrophages (Mandell 1993).  Mononuclear cells have been identified as 
reservoir for HIV in BM (Louache 1992; Neal 1995).  Hematopoietic cells and stromal cells can 
be infected during HIV infection; however, dysfunction of the stromal support system has been 
proposed to cause bone marrow changes in hematopoiesis (Douek 2003).  Our prior studies have 
found hematologic abnormalities and bone marrow changed affecting circulating cells (Chapter 
3- 6).   
The objective of this study was to determine numbers and phenotype of SIV infected 
cells in bone marrow during progressive SIV disease.  We hypothesized mononuclear cells 
would be infected in bone marrow in very low proportions compared to total nucleated cells.  We 
performed semi-quantitative and quantitative analyses of bone marrow to detect SIV RNA and 
DNA.    
MATERIAL AND METHODS 
 
Experimental Database II-IV  
 
Experimental database and definitions are described in Appendix II.  . 
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Hematologic Data and Definitions 
 
Hematologic data and definitions are described in Appendix I. 
Whole Blood Absolute CD4+ Lymphocyte Count 
 
Flow cytometry analysis and whole blood absolute CD4+ lymphocyte count are 
described in Appendix III.   
Plasma Viral Load 
 
Plasma viral loads and definitions are described in Appendix IV.   
SIV In situ Hybridization  
 
SIV RNA and DNA non-radioactive in situ hybridization (ISH) was performed on bone 
marrow sections as previously described including appropriate positive and negative controls 
(Borda 2004; Kitagawa 1991; Veazey 1998; Wang 2007).  RNA ISH was performed for all 
infected subjects in ED IV listed in Table II.5 (Appendix II) and DNA ISH was performed on 
randomly selected SIV infected macaques listed in Table 7.2.  Formalin fixed paraffin-embedded 
bone marrow tissue sections and controls were deparaffinated in xylene followed by hydration in 
serial alcohol rinses ending in a final distilled diethylpyrocarbonate (DEPC) water rinse.  On day 
1, tissues were incubated in 0.2M HCl followed by a 1X sodium citrate (SSC) wash and antigen 
retrieval was performed by steam in 0.01M citrate buffer at pH 6.0 with a conventional 
microwave.  A 60 minute pre-hybridization incubation was performed followed by overnight 
incubation at 45°C in hybridization buffer with either SIV RNA digoxigenin labeled probe 
(Lofstrand Labs Limited; Gaithersburg, MD) or SIV DNA digoxigenin labeled probe (TNPRC 
Molecular Core, gifted from Terri Rasmussen) for detection of SIV RNA and SIV DNA ISH 
respectively.  Short washes in successive 1X SSC dilutions were conducted on day 2 and excess 
1X SSC was removed and tissues incubated in protein block (Serum Free Protein Blocker, 
134 
 
DAKO; Carpenteria, CA).  Appropriately diluted sheep Fab fragments of anti-digoxigenin 
antibody (Roche Diagnostics; Indianapolis, IN) were applied and sections were incubated 
overnight in dark humidified chambers at 4°C.  Two post-hybridization buffers were applied to 
wash tissues on day 3 and sections were developed with the chromogen nitro blue tetrazolium 
chloride/5-Bromo-4-chloro-3-indolyl phosphate (NBT-BCIP) (Roche).  SIV infected cells were 
distinguished by brown intranuclear staining.  For RNA ISH, 3 hour NBT-BCIP incubation was 
performed.  Twenty-seven hour incubation with NBT-BCIP was performed for DNA ISH.  A 
blinded evaluation of non-overlapping fields covering the entire section was performed by one 
microscopist using a Zeiss Axiostar Plus microscope (Zeiss; Thornwood, NY) was performed. 
Photographs were taken of representative sections using a 40X objective on a Leica DMLb 
microscope (Leica; Bannockburn, IL) using Spot Insight color camera and Spot Imaging 
Software (Diagnostic Instruments; Sterling Heights, MI). 
SIV RNA Fluorescent In situ Hybridization and Combined Fluorescent 
Immunohistochemistry detection by Confocal Microscopy 
 
Fluorescent in situ hybridization (FISH) and fluorescent immunohistochemistry (FIHC) 
were performed on selected infected macaques in Table 7.2 and appropriate controls as 
previously described (Borda 2004; Wang 2008b; Wang 2007).  Bone marrow and mesenteric 
lymph node tissue were evaluated from eight infected RM from ED II and eight infected RM 
from ED III by FISH.  Tissues from subjects from ED II were triple labeled for detection of SIV 
by FISH and by HAM56 and infected lymphocytes by CD3 by FIHC. 
Briefly, ISH was completed and sections were incubated overnight in 1X tris buffered 
saline (TBS).  A fluorescent antibody was applied in lieu of a chromogen on day 3.  After 
overnight incubation,  three serial 1X SSC washes were performed then tissues were incubated in 
1X diluted protein block (5X In Situ Hybridization Blocking Solution, Vector Laboratories; 
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Burlingame, CA) for 30 minutes.  Appropriately diluted sheep Fab fragments of anti-digoxigenin 
antibody (Roche Diagnostics; Indianapolis, IN) were applied and sections were incubated for 60 
minutes in dark humidified chambers.  Three serial 1X TBS washes were performed followed by 
incubation with Permanent Red for 20 minutes.  SIV RNA was detected by permanent fast red 
which fluoresces at 568 nm.   FIHC was performed afterward, for a select group of ED II 
macaques, following incubation in 1X TBS overnight.   On day 4, tissues were incubated for 60 
minutes with 10% normal goat serum (NGS) (Gibco; Carlsbad, CA) followed by incubation with 
the primary antibody (macrophage) HAM56 diluted in NGS and incubated for another 60 
minutes (Table 7.1).  Three serial washes in PBS-fish skin gelatin (FSG)-Tx100 then PBS-FSG 
were followed by incubation with the secondary antibody appropriately diluted in NGS for 
another 60 minutes (Table 7.1).  Three serial washes in PBS-FSG-TX100 and PBS-FSG were 
performed.  Tissues were incubated overnight in PBS-FSG then the FIHC protocol was repeated 
on day 5 using CD3 as the primary antibody with an appropriate secondary antibody (Table 7.1).   
Sections were examined by confocal microscopy at the TNPRC Confocal Microscopy 
Core.  A Leica TCS SP2 confocal microscope with three lasers was utilized (Leica 
Microsystems; Exton, PA) to image serial optical slices of 750 um
2
 with a 20x objective.   
Table 7.1. Primary and Secondary Antibody Staining for Fluorescent 
Immunohistochemistry of Experimental Database II 
 
 Macrophage Staining Lymphocyte Staining 
Primary Antibody 
Reagent, dilution 
Clone 
Resource 
 
HAM56, 1:20 
Mouse anti-human macrophage 
DAKO; 
Carpenteria, CA  
CD3 1:1000 
Rabbit anti-human, Clone  
DAKO; 
Carpenteria, CA 
Secondary Antibody 
Reagent, dilution 
Fluorochrome 
Resource 
 
Goat anti-mouse IgM, 1:500 
FITC Alexa 488 
Invitrogen; 
Carlsbad, CA 
Goat anti-rabbit IgG1 1:1000 
Far-red Alexa 633 
Invitrogen; 
Carlsbad, CA 
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Grading of SIV Infected Tissues 
 
Subjective grading of bone marrow and lymph node tissue by ISH and FISH was 
performed as previously described  (Borda 2004).  A blinded evaluation by one microscopist of 
all fields per bone marrow tissue and 5 fields of lymph node tissue was performed by light 
microscopy using a Zeiss Axiostar Plus microscope with a 20X objective (Zeiss; Thornwood, 
NY). Grading was 0 if no infected cells were detected (-); 1 to 10 infective cells detected in all 
microscopic fields (+); and greater than 10 infective cells detected in all microscopic fields ( ++).  
Quantifying SIV Infected Cells in Tissues 
 
FISH staining of bone marrow and lymph node of select SIV infected subjects were 
quantitatively evaluated for numbers of SIV infected cells/mm
2
 as previously described (Wang 
2007).  A blinded evaluation by one microscopist of random, non-touching fields per tissue was 
performed by confocal microscopy.  Five microscopic fields were evaluated and SIV positive 
staining cells were manually counted and means calculated and reported  as SIV infected 
cells/mm
2 
 per tissue. 
DNA Polymerase Chain Reaction Analysis 
 
DNA polymerase chain reaction (PCR) was performed with appropriate controls as 
previously described (Poonia 2006; Vajdy 2001).  Bone marrow collected from select ED III 
subjects  (Table 7.3) at necropsy was snap frozen in Tissue-Tek O.C.T. Compound (Sakura 
Finetek; Torrance, CA) then in dry-ice cooled isopentylbutane and maintained at -80°C.  Six 
frozen sections at 10µm each were prepared for DNA extraction and SIV DNA PCR analysis.  
DNA extraction was performed as per manufacturer directions for tissue (DNeasy Blood and 
Tissue Kit, Qiagen; Valencia, CA).  Tissue was washed in phosphate buffered saline (PBS) and 
digested/lysed with Proteinase K.  Binding of DNA was performed then washed with a final 
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elution step.  Spectrophotometric analysis of nucleic acid material was performed and all levels 
were >10µg/mL.  DNA primers were SIV specific (Integrated DNA Technologies; San Diego, 
CA).  DNA PCR analysis was performed using a Robocycler Gradient 40 analyzer (Stratagene; 
La Jolla, CA).  A minimum of 35 rounds of amplification were performed to detect viral 
fragments. 
Real Time Polymerase Chain Reaction Analysis 
 
Quantitative real time PCR (qRT-PCR) analysis was performed as previously described 
(Mohan 2008).  Bone marrow tissue was collected from eight ED III subjects at necropsy in 
RNA later (Ambion; Austin, TX) then frozen and maintained at -80°C.  Bone marrow tissue was 
then defrosted and approximately a 1/2 cm
2
 specimen was prepared for RNA extraction and SIV 
qRT-PCR.  RNA extraction was performed as per manufacturer directions (Rneasy Mini Kit, 
Qiagen; Valencia, CA) with DNase digestion (RNase-free DNase Kit, Qiagen; Valencia, CA).  
Tissue was washed in PBS and disrupted/homogenized.  DNase digestion was performed.  Then, 
binding of RNA was performed followed by washes with a final elution step.  
Spectrophotometric analysis of nucleic acid material was performed and each sample was 
standardized to 50µg/mL.  RNA primers were SIV specific (TNPRC Molecular Core, gifted 
from Terri Rasmussen).  qRT-PCR was performed using the RT PCR 7500 Fast Real Time PCR 
System (Applied Biosystems, Inc.; Foster City, CA).  
Statistical Analysis 
 
For data evaluation, controls were non-SIV infected macaques and SIV infected subjects 
were grouped into periods defined as early and chronic based on disease progression as chronic 
asymptomatic SIV disease (ASY), chronic advanced SIV disease (ASD), and AIDS (Appendix 
II).   Macaques developing AIDS were fast and slow progressors at >260 DPI. 
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Statistical difference, p ≤0.05, for periods of SIV infection in SIV infected macaques was 
determined using the Mann Whitney non-parametric unpaired t test  and correlations were 
determined using non-parametric Spearman correlation coefficients GraphPad Prism with 
Significance was considered as (GraphPad Software; La Jolla, CA).  Spearman correlation and p 
values for correlations of gating strategies were defined in tables.  Data are shown as means + 
SEM. Ss 
Percentages of immunophenotypic populations for control and SIV infected macaques 
were compared using the Mann Whitney non-parametric unpaired t test,  and correlations were 
determined using non-parametric Spearman correlation coefficients GraphPad Prism with 
significance was considered as (GraphPad Software; San Diego, CA).   
Graphs represent the means and SEM.  Significant differences were defined as  p≤0.05. 
RESULTS 
 
Plasma Viral Load and Whole Blood Absolute CD4+ Lymphocyte Counts During SIV 
Infection 
 
Viral load (Table IV.1 and Table IV.2 in Appendix IV) and CD4+ lymphocyte counts 
(Table III.1 and Table III.2 in Appendix III) were determined for all SIV infected RM (ED IV) 
from blood obtained on the day of necropsy.  A trend of increased viral load and decreased CD4 
counts was noted though the ASD period had the highest viral load and AIDS had the lowest 
CD4 counts but correlations were not identified (Figure 7.1).  CD4+ lymphocyte counts were 
significantly different from early through AIDS period (p<0.0001), ASY to AIDS period 
(p=0.0016), and ASD to AIDS period (p=0.0042).  Viral load was significantly different for 
early to ASY period (p=0.0004), early to AIDS period (p=0.0110), and ASY to ASD periode 
(p=0.0281). 
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Figure 7.1. CD4 lymphocyte count and plasma viral load for SIV infected macaques 
SIV viral load copies during various phases of SIV disease.  Phases of SIV infection were early, 
chronic asymptomatic SIV disease (ASY), chronic advanced SIV disease (ASD), and AIDS.  
Comparison of various phases of SIV infection by Mann Whitney t tests (**p<0.001, ***p<0.01, 
and ****p<0.05).  Values are shown as mean + SEM. 
 
 
Detection of Cellular Viral RNA and DNA in Bone Marrow During SIV Infection  
 
ISH was performed on bone marrow of SIV infected macaques with few positive results.  
For RNA detection, SIV infected cells were observed in bone marrow tissue from 2 of 47 
macaques (HG49 and FT46) (Figure 7.2 and Table 7.2).  For DNA detection, bone marrow from 
2 of 6 macaques (AL07 and HG56) identified virus (Figure 7.3 and Table 7.2 and Table 7.3).   
FISH with FIHC was performed on BM and mesenteric lymph node tissue for 8 infected 
macaques and  FISH only was performed on BM and mesenteric lymph node tissue for 8 other 
infected macaques (Table 7.2).  SIV infected cells were detected for 3/16 infected subjects 
(BV13, FT46 and HG49).  Phenotype of infected cells revealed HAM56+ macrophages, CD3+ T 
cells, double and single positive cells, and HAM56-CD3- cells (Figure 7.4).  Rare giant multi-
nucleated cells were SIV positive in lymphoid tissue but HAM56-CD3-. 
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Table 7.2. SIV Detection in Bone Marrow and Lymph Node Tissue 
 
 Subject IDa DPIb 
RNA ISH 
BMc 
DNA ISH 
BMd 
RNA FISH 
BMe 
RNA FISH 
LNf 
BA57 8  - NPg  - ++ 
BV13 8  - NP + ++ 
AV91 10  - NP  - ++ 
HI63 13  - NP  - ++ 
M992 13  - NP  - ++ 
BI58 22  - NP  - ++ 
FT46 71 +  - + ++ 
DI28 80  - NP  - ++ 
FE53 140  -  - + ++ 
HG49 145 +  -  - ++ 
HI68 155  -  - NP NP 
HG56 156  - +  - ++ 
N998 180  - NP  - ++ 
AL07 195  - + NP NP 
L164 195  - NP  - ++ 
HG58 283  -  - NP NP 
R544 414  - NP  - ++ 
BE64 742  - NP  - ++ 
P045 809  - NP  - ++ 
ID = identification; b) DPI = days post-inoculation; c) RNA ISH BM = RNA in situ hybridization of bone marrow tissue; d) 
DNA ISH BM = RNA in situ hybridization of bone marrow tissue; e) RNA FISH BM = RNA fluorescent in situ hybridization of 
bone marrow tissue; f) RNA FISH BM = RNA fluorescent in situ hybridization of lymph node tissue; g) NP = not performed; 
Subjective grading scale as defined in text 
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Figure 7.2. SIV viral RNA in bone marrow 
Photomicrograph of RNA SIV in situ hybridization staining in bone marrow for macaque FT46 
that identified an infected cell (brown color).  Field represents a 40X objective image (400X) on 
a Leica DMLb microscope (Leica; Bannockburn, IL) using Spot Insight color camera and Spot 
Imaging Software (Diagnostic Instruments; Sterling Heights, MI). 
 
 
 
 
 
Figure 7.3. SIV viral DNA in bone marrow 
Photomicrographs of DNA SIV in situ hybridization staining in bone marrow for macaque AL07 
that identified viral DNA in a few cells (brown color).  Field represents a 40X objective image 
(400X) on a Leica DMLb microscope (Leica; Bannockburn, IL) using Spot Insight color camera 
and Spot Imaging Software (Diagnostic Instruments; Sterling Heights, MI). 
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Figure 7.4. Immunophenotypic SIV detection in bone marrow 
Photomicrograph of Rhesus macaque BV13 fluorescent in situ hybridization and 
immunohistochemical staining of bone marrow tissue.  SIV in situ hybridization represented in 
red, HAM56 macrophages represented in green, CD3 lymphocytes represented in blue.  Infected 
cells are identified as SIV+HAM56-CD3+ (white arrow), SIV+HAM56+CD3- (yellow arrow) 
and SIV+HAM56-CD3- (pink arrow).   Field represents a 100X objective image using a Leica 
TCS SP2 confocal microscope (Leica Microsystems; Exton, PA). 
 
 
Viral DNA Was Detected in Bone Marrow Tissue During SIV Infection 
 
Ultrasensitive PCR for detection of SIV DNA in bone marrow tissue revealed positive 
results (Table 7.3).   The first PCR analysis revealed positive results for HG49, FE53, HG56, and 
HI68 found in the first panel in Figure 7.5.  Increased cycles of analysis revealed positive results 
for AV91, HI63, BA57, and M992 depicted in the second panel in Figure 7.5.  Finally >39 
cycles revealed positive results for AL07 and FA14 depicted in the third panel in Figure 7.5. 
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Table 7.3. Polymerase Chain Reaction (PCR) Detection of Viral DNA in Bone Marrow 
 
Subject Identification DNA PCR 
Acute   
AV91  + 
BA57  + 
HI63  + 
M992  + 
Chronic   
AL07  + 
FA14  + 
FE53  + 
HG49  + 
HG56  + 
HG58  + 
HI68   + 
 
 
Figure 7.5. SIV viral DNA in bone marrow tissue 
Polymerase chain reaction (PCR) for viral DNA SIV in bone marrow tissue in three panels.  N is 
the negative macaque control.  P is the positive macaque control.  S is bone marrow tissue from 
the SIV infected Rhesus macaque subjects.  PCR as defined in text. 
 
 
 
 
 
 
 
M M M SPP SNN P S
H
G
4
9
F
E
5
3
H
G
5
6
H
I6
8
A
V
9
1
H
I6
3
B
A
57
M
9
92
A
L
0
7
A
L
0
7
F
A
14
144 
 
SIV Virus was Quantifiable During SIV Infection 
 
qRT-PCR was performed on bone marrow from four early infected RM AV91, BA57, 
HI63 and M992 and four chronically infected RM FE53 (symptomatic), FT46 (symptomatic), 
HG49 and (asymptomatic), HG56 (AIDS) (Table 7.4).   RNA was detectable by PCR for all SIV 
infected animals without correlation to ISH or FISH detection.  Viral load was correlated to 
numbers of SIV infected cells in lymph node (Spearman r=0.7381, p value=0.0458).  qRT-PCR 
bone marrow analysis was negatively correlated to numbers of SIV infected cells in bone 
marrow (Spearman r= -0.7326, p value=0.0458). 
DISCUSSION 
 
Our findings of few infected cells in bone marrow during all periods of SIV infection is 
supported by findings of others (Doweiko 1993; Harbol 1994).  We identified only 4% of RM 
with infected BM cells by SIV RNA ISH which is lower than reported by Kitagawa et al. at 65% 
(15/23) subjects (Kitagawa 1991).  HIV was detected by RNA ISH in marrow of 16% (6/37) of 
HIV infected people including those with AIDS (Weiser 1996).  By DNA ISH analysis of 
marrow, we detected 28% infection (2/7).  RNA ISH findings were not consistent.  Only 1 
macaque was detected with infected bone marrow cells by both in situ techniques (FT46), but 
mesenteric lymph node tissue from all SIV infected subjects was positive at all post-inoculation 
stages of SIV.   
Morphologic examination of ISH and FISH SIV tissues revealed SIV infected T 
lymphocytes, macrophages, and unclassified CD3-HAM56- cells.  However, the number of 
infected cells was too low in marrow to determine the predominant infected cell type.  The 
unclassified CD3-HAM56- cells were mononuclear cells and not multi-nucleated cells such as 
osteoclasts or megakaryocytes.  Interestingly, prior reports of SIV infected marrow cells are  
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Table 7.4. Detection of SIV  
 
 Subject 
IDa  DPIb 
Plasma Viral 
Load qRT-PCRc RNA ISH Md RNA FISH BMe SIV RNA FISH LNf  DNA ISH BMg  DNA PCRh 
  
x 104 copies/mL copies/mL 
 
cells/mm2 cells/mm2 
  
BA57 8 1428 508  - 0 11.36 NP + 
AV91 10 15719 1904  - 0 26.83 NPe + 
HI63 13 2431 1032  NP 0 4.16 NP + 
M992 13 3494 3424  - 0 4.61 NP + 
FT46 71 17079 96 + 0.68 13.73 - NP 
FE53 140 34 21  - 0.23 2.03 - + 
HG49 145 10 122  + 0 2.93 - NP 
HG56 152 1952 1660  - 0 6.75 + + 
ID = identification; b) DPI = days post-inoculation;  c) qRT-PCR = quantitative real time polymerase chain reaction;  d) RNA ISH BM = RNA in situ hybridization of bone 
marrow tissue;  e) RNA FISH BM = RNA fluorescent in situ hybridization of bone marrow tissue;  f) RNA FISH BM = RNA fluorescent in situ hybridization of lymph node 
tissue;  g) DNA ISH BM = RNA in situ hybridization of bone marrow tissue;  h) DNA PCR = DNA polymerase chain reaction 
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predominantly macrophage or monocyte lineage cells rather than lymphoid cells especially early 
in infection (Kitagawa 1991; Mandell 1995).  BM macrophages or monocytes were observed to 
be infected at 1-2 copies per 100 cells in HIV patients by Davis et al. (Davis 1991).   
Macrophages were found to be HIV positive from HIV infected cultures of BM from 
healthy human donors (Canque 1995). Both pDCs and mDCs can be infected with HIV-1 
(McKenna 2005).  HIV-infected BM mononuclear cells, predominantly CD3+ lymphocytes at a 
rate of 10-200 HIV copies per 1000 CD3+ T lymphocytes, were detected in symptomatic HIV 
patients without evidence of infection within CD34+ cells, CFU-GM colonies, or macrophage 
progenitors (Davis 1991).   
Studies have produced conflicting information regarding HIV and its ability to infect 
CD34+ hematopoietic stem cells.  In vitro studies demonstrated HIV to infect marrow stem cells 
and thus produce fewer colony forming units in culture (Harbol 1994).  CD34+ bone marrow 
mononuclear were infected in vitro were with HIV89.6 (Carter 2010) and HIV-1 (Folks 1988).  
Other studies have documented few HIV patients with HIV-1 DNA in CD34+ hematopoietic 
stem cells (Harbol 1994).  CD34+ from BM of asymptomatic HIV infected patients was not 
positive for HIV RNA (Neal 1995).  In patients with high viral loads, CD34+ cells isolated from 
bone marrow mononuclear cells obtained by BM aspirate were found to express the HIV89.6 
clone Gag protein (Carter 2010).  Also in HIV human patients on HAART therapy with 
undetectable viral loads, CD34+ cells isolated from bone marrow mononuclear cell fractions, 
obtained by BM aspirates, had quantifiable HIV DNA viral genomes (Carter 2010).   
HIV has been detected in megakaryocytes of 10/10 AIDS patients with TCP by in situ 
hybridization for RNA based on morphologic appearance (Zucker-Franklin 1989a).  One SIV 
infected RM was reported  with infected megakaryocytes by in situ hybridization identification 
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which displayed severe lymphoid depletion and was co-infected with type D retrovirus serotype-
1 (Kitagawa 1991).  HIV was reported to infect megakaryocytes by CXCR4 co-receptor and 
monocytic cells by CCR5 co-receptor in BM despite both co-receptors being expressed on both 
cell types (Lee B. 1999). 
Viral DNA was detected in BM in 2 macaques by ISH and in 11/11 (100%) macaques by 
PCR.  Only 5/11 macaques had both ISH and PCR performed and one macaque, HG56, was 
positive by both techniques.  BM aspirate from advanced HIV disease and AIDS patients were 
detected with proviral DNA in 1-10% of CD4+ T lymphocytes and low numbers of CD14+ 
monocyte/macrophages and rarely in CD34+ cells and absent in macrophage progenitors (Davis 
1991).  Viral HIV DNA was found in plasmacytoid and monocytoid dendritic cells isolated from 
HIV patients (Donaghy 2003).  Proviral DNA was not detected from CFU-GM progenitor cells 
derived in vitro from CD34+ cells isolated from bone marrow aspirates of HIV infected patients 
(Davis 1991).  HIV viral DNA could not be detected in sorted BM CD34+ hematopoietic stem 
cells from HIV patients (Marandin 1996) (De Luca 1993) though Re et al. identified viral DNA 
copies in CD34+BM cells from 1/11 HIV patients (Re 1993).  Viral DNA was not detected from 
CD34+ BM cells in SHIV infected cynomolgus macaques (Thiebot 2001). 
Davis et al estimated fewer than 1 per 200 CFU-GM cells in BM may be infected with 
HIV viral DNA (Davis 1991).    Viral DNA was not detected by PCR  in CD34+ sorted bone 
marrow cells from RM infected with different strains of SIV (van Wely 1993).  One week post-
HIV infection of in vitro CD34+ BM cells with a negative Gag expression followed by addition 
of GM-CSF and TNF-α allowed detection of Gag expression (Carter 2010).  Hillyer et al. 
identified a weak signal for SIVsmm9 virus by PCR in CFU-GM progenitor cells derived from 
infected RM (Hillyer 1993b). Culture of BM cells from HIV infected patients did not reveal 
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detection of RNA or proviral detection in CFU-E, BFU-E, CFU-GM, or CFU-MK (Louache 
1992).  Davis et al. proposed transmission of virus from progenitor to differentiated cells is 
highly unlikely (Davis 1991). 
We quantified SIV RNA from 8/8 subjects including 1/8 identified by both ISH and 
FISH, 1/8 identified by ISH, and 1/8 identified by FISH.  Even though did not observed infected 
cells in all macaques, DNA or RNA was present in most.  Positive identification of virus is 
limited by ability of the test to detect a minimum number of viral copies. 
We identified only chronically infected macaques with quantifiable SIV and observed 
positive cells in BM despite quantifiable SIV in early macaques also.  Weiser et al further 
concluded HIV active replication of bone marrow did not occur in all stages of infection as in 
other lymphoid organs (Weiser 1996).  We conclude active infection and viral DNA are present 
in BM, notably in the chronic periods during progressive SIV infection and recommend multiple 
techniques be used for detection of SIV in bone marrow.   Testing to determine integration of 
viral DNA is also recommended. 
SUMMARY 
 
SIV was detected in bone marrow by multiple techniques.  RNA copies of SIV could be 
quantitated at all phases of infection while microscopic observation could only be detected in the 
chronic phases.  Copies of RNA present in BM were negatively correlated to numbers of SIV 
infected cells in marrow.  DNA copies of SIV were also detected at all phases of infection by 
polymerase chain reaction while microscopic observation could only be detected in the chronic 
phases.  Low numbers of bone marrow cells were infected with SIV including macrophages, 
CD3+ T lymphocytes, and unclassified mononuclear cells.  Evaluation of subsets of T cells in 
the following chapter will elucidate shifts during chronic infection. 
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CHAPTER 8: CD4 T CELLS ARE MAINTAINED AND CD8 T 
CELLS ARE INCREASED IN BONE MARROW DURING SIV 
INFECTION 
 
INTRODUCTION 
 
Loss of circulating CD4+ T cells is a hallmark of SIV and HIV disease (Veazey 1998).  
Activated, memory CD4+ T cells co-expressing CCR5 expression are depleted during SIV 
infection in secondary and tertiary lymphoid tissues (Veazey 1998; Veazey 2000a).  Recently, 
β7HighCD4+ circulating T cells have been observed to decrease parallel with CD4+CCR5+ T cell 
loss within the gastrointestinal tract even as circulating CD4+CCR5+ T cells approach pre- SIV 
infection  levels (Wang 2009).  Until recently, BM CD4+ lymphocytes during SIV infection 
were poorly characterized.  Paiardini et al. reported during SIV infection, BM CD4+ 
lymphocytes proliferate at lower levels compared to non-SIV infected RM indicating loss of 
homeostatic mechanisms (Paiardini 2009). 
The objective of this study was to determine absolute changes in lymphocytes population 
in WB and BM tissue.  Our prior studies evaluated percentages of lymphocytes in whole blood 
(Chapter 3) and bone marrow (Chapter 4-6) during early and chronic stages of SIV.  In whole 
blood we defined increased percentages but steadily declining absolute numbers during SIV 
disease.  Prior studies have reported T cells migrate through blood within the body including 
bone marrow (Di Rosa 2005; Palendira 2008).  Sopper et al. determined the lymphoid organ with 
highest numbers of lymphocytes was the thymus, followed by the spleen, lymph node, bone 
marrow, spleen, blood and lung in the RM (Sopper 2003). Moreover, we defined increased BM 
cellularity during chronic SIV infection (Chapter 4) and increased percentages of BM 
lymphocytes during chronic infection (Chapter 5 and Chapter 6).  Further, we described 
maintenance of lymphocytes in BM as APCs declined during SIV disease (Chapter 6).  Finally, 
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we established viral RNA and DNA were easily detected in BM during SIV infection, yet 
productively infected mononuclear cells were rare (Chapter 7). 
We hypothesized absolute numbers of T lymphocytes would decrease in the bone marrow 
compartment for CD4+ and CD8+ lymphocytes including naïve, memory, and activated subsets 
during progressive SIV infection and independent of the whole blood compartment lymphocyte.  
We additionally hypothesized the dual loss of lymphocytes in WB and BM would trigger 
compsensatory changes in lymphocyte homeostasis and regulation between the compartments.  
Bone marrow was analyzed by immunohistochemistry, flow cytometry, and absolute counts for 
comparison with blood to determine both percent and absolute values for select lymphocyte 
subsets.   
MATERIAL AND METHODS 
 
Experimental Database II 
 
Experimental database and definitions are described in Appendix II.   
Hematologic Data and Definitions 
 
Hematologic data and definitions are described in Appendix I. 
Flow Cytometry Analysis 
 
Whole blood and BM tissue collection, flow cytometry preparation, flow cytometry 
acquisition, flow cytometry analysis, and definitions are described in Appendix III.  
Immunophenotype of hematopoietic cells was performed for select populations (Table 8.1) based 
on multiple gating strategies in a particular order relating to grandparent, parent, sibling, and 
terminal populations.  All antibodies were from BD Biosciences (San Jose, CA). 
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Table 8.1. Lymphocyte Phenotypic Panels for Four Color Flow Cytometry by Antibody 
and Clone   
 
Flow Cytometry Panel FITC PE PerCP APC 
Lymphocyte Panel I CD3 
Clone SP34-2 
CD8 
Clone SK1 
CD20 
Clone L27 
CD4 
Clone L200 
Lymphocyte Panel II CD20 
Clone L27 
CD3 
Clone SP34-2 
CD8 
Clone SK1 
CD4  
Clone L200 
Lymphocyte Panel III CD3 
Clone SP34-2 
CD20 
Clone L27 
CD8 
Clone SK1 
CD4 
Clone L200 
Early Lymphocyte Panel 
CD7 
Clone M-T701 
CD137 
Clone 4B4-1 
CD8 
Clone SK1 
CD4 
Clone L200 
Proliferation  
Lymphocyte Panel I 
BrdU 
Clone 3D4 
CD3 
Clone SP34-2 
CD8 
Clone SK1 
CD4 
Clone L200 
Proliferation  
Lymphocyte Panel II 
BrdU 
Clone 3D4 
CD195 
Clone 3A9 
CD8 
Clone SK1 
CD4 
Clone L200 
Proliferation  
Lymphocyte Panel III 
Ki67 
Clone B56 
β7 
Clone FIB504 
CD8 
Clone SK1 
CD4 
Clone L200 
Proliferation  
Lymphocyte Panel IV 
Ki67 
Clone B56 
CD195 
Clone 3A9 
CD8 
Clone SK1 
CD4 
Clone L200 
Naïve and Memory 
Lymphocyte Panel 
CD95 
Clone DX2 
CD28 
Clone CD28.2 
CD8 
Clone SK1 
CD4 
Clone L200 
Naïve and Memory and 
Lymph Node Tissue Homing Molecule 
Lymphocyte Panel 
CD45RA 
Clone 5H9 
CD62L 
Clone SK11 
CD8 
Clone SK1 
CD4 
Clone L200 
Early Activation  
Lymphocyte Panel 
CD25 
Clone M-A251 
CD69 
Clone L78 
CD8 
Clone SK1 
CD4 
Clone L200 
Late Activation 
Lymphocyte Panel 
CD45RA 
Clone 5H9 
HLA-DR 
Clone L243 
CD8 
Clone SK1 
CD4 
Clone L200 
Integrin Gut Associated  
Lymphoid Tissue Homing Molecule  
Lymphocyte Panel 
CD45RA 
Clone 5H9 
βeta7 (β7) 
Clone FIB504 
CD8 
Clone SK1 
CD4 
Clone L200 
CCR5 Chemokine Receptor (CD195) 
Lymphocyte Panel 
CD45RA 
Clone 5H9 
CD195 
Clone 3A9 
CD8 
Clone SK1 
CD4 
Clone L200 
CXCR4 Chemokine Receptor (CD184) 
Lymphocyte Panel 
CD45RA 
Clone 5H9 
CD184 
Clone 12G5 
CD8 
Clone SK1 
CD4 
Clone L200 
CXCR3 Chemokine Receptor (CD183) 
Lymphocyte Panel 
CD45RA 
Clone 5H9 
CD183 
Clone 
CD8 
Clone SK1 
CD4 
Clone L200 
 
Identification of Lymphocytes 
 
Lymphocyte phenotype panels in Table 8.1 were utilized to define populations using 
Boolean gating schemes as previously described (Veazey 2000b).  Lymphocytes were identified 
in bone marrow and whole blood by first gating through lymphocytes (Figure 8.1).  Lymphocyte 
subsets were then identified as CD4+ or CD8+ or CD7+ (early maturation marker) cells as 
shown in Figure 8.2B and 8.2C and 8.2D respectively.   CD4+ and CD8+ subsets were identified 
in four quadrant gating as single, double positive, or negative populations in Figure 8.2F.   For  
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A.                                                        B. 
             
Figure 8.1. Lymphocyte populations in bone marrow and whole blood 
Phenotypic gating of lymphocyte populations by FSC versus SSC gating dot plots by 
multilineage gate of bone marrow (A.) and lymphocyte gate of whole blood (B.).  Lymphocytes 
are delineated by the oval gates. 
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identification of T lymphocytes, the CD3+ population was identified (Figure 8.2A) first then 
subsequent gates were applied (Figure 8.2B-E).   Lymphocyte populations were detected using 
the lymphocyte panel and early lymphocyte panel defined in Table 8.1. 
Proliferation Lymphocyte Phenotypic Panel 
 
Proliferating lymphocytes were identified by bromodeoxyuridine (BrdU) while 
lymphocytes active in the cell cycle were identified by Ki67 in bone marrow and whole blood 
(Table 8.1).  Lymphocytes were identified in bone marrow and whole blood as shown in Figure 
8.1 and Figure 8.2.  Four terminal phenotypes or gates were identified within the parent gate.  
The terminal gate was identified by the proliferation marker, either BrdU or Ki67, vs. 
lymphocyte marker, either CD4 or CD8, plot for determination of double positive cells (Figure 
8.3).   
  A.                          B.                        C.                          D.                         E.
 
Figure 8.2. Phenotypic identification of lymphocyte subsets 
Phenotypic identification of lymphocytes in bone marrow (upper panels) and whole blood (lower 
panel) by gating from the parent lymphoid or lymphocyte gate by FSC versus SSC plot 
respectively.  A. CD3+ lymphocytes by CD3 versus SSC plot.  B. CD4+ lymphocytes by CD4 
versus SSC plot.  C. CD8+ lymphocytes by CD8 versus SSC plot.  D. CD7+ early lymphocytes 
by CD7 versus SSC plot.  E. Four quadrant gating CD4 versus CD8 identified quadrants (Q) as 
Q1 or CD4-CD8+; Q2 or CD4+CD8+; Q3 or CD4-CD8-; and Q4 or CD4+CD8- lymphocytes.  
Cells were identified as described in text. 
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            A.                                    B. 
 
Figure 8.3. Phenotypic identification of proliferating CD4 and CD8 lymphocytes  
Phenotypic identification of proliferating lymphocytes in bone marrow and whole blood by 
gating from the parent lymphoid or lymphocyte gate by FSC versus SSC plot respectively.  A. 
BrdU+CD4+ lymphocytes by BrdU versus CD4 plot (upper panel) and Ki67+CD4+ 
lymphocytes by Ki67 versus CD4 plot (lower panel).  B. BrdU+CD8+ lymphocytes by BrdU 
versus CD8 plot (upper panel) and Ki67+CD8+ by Ki67 versus CD8 plot (lower panel).  Cells 
were identified as described in text. 
 
 
Naïve and Memory, Tissue Homing, Activation, and Chemokine Receptor Lymphocyte 
Phenotypic Panels 
 
Lymphocytes were identified in bone marrow and whole blood as shown in Figure 8.1 
and Figure 8.2.  The terminal phenotype was from the parent gates as a four quadrant gate of the 
FITC antibody vs. the PE antibody for each panel as defined in Table 8.1.  Four quadrant gating 
single positive, double positive, and negative populations (Figure 8.4).  FL1 included CD95, 
CD25, and CD45RA as defined in Table 8.1.  FL2 included CD28, CD69, CD62L, HLA-DR, β7, 
CD195, CD184, and CD183 as defined in Table 8.1.  Total cells were the sum of all positive 
populations. 
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Figure 8.4. Phenotypic identification of lymphocytes by four quadrant gating 
Phenotypic identification of naïve, memory, homing, and activated lymphocytes also chemokine 
receptors on lymphocytes in bone marrow and whole blood by gating described in Table 8.1.  
The terminal gates of interest were determined by four quadrant gating of FL1 or FITC versus 
FL2 or PE dot:  FL1 or FITC vs. FL2 or PE defined quadrants as Q1 or FL1-FL2+ or single 
positive FL2, Q2 or FL1+FL2+ or double positive, Q3 or FL1-FL2- or double negative, and Q4 
or FL1+FL2- or single positive FL1 lymphocytes. 
 
 
Plasma Viral Load 
 
Plasma viral loads and definitions are described in Appendix IV.   
Quantitation of Macrophages and Lymphocytes in Bone Marrow Tissue 
 
Five µm sections of formalin fixed paraffin-embedded bone marrow tissue were 
processed for macrophage and CD3 T lymphocyte IHC staining.  IHC was performed as 
previously described (Borda 2004; Wang 2008b).  Briefly, tissue sections were fixed in xylene 
then rehydrated in alcohol gradients and finally distilled water.  Antigen retrieval was achieved 
by steam in 1X citrate buffer pH 6.0 for 20 minutes and then cooled slides were washed in TBS 
solution.  A tissue protein block with DAKO Protein Blocker, Serum Free (Carpenteria, CA) was 
performed followed with a tissue peroxidase block using DAKO Peroxidase Blocking Reagent 
(DAKO).   After a TBS wash, tissue was incubated with mouse anti-human HAM56 macrophage 
antibody (DAKO) for 60 minutes.  Slides were washed again in TBS and peroxidase 
amplification was implemented with VectaStain Elite Peroxidase ABC Kit (Vector Laboratories; 
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Burlingame, CA) per manufacturer direction followed by another TBS wash.  Macrophages were 
detected by DAB chromogen (DAKO) developed for 4 minutes.  Following an overnight TBS 
incubation and wash, the tissue was treated as before by protein block, TBS wash, peroxidase 
block, and TBS wash.  Rabbit anti-human CD3 antibody (DAKO) was applied for 60 minutes.  
A TBS wash and amplification was performed with a biotin free alkaline phosphatase system by 
Biocare Medical Mach3 Probe and Polymer system (Biocare; Concord, CA) per manufacturer 
directions.  CD3+ T lymphocytes were detected by Ferangi blue (Biocare) chromogen after 5 
minutes development.  Tissues were incubated overnight in TBS then air dried and cover slipped.  
Tissues were imaged using a 20X objective on a Leica DMLb microscope (Leica; Bannockburn, 
IL) with Spot Insight color camera and Spot Imaging Software (Diagnostic Instruments; Sterling 
Heights, MI).  Each tissue section was examined and 5 random non-touching fields were 
collected.  Image-Pro Plus 4.0 (Media Cybernetics; Silver Springs, MD) software allowed the 
images to be manually blindly counted for Ham56+ brown cells and CD3+ blue cells within a 
standard area reported as mean cells/mm
2
 from an area of 2800 mm
2 
per image (Figure 8.5). 
Quantitation of Lymphocyte Subsets in Bone Marrow and Whole Blood 
 
BM absolute numbers were determined.  Percentages of CD3+CD4+ and CD3+CD8+ 
lymphocytes within BM determined by flow cytometry were multiplied by the mean CD3 
absolute lymphocyte count from the IHC analysis of bone marrow tissue for each subject to 
obtain absolute numbers of CD3+CD4+ and CD3+CD8+ lymphocytes respectively. Next, T 
lymphocyte numbers in marrow were multiplied by the lymphocyte percentage of CD4+ or 
CD8+ subsets.  The resultant new product was the absolute bone marrow immunophenotype 
lymphocyte count (ILC) defined as lymphocytes/mm
2
 for each subset.   
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Figure 8.5. Identification of lymphocytes and macrophages in bone marrow tissue 
Image representative of immunohistochemical staining for CD3+ lymphocytes (blue cells, open 
arrow) and macrophages (brown cells, closed arrow) in a paraffin embedded bone marrow tissue 
section.  Field represents a 20X objective image (200X) on a Leica DMLb microscope (Leica; 
Bannockburn, IL) using Spot Insight color camera and Spot Imaging Software (Diagnostic 
Instruments; Sterling Heights, MI). 
 
WB absolute numbers were determined suing CBC data.  Percentages of CD4+ and 
CD8+ lymphocytes within the flow cytometry WB lymphocyte gate were multiplied by the 
absolute lymphocyte count from the CBC analysis for each individual subject to obtain absolute 
numbers of CD4+ and CD8+ lymphocytes respectively. Next, T lymphocyte numbers in marrow 
were multiplied by the lymphocyte percentage of CD4+ or CD8+ subsets.  The resultant new 
product was the absolute bone marrow defined as 10
3 
lymphocytes/µL. 
Statistical Analysis 
 
For data evaluation, controls were non-SIV infected macaques and SIV infected subjects 
were grouped into periods defined as early and chronic based on disease progression as chronic 
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asymptomatic SIV disease (ASY), chronic advanced SIV disease (ASD), and AIDS (Appendix 
II).   Macaques developing AIDS were slow progressors at >260 DPI. 
Percentages and absolute numbers of immunophenotypic populations for control and SIV 
infected macaques were compared for differences using the Mann Whitney non-parametric 
unpaired t test  and correlations were determined using non-parametric Spearman r correlation 
coefficients in GraphPad Prism with significance considered as p<0.05 (GraphPad Software; La 
Jolla, CA).  Means of data are represented by graphs where error bars represent the SEM.  
Percentages and absolute numbers of  immunophenotypic populations for control and 
SIV infected macaques were compared using the Mann Whitney non-parametric unpaired t test,  
and correlations were determined using non-parametric Spearman correlation coefficients 
(GraphPad Software; San Diego, CA).   
Graphs represent the means and SEM.  Significant differences were defined as  p≤0.05. 
 
RESULTS 
 
Phenotyping Lymphocyte Populations During SIV Infection 
 
Lymphocyte populations were compared during progressive SIV infection in the marrow 
and blood compartment by FSC vs. SSC plot (Figure 8.6). The BM phenotypic lymphocyte gate 
demonstrated a decline in the early phase and stabilization in the chronic phase, though stages by 
clinical disease varied which was supported by our prior study (Chapter 5 and Chapter 6).  Early 
in infection, BM showed a decrease while WB maintained percentages, however both 
compartments peaked in the ASY period followed by drop in the ASD and AIDS periods in SIV.   
Of note, the BM multilineage gate represented immature hematopoietic cells and the erythroid 
lineage cells, so further determination of lymphocytes and subsets was needed to ascertain 
changes in SIV infection .   
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Figure 8.6. Percentages of total cells in phenotypic lymphocyte gates of bone marrow and 
whole blood during SIV 
Mean lymphocyte populations by FSC versus SSC plots during SIV infection.  A.  Percentage of 
cells in lymphoid gate of bone marrow.  B. Percentage of cells in lymphocyte gate of whole 
blood.  Mann Whitney t tests compared populations between control cohort and each infected 
time period of SIV (****p<0.05).  Infected time periods were early, ASY was chronic 
asymptomatic group, ASD was advanced SIV disease or chronic symptomatic group, and AIDS 
displayed as mean values + SEM. 
 
 
Percentages of Lymphocytes that Expressed the Early CD7+ Lymphocyte Phenotype 
During SIV Infection 
 
CD7 is expressed on T lymphocytes starting early in the maturation process.  Percentages 
of lymphocytes from control RM that expressed the early maturation T lymphocyte phenotype 
were ~ 10X higher in WB than BM (Figure 8.7).  CD7 expression on CD8+ lymphocytes in BM 
(>60%) but CD4+ in WB (>60%) for control macaques (Figure 8.8).  Overall, percentages of 
CD7+  lymphocytes decreased post-infection in both BM and WB compartments expressed as a 
steady decline for WB (Figure 8.7) which mimicked the lymphocyte gated populations.  Peak 
populations for CD8+ lymphocytes in both compartments occurred during AIDS while in the 
same phase CD4+ lymphocytes were the most depressed.  BM CD7+CD4+ and CD7+CD8+ 
cells negatively correlated (Spearman coefficient = -0.3748, p = 0.0265).  WB CD7+CD4+ 
lymphocytes declined post-infection while in the same periods CD7+CD8+ lymphocytes 
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increased.  Phenotypic evaluation of specific lymphocyte populations was performed to examine 
if loss in early lymphocytes of both compartments translated to loss of mature lymphocytes. 
 
Figure 8.7. Percentages of early maturation markers expressed on lymphocytes in bone 
marrow and whole blood during SIV 
Expression of CD7, an early maturation marker, on lymphocyte subsets during SIV infection.   
A. Percentages of CD7+ lymphocytes in bone marrow.  B. Percentages of CD7+ lymphocytes in 
whole blood.  C. CD4 versus CD8 expression on CD7 lymphocytes in bone marrow by 
percentage.  D. CD4 versus CD8 expression on CD7 lymphocytes in whole blood by percentage.  
Mann Whitney t tests compared populations between control cohort and each infected time 
period of SIV (**p<0.001, ***p<0.01, and ****p<0.05).  Infected time periods were early, ASY 
was chronic asymptomatic group, ASD was advanced SIV disease or chronic symptomatic 
group, and AIDS displayed as mean values + SEM. 
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Percentages of T Lymphocytes During SIV Infection 
 
Percentages of T lymphocytes were ~ 7X higher in WB than BM for control macaques 
(Figure 8.8).  Based on CD3+ phenotype, nearly 50% of BM T cells and nearly 80% of WB T 
cells expressed CD7 in control macaques.  Mature BM T lymphocyte populations remained 
fairly stable during progressive SIV infection compared to loss in circulation by phenotypic 
analysis.  In the ASY phase, BM CD3+ cells were depressed but rebounded in later phases.  
However, depression of WB CD3+ cells was noted early in infection with failed attempts to 
rebound as disease progressed to AIDS.  Absolute numbers of lymphocytes were determined to 
verify BM lymphocytes were maintained during SIV disease. 
 
Figure 8.8. Percentages of CD3+ lymphocytes in bone marrow and whole blood during SIV 
Percentage of CD3+ T lymphocytes during SIV infection in A. bone marrow and B. whole blood 
by percentage.  Mann Whitney t tests compared populations between control cohort and each 
infected time period of SIV (****p<0.05).  Infected time periods were early, ASY was chronic 
asymptomatic group, ASD was advanced SIV disease or chronic symptomatic group, and AIDS 
displayed as mean values + SEM. 
 
 
Absolute Numbers of T Lymphocytes During SIV Infection  
 
Post-infection, absolute numbers of T lymphocytes and macrophages in BM determined 
by IHC analysis increased compared to control macaques, with the smallest increase in the ASY 
period and highest in the ASD period (Figure 8.9).  The ratio of CD3+ lymphocytes to HAM56+  
CD3+ Lymphocyte Population
in Bone Marrow
C
O
N
TR
O
L
E
AR
LY
A
SY
A
SD
A
ID
S
0
20
40
60
80
100
%
 C
e
lls
 i
n
L
y
m
p
h
o
id
 G
a
te
CD3+ Lymphocyte Population
in Whole Blood
C
O
N
TR
O
L
E
AR
LY
A
SY
A
SD
A
ID
S
0
20
40
60
80
100
%
 C
e
lls
 i
n
L
y
m
p
h
o
c
y
te
 G
a
te
B.A.
165 
 
 
Figure 8.9. Absolute numbers of CD3 lymphocytes and macrophages in bone marrow 
during SIV 
Immunohistochemical evaluation of bone marrow tissue for CD3 T lymphocytes and HAM56 
(macrophages) in SIV.  A. Absolute numbers of CD3+ T lymphocytes and macrophages.  B. The 
ratio of CD3+ T lymphocytes to HAM56 macrophages in bone marrow.  Mann Whitney t tests 
compared populations between control cohort and each infected time period of SIV (***p<0.01, 
and ****p<0.05).  Infected time periods were early, ASY was chronic asymptomatic group, 
ASD was advanced SIV disease or chronic symptomatic group, and AIDS displayed as mean 
values + SEM. 
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macrophages was 1 for control macaques while infected macaque ratios were 1.5-2X higher than 
controls.   Meanwhile, absolute numbers of total lymphocytes dropped during the same SIV 
phases (Figure 8.10).  Absolute numbers of several lymphocyte subsets were calculated to 
characterize the increase in the BM compartment in relation to the loss of the WB compartment.  
 
Figure 8.10. Absolute numbers of lymphocytes in whole blood during SIV 
Absolute numbers of whole blood lymphocytes by CBC analysis during SIV infection.  Mann 
Whitney t tests compared populations between control cohort and each infected time period of 
SIV (**p<0.001).  Infected time periods were early, ASY was chronic asymptomatic group, 
ASD was advanced SIV disease or chronic symptomatic group, and AIDS displayed as mean 
values + SEM. 
 
Absolute Numbers of Lymphocytes During SIV Infection 
 
CD3+ T lymphocytes in bone marrow of control RM were predominantly composed of 
CD8+ cells (~75%) and fewer CD4+ cells (~25%) by percentage and absolute numbers with a 
CD4:CD8 ratio less than 1, the opposite of WB for naïve RM (Figure 8.11).  Whole blood had 
higher percentages of CD4+ lymphocytes ~50% of the lymphocyte population compared to 
CD8+ lymphocytes at <30% of lymphocytes in controls for a CD4:CD8 percent ratio greater 
than 1.  For control macaques, the WB CD4:CD8 ratio was about 2X higher than the BM 
CD4:CD8 ratio.   
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Figure 8.11. Percentages and absolute numbers of CD3, CD4, and CD8 lymphocytes in 
bone marrow and whole blood during SIV 
Expression of CD3, CD4, and CD8 on lymphocytes during SIV infection by percent and absolute 
numbers in bone marrow and whole blood.  A. Percent lymphocytes in bone marrow.  B. 
Absolute lymphocyte numbers in bone marrow.  C. CD3+CD4+ to CD3+CD8+ ratio of bone 
marrow percent lymphocytes.  D. CD3+CD4+ to CD3+CD8+ ratio of bone marrow absolute 
lymphocytes.  E. Percent lymphocytes in whole blood.  F. Absolute lymphocyte numbers in 
whole blood.  G. CD4+ to CD8+ ratio of whole blood percent lymphocytes.  H. CD4+ to CD8+ 
ratio of whole blood absolute lymphocytes.  Mann Whitney t tests compared populations 
between control cohort and each infected time period of SIV (**p<0.001, ***p<0.01, and 
****p<0.05).  Infected time periods were early, ASY was chronic asymptomatic group, ASD 
was advanced SIV disease or chronic symptomatic group, and AIDS displayed as mean values + 
SEM. 
 
Figure on next page. 
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BM lymphocytes by percent and absolute numbers revealed increases in lymphocytes 
during SIV infection which were mostly attributed to increased CD3+CD8+ lymphocytes and to 
a lesser extent CD3+CD4+ lymphocytes.  Absolute numbers of CD4+ BM lymphocytes were 
maintained near control levels but depressed in the ASY and AIDS period.   Absolute numbers 
of CD8+ BM lymphocytes in progressive infection were about 2-3X higher than in controls with 
peak in later periods (p<0.05). Post-infection, BM CD3+, CD3+CD4+, and CD3+CD8+ 
lymphocytes were highest in the ASD period and lowest in the ASY period.   
Infected macaques had low levels of circulating lymphocytes in later phases, especially the AIDS 
phase, for CD3+, CD4+, and CD8+ lymphocytes.  CD8+ lymphocytes were elevated initially 
during SIV infection but dropped in absolute numbers in advanced stages while CD3+ and CD4+ 
lymphocytes remained depressed. Post-infection, WB CD3+, CD4+, and CD8+ lymphocytes 
were highest in the ASY phase and lowest in the AIDS phase.   
For both compartments, the CD4:CD8 ratio was never restored to control levels in 
infected macaques. CD4:CD8 ratios were decreased post-infection with depression in the ASY 
phase for BM (p<0.05) and in AIDS for WB (p<0.05). 
Similar patterns of total CD8+ and CD4+ lymphocytes were observed for both 
compartments (Figure 8.12).  In both compartments, double positive (CD4+CD8+) lymphocytes 
were minimally changed by percentage or absolute number during SIV disease.  Interestingly, 
BM CD3+ double negative (CD4-CD8-) lymphocytes were increased during infection (p<0.05) 
similar to BM CD3+CD4+ lymphocytes.  In fact, BM CD3+CD4-CD8- lymphocytes were found 
in greater numbers than CD3+CD4+CD8- for the early and AIDS stages of SIV disease. A 
moderate negative correlation was observed between CD3+ lymphocyte WB and BM absolute  
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Figure 8.12. Percentages and absolute numbers of CD4/CD8 lymphocytes in bone marrow 
and whole blood during SIV 
Expression of CD4 and CD8 on lymphocytes during SIV infection by percent and absolute 
numbers in bone marrow and whole blood.  A. Percent T lymphocytes in bone marrow.  B. 
Absolute T lymphocyte numbers in bone marrow.  C. Percent lymphocytes in whole blood.  D. 
Absolute lymphocyte numbers in whole blood.  Mann Whitney t tests compared populations 
between control cohort and each infected time period of SIV (**p<0.001, ***p<0.01, and 
****p<0.05).  Infected time periods were early, ASY was chronic asymptomatic group, ASD 
was advanced SIV disease or chronic symptomatic group, and AIDS displayed as mean values + 
SEM. 
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numbers (Spearman coefficient = -0.4960, p = 0.0033).  Correlations were not observed between 
WB and BM absolute CD4+ lymphocytes or WB and BM absolute CD8+ lymphocytes. 
Lymphocyte Subset Proliferation During SIV Infection 
 
BrdU is incorporated into lymphocytes during the S phase (synthesis) during cell 
replication while Ki67 staining identified lymphocytes within all active stages of cell cycle 
replication excluding G0 or resting cells (Figure 8.13 and Figure 8.14 respectively).  Controls 
revealed most BM CD3+CD4+ lymphocytes in the active phases of the cell cycle were 
replicating confirmed by both percent and absolute number.  Absolute numbers of BM 
CD3+CD8+ lymphocytes revealed 1/10
th
 were actively replicating in controls.  Control 
macaques expressed nearly equal numbers of proliferating CD3+CD4+ and CD3+CD8+ 
lymphocytes in BM though more CD3+CD8+ cells were in the active cell cycle.  Proliferating 
lymphocytes of controls were similar between percent and absolute number in blood with 20% 
CD4+ lymphocytes and 30% CD8+ lymphocytes replicating. The ratio of S phase by BrdU 
staining to all active cell cycle stages by Ki67 staining or proliferation ratio was higher for the 
BM  CD3+CD4+ lymphocyte compartment compared to the WB compartment but lower for BM 
CD3+CD8+ lymphocytes than WB in control subjects (Table 8.2).   
Active cell cycle (Ki67) and proliferating (BrdU) CD3+CD4+ BM lymphocytes were 
similar in patterns with declines in the early and AIDS periods of SIV.  CD3+CD8+ BM 
lymphocytes were increased both by BrdU and Ki67 expression post-infection.  Significant 
differences in the chronic period for CD4+ BM lymphocytes were noted consistent with cell 
cycle dysregulation also in the early and AIDS periods for CD8+ BM lymphocytes.  The 
CD4:CD8 BM ratios were variable due to differences in absolute numbers during the stages of 
SIV (Table 8.3).   
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Figure 8.13. Percentages and absolute numbers of CD4 and CD8 proliferating lymphocytes 
(BrdU+) in bone marrow and whole blood during SIV 
Expression of BrdU on lymphocytes during SIV infection by percent and absolute numbers in 
bone marrow and whole blood to detect S phase of the cell cycle or replication as described in 
text.  A. Percent CD4+ BrdU+ lymphocytes in bone marrow.  B. Absolute CD3+CD4+ BrdU+ 
lymphocyte numbers in bone marrow.   C. Percent CD4+ BrdU+ lymphocytes in whole blood.  
D. Absolute CD4+ BrdU+ lymphocyte numbers in whole blood.  E. Percent CD8+ BrdU+ 
lymphocytes in bone marrow.  F. Absolute CD3+CD8 BrdU+ lymphocyte numbers in bone 
marrow.  G. Percent CD8+ BrdU+ lymphocytes in whole blood.  H. Absolute CD8+ BrdU+ 
numbers in whole blood.  Mann Whitney t tests were performed between control cohort and each 
infected time period of SIV (****p<0.05).  Infected time periods were early, ASY was chronic 
asymptomatic group, ASD was advanced SIV disease or chronic symptomatic group, and AIDS 
displayed as mean values + SEM. 
 
Figure on next page. 
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Figure 8.14. Percentages and absolute numbers of CD4 and CD8 lymphocytes within the 
active cell cycle (Ki67+) in bone marrow and whole blood during SIV 
Expression of Ki67 on lymphocytes during SIV infection by percent and absolute numbers in 
bone marrow and whole blood to detect cells active in the cell cycle or non-resting cells as 
described in text.  A. Percent CD4+ Ki67+ lymphocytes in bone marrow.  B. Absolute 
CD3+CD4+ Ki67+ lymphocyte numbers in bone marrow.  C. Percent CD4+ Ki67+ lymphocytes 
in whole blood.  D. Absolute CD4+ Ki67+ lymphocyte numbers in whole blood.   E. Percent 
CD8+ Ki6+ lymphocytes in bone marrow.  F. Absolute CD3+CD8 Ki67+ lymphocyte numbers 
in bone marrow. G. Percent CD8+ Ki67+ lymphocytes in whole blood.  H. Absolute CD8+ Ki6+ 
lymphocyte numbers in whole blood.  Mann Whitney t tests were performed between control 
cohort and each infected time period of SIV (***p<0.01, and ****p<0.05).  Infected time 
periods were early, ASY was chronic asymptomatic group, ASD was advanced SIV disease or 
chronic symptomatic group, and AIDS displayed as mean values + SEM. 
 
Figure on next page. 
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CD4+ lymphocytes expressing Ki67 decreased post-infection in blood but proliferation 
was low only in the ASY period.  Similar patterns of BrdU+ expression CD8+ WB lymphocytes.  
The ratio of BrdU to Ki67 of circulating lymphocytes increased in CD4+ cells suggesting cell 
cycle regulation was disturbed (Table 8.2).  Nonetheless, absolute numbers varied for WB CD4+ 
and CD8+ lymphocytes characterized by significantly decreased ratios of CD4 to CD8 ratios 
with variations of up to 80% lower than control macaques post-infection (Table 8.3).   
Table 8.2. Mean BrdU to Ki67 Ratio of Absolute Numbers of Lymphocytes During 
Progressive SIV Infection 
  
BrdU:Ki67 Lymphocyte Ratio Control Early Asymptomatic Symptomatic AIDS 
CD3+CD4+ Bone Marrow 0.656 0.641 0.3655**** 0.403**** 0.831 
CD3+CD8+ Bone Marrow 0.073 0.032 0.031 0.061 0.044 
CD4+ Whole Blood 0.277 0.316 0.420 0.446 1.092 
CD8+ Whole Blood 0.380 0.347 0.392 0.586 0.506 
Comparison of control cohort to various phases of SIV infection by Mann Whitney t tests (****p<0.05) 
Table 8.3. Mean CD4:CD8 Ratio of Absolute Numbers of Lymphocytes During Progressive 
SIV Infection 
  
CD4:CD8 Lymphocyte Ratio Control Early Asymptomatic Symptomatic AIDS 
BrdU Bone Marrow 0.313 0.062 0.111 0.078 2.384 
Ki67 Bone Marrow 0.069 0.002 0.008 0.005 0.052 
BrdU Whole Blood 1.489 0.243*** 0.338 0.289**** 0.404 
Ki67 Whole Blood 1.928 0.358*** 0.477**** 0.388 0.168**** 
Comparison of control cohort to various phases of SIV infection by Mann Whitney t tests (**p<0.001, ***p<0.01, and 
****p<0.05) 
Memory Lymphocytes During SIV Infection 
 
Naïve and memory lymphocytes were evaluated for changes during SIV disease by CD95 
versus CD28 staining as three subsets:  naïve lymphocytes CD95-CD28+; central memory (CM) 
lymphocytes CD95+CD28+; and effector memory (EM) lymphocytes, CD95+CD28- (Pitcher 
2002) (Figure 8.15).  Another classification of naïve and memory lymphocytes by CD45RA 
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versus CD62L staining was used to identify four subsets: CD45RA+CD62L+ naïve cells; 
CD45RA-CD62L+ central memory cells; CD45RA-CD62L- effector memory cells; and 
CD45RA+CD62L- cells represent terminally differentiated effector memory (TDEM) 
lymphocytes and recently activated naïve lymphocytes (Kaur 1998; Koopman 2004; Ostrowski 
1999) (Figure 8.16).   
In controls, BM CD4+ naïve and CM lymphocytes were about equal in numbers by 
different gating, but EM and TDEM were present by CD45RA strategy and minimal by CD95/28 
strategies.  WB CD4+ naïve and EM lymphocytes were about equal in numbers by different 
gating yet only CM cells were detected by CD95/28 gating and only TDEM cells by CD62L 
gating.  BM CD8+ naïve and memory cells were equal in numbers for CD95/CD28 strategies but 
EM > TDEM > naïve > CM for CD45RA gating.  For CD8+ WB lymphocytes, naïve cells > 
TDEM > EM > CM for CD45RA gating but naïve and memory populations were equal in 
number by CD95/CD28 strategies.  BM CD8+ naïve and memory cells were about double BM 
CD4+ numbers in control macaques.  Naïve CD4+ and CD8+ lymphocytes were equally 
represented in circulation for control macaques while CD4+ WB memory cells were about 
double CD8+ WB memory cells. 
Naïve BM CD4+ and CD8+ lymphocytes increased in the early and ASD phases and 
were maintained at near control levels in the ASY and AIDS periods.  Naïve circulating CD4+ 
and CD8+ lymphocytes were low post-infection with near depletion in AIDS. 
CM CD8+ lymphocytes were increased post-infection which was also noted for CD4+ 
CM lymphocytes except in the ASY period.  CM BM cells were minimally detected by CD45RA 
gating.  WB CM lymphocytes were low post-infection for CD4+ and maintained for CD8+ cells 
until AIDS when all were nearly eliminated. 
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Figure 8.15. Percentages and absolute numbers of CD4 and CD8 CD95/CD28 naïve and 
memory lymphocytes in bone marrow and whole blood during SIV 
Expression of CD95 and CD28 on lymphocytes during SIV infection by percent and absolute 
numbers in bone marrow and whole blood to detect naïve and memory lymphocytes as described 
in text.  A. Percent CD4+ lymphocytes in bone marrow.  B. Absolute CD3+CD4+ lymphocyte 
numbers in bone marrow.  C. Percent CD4+ lymphocytes in whole blood.  D. Absolute CD4+ 
lymphocyte numbers in whole blood.   E. Percent CD8+ lymphocytes in bone marrow.  F. 
Absolute CD3+CD8+ lymphocyte numbers in bone marrow.  G. Percent CD8+ lymphocytes in 
whole blood.  H. Absolute CD8+ lymphocyte numbers in whole blood. Mann Whitney t tests 
compared populations between control cohort and each infected time period of SIV (**p<0.001, 
***p<0.01, and ****p<0.05).  Infected time periods were early, ASY was chronic asymptomatic 
group, ASD was advanced SIV disease or chronic symptomatic group, and AIDS displayed as 
mean values + SEM. 
 
Figure on next page. 
 
 
 
179 
 
 
 
 
 
Lymphocyte Population
in Bone Marrow
C
D
95
-C
D
28
+
C
D
95
+C
D
28
+
C
D
95
+C
D
28
-
TO
TA
L 
C
D
95
TO
TA
L 
C
D
28
0
20
40
60
80
100
%
 C
D
4
+
 C
e
lls
 i
n
L
y
m
p
h
o
id
 G
a
te
CD3+CD4+ Lymphocyte Population
in Bone Marrow
C
D
95
-C
D
28
+
C
D
95
+C
D
28
+
C
D
95
+C
D
28
-
TO
TA
L 
C
D
95
TO
TA
L 
C
D
28
0
20
40
60
C
e
lls
 /
 m
m
2
Lymphocyte Population
in Whole  Blood
C
D
95
-C
D
28
+
C
D
95
+C
D
28
+
C
D
95
+C
D
28
-
TO
TA
L 
C
D
95
TO
TA
L 
C
D
28
0
20
40
60
80
100
%
 C
D
4
+
 C
e
lls
 i
n
L
y
m
p
h
o
c
y
te
  
G
a
te
CD4+ Lymphocyte Population
in Whole  Blood
C
D
95
-C
D
28
+
C
D
95
+C
D
28
+
C
D
95
+C
D
28
-
TO
TA
L 
C
D
95
TO
TA
L 
C
D
28
0.0
0.5
1.0
1.5
2.0
 C
e
lls
 *
1
0
3
/

L
Lymphocyte Population
in Bone Marrow
C
D
95
-C
D
28
+
C
D
95
+C
D
28
+
C
D
95
+C
D
28
-
TO
TA
L 
C
D
95
TO
TA
L 
C
D
28
0
20
40
60
80
100
%
 C
D
8
+
 C
e
lls
in
 L
y
m
p
h
o
id
 G
a
te
CD3+CD8+ Lymphocyte Population
in Bone Marrow
C
D
95
-C
D
28
+
C
D
95
+C
D
28
+
C
D
95
+C
D
28
-
TO
TA
L 
C
D
95
TO
TA
L 
C
D
28
0
20
40
60
80
100
120
140
160
C
e
lls
 /
 m
m
2
Lymphocyte Population
in Whole  Blood
C
D
95
-C
D
28
+
C
D
95
+C
D
28
+
C
D
95
+C
D
28
-
TO
TA
L 
C
D
95
TO
TA
L 
C
D
28
0
20
40
60
80
100
%
 C
D
8
+
 C
e
lls
 i
n
L
y
m
p
h
o
c
y
te
  
G
a
te
CD8+ Lymphocyte Population
in Whole Blood
C
D
95
-C
D
28
+
C
D
95
+C
D
28
+
C
D
95
+C
D
28
-
TO
TA
L 
C
D
95
TO
TA
L 
C
D
28
0.0
0.5
1.0
1.5
2.0
C
e
lls
 *
1
0
3
/

L
C. D.
B.
F.
H.
E.
G.
A.
CONTROL EARLY ASYMPTOMATIC or ASY ADVANCED SIV DISEASE or ASD AIDS
180 
 
Figure 8.16. Percentages and absolute numbers of CD4 and CD8 CD45RA/CD62L naïve 
and memory lymphocytes in bone marrow and whole blood during SIV 
Expression of CD45RA and CD62L on lymphocytes during SIV infection by percent and 
absolute numbers in bone marrow and whole blood to detect naïve and memory lymphocytes as 
described in text.  A. Percent CD4+ lymphocytes in bone marrow.  B. Absolute CD3+CD4+ 
lymphocyte numbers in bone marrow.  C. Percent CD4+ lymphocytes in whole blood.  D. 
Absolute CD4+ lymphocyte numbers in whole blood.   E. Percent CD8+ lymphocytes in bone 
marrow.  F. Absolute CD3+CD8+ lymphocyte numbers in bone marrow.  G. Percent CD8+ 
lymphocytes in whole blood.  H. Absolute CD8+ lymphocyte numbers in whole blood. Mann 
Whitney t tests compared populations between control cohort and each infected time period of 
SIV (***p<0.01, and ****p<0.05).  Infected time periods were early, ASY was chronic 
asymptomatic group, ASD was advanced SIV disease or chronic symptomatic group, and AIDS 
displayed as mean values + SEM. 
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BM EM CD4+ lymphocytes by CD45RA gating followed the naïve BM CD4+ memory 
pattern.  However, CM CD4+ BM lymphocytes by CD95/CD28 gating were decreased post-
infection.  BM EM CD8+ BM lymphocytes were increased post-infection especially in later 
periods.  WB EM CD4+ lymphocyte declined over time post-infection with greatest loss in 
AIDS while CD8+ lymphocytes were increased until finally depleted in AIDS.  The same pattern 
of EM was observed for TDEM in blood. 
Early and Late Activation of Lymphocytes During SIV Infection 
 
Lymphocyte subsets were classified using both early (CD69) and late (CD25, HLA-DR) 
markers of immune activation.  CD25-CD69+ cells were considered very early activated, 
CD25+CD69-  was considered a mid-stage marker, CD25+CD69+ was an early to middle stage 
marker, and HLA-DR+ was a late marker for lymphocyte activation.  Incongruity was observed 
between the percentage and absolute phenotype for circulating CD4+ lymphocytes while other 
subsets were congruent. 
Early to middle stage activated cells (Figure 8.17) and late stage activated cells (Figure 
8.18) were examined in bone marrow and whole blood.  In control macaques, activated CD4+ 
BM lymphocytes were represented by late > early > middle > early to middle stages.  For CD4+ 
WB lymphocytes in circulation, numbers of activated cells were late > middle > early > early to 
middle stages.  CD4+ lymphocytes were found in all stages of activation while CD8+ 
lymphocytes expressed early stages > later stages in BM and WB but middle and middle to late 
stages were not observed. 
BM CD4+ lymphocytes displayed increased numbers of early and middle stage activated 
cells early during infection that waned in AIDS, while late and early-to-middle stage activated 
cells slowly increased over time.  Circulating CD4+ lymphocytes showed decreased activation  
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Figure 8.17. Percentages and absolute numbers of CD4 and CD8 CD25/CD69 activated 
lymphocytes in bone marrow and whole blood during SIV 
Expression of CD25 and CD69 on lymphocytes during SIV infection by percent and absolute 
numbers in bone marrow and whole blood to detect activated lymphocytes as described in text.  
A. Percent CD4+ lymphocytes in bone marrow.  B. Absolute CD3+CD4+ lymphocyte numbers 
in bone marrow.  C. Percent CD4+ lymphocytes in whole blood.  D. Absolute CD4+ lymphocyte 
numbers in whole blood.   E. Percent CD8+ lymphocytes in bone marrow.  F. Absolute 
CD3+CD8+ lymphocyte numbers in bone marrow.  G. Percent CD8+ lymphocytes in whole 
blood.  H. Absolute CD8+ lymphocyte numbers in whole blood. Mann Whitney t tests compared 
populations between control cohort and each infected time period of SIV (**p<0.001, 
***p<0.01, and ****p<0.05).  Infected time periods were early, ASY was chronic asymptomatic 
group, ASD was advanced SIV disease or chronic symptomatic group, and AIDS displayed as 
mean values + SEM. 
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Figure 8.18. Percentages and absolute numbers of CD4 and CD8 CD45RA/HLA-DR 
activated lymphocytes in bone marrow and whole blood during SIV 
Expression of CD45RA and HLA-DR on lymphocytes during SIV infection by percent and 
absolute numbers in bone marrow and whole blood to detect activated lymphocytes.  A. Percent 
CD4+ lymphocytes in bone marrow.  B. Absolute CD3+CD4+ lymphocyte numbers in bone 
marrow.  C. Percent CD4+ lymphocytes in whole blood.  D. Absolute CD4+ lymphocyte 
numbers in whole blood.   E. Percent CD8+ lymphocytes in bone marrow.  F. Absolute 
CD3+CD8+ lymphocyte numbers in bone marrow.  G. Percent CD8+ lymphocytes in whole 
blood.  H. Absolute CD8+ lymphocyte numbers in whole blood. Mann Whitney t tests compared 
populations between control cohort and each infected time period of SIV (***p<0.01, and 
****p<0.05).  Infected time periods were early, ASY was chronic asymptomatic group, ASD 
was advanced SIV disease or chronic symptomatic group, and AIDS displayed as mean values + 
SEM. 
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post-infection with significant loss in AIDS.  Increases in early and late activation CD8+ 
lymphocytes were noted during progressive infection that were maintained in BM, but declined 
in blood in AIDS.   
Homing Molecule Expression on Lymphocytes During SIV Infection 
 
Molecules on lymphocytes important for homing to secondary or tertiary lymphoid 
tissues were evaluated during SIV infection.  Subjects were not available in the early phase for 
evaluation of the intestinal homing molecule β7.   
BM lymphocytes expressing β7 were observed in marrow and blood (Figure 8.19).  For 
control macaques, BM CD8+ lymphocytes expressed β7 ~2X greater than CD4+ BM 
lymphocytes which was also observed for WB CD8+CD45RA- β7 cells compared to WB 
CD4+CD45RA- β7 cells. In BM, CD8+ lymphocytes post-infection were increased compared to 
the controls while CD4+ lymphocytes were decreased compared to the control group.  Whole 
blood CD4+ cells displayed decreased numbers of intestinal homing lymphocytes with near 
depletion in AIDS compared to controls while CD8+ cells were similar in number except in the 
ASY period.   
CD62L (L selectin receptor) is considered important for homing to peripheral lymphoid 
tissue (PeLT) (Figure 8.20) (Sallusto 1999).  Higher numbers of CD4+ BM, CD4+ WB, and 
CD8+ BM lymphocytes expressed CD62L than β7 for controls.  CD8+ lymphocytes in blood of 
control RM were about equal in numbers for expression of both homing markers.  BM 
lymphocytes were more variable in patterns during SIV disease with peak in the ASD period and 
depression in the ASY and AIDS periods.  Circulating lymphocytes had decreased expression of 
CD62L as disease progressed with depletion in AIDS.   
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Figure 8.19. Percentages and absolute numbers of CD4 and CD8 expressing mucosal 
homing molecule marker β7 in bone marrow and whole blood during SIV 
Co-expression of CD45RA and β7 on lymphocytes during SIV infection by percent and absolute 
numbers in bone marrow and whole blood to detect intestinal homing lymphocytes as described 
in text.  A. Percent CD4+ lymphocytes in bone marrow.  B. Absolute CD3+CD4+ lymphocyte 
numbers in bone marrow.  C. Percent CD4+ lymphocytes in whole blood.  D. Absolute CD4+ 
lymphocyte numbers in whole blood.   E. Percent CD8+ lymphocytes in bone marrow.  F. 
Absolute CD3+CD8+ lymphocyte numbers in bone marrow.  G. Percent CD8+ lymphocytes in 
whole blood.  H. Absolute CD8+ lymphocyte numbers in whole blood. Mann Whitney t tests 
compared populations between control cohort and each infected time period of SIV (***p<0.01, 
and ****p<0.05).  Infected time periods were early, ASY was chronic asymptomatic group, 
ASD was advanced SIV disease or chronic symptomatic group, and AIDS displayed as mean 
values + SEM. 
 
Figure on next page. 
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Figure 8.20. Percentages and absolute numbers CD62L+ CD4 and CD8 lymphocytes in 
bone marrow and whole blood during SIV 
Expression of CD45RA and CD62L on lymphocytes during SIV infection by percent and 
absolute numbers in bone marrow and whole blood to detect homing lymphocytes as described 
in text.  A. Percent CD4+ lymphocytes in bone marrow.  B. Absolute CD3+CD4+ lymphocyte 
numbers in bone marrow.  C. Percent CD4+ lymphocytes in whole blood.  D. Absolute CD4+ 
lymphocyte numbers in whole blood.   E. Percent CD8+ lymphocytes in bone marrow.  F. 
Absolute CD3+CD8+ lymphocyte numbers in bone marrow.  G. Percent CD8+ lymphocytes in 
whole blood.  H. Absolute CD8+ lymphocyte numbers in whole blood. Mann Whitney t tests 
compared populations between control cohort and each infected time period of SIV (**p<0.001, 
***p<0.01, and ****p<0.05).  Infected time periods were early, ASY was chronic asymptomatic 
group, ASD was advanced SIV disease or chronic symptomatic group, and AIDS displayed as 
mean values + SEM. 
 
Figure on next page. 
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Expression of Chemokine Receptors on Lymphocytes During SIV Infection 
 
Chemokine receptors were evaluated during progressive SIV disease including CCR5 
(CD195) (Figure 8.21), CXCR4 (CD184) (Figure 8.22), and CXCR3 (CD183) (Figure 8.23).  
Differences for CD4+ WB lymphocytes between percent and absolute numbers were detected.  
Control macaques expressed higher levels of CXCR3 than CCR5 or CXCR4 on BM CD8+ T 
cells while CD4+ T cell expression of  CXCR4 was higher than CCR5 or CXCR3.  Compared to 
WB, BM CD8+ T cells had higher CXCR3 (1.6X) and CCR5 (2X) expression, though not equal 
in proportion, and lower (1.5X) CXCR4 expression in controls.  BM CD4+ T cells were equal to 
WB for CXCR3 expression, 1.5X lower compared to WB for CXCR4 expression and nearly 4X 
higher than WB CCR5 expression. 
In control macaques, BM CD4+CD45RA+ lymphocytes, BM CD8+CD45RA+ 
lymphocytes, blood CD4+CD45RA-, and blood CD8+ CD45RA+ T lymphocytes had CXCR4 > 
CXCR3 > CCR5 expression.  In control macaques, BM T cells CD8+CD45RA- lymphocytes 
had CXCR3 > CCR5 > CXCR4 expression.  BM T cells CD4+CD45RA- T lymphocytes and 
circulating CD8+CD45RA- T lymphocytes in control macaques had CCR5 > CXCR3 > CXCR4 
expression. Circulating T cells CD4+CD45RA+ lymphocytes in control macaques had CXCR4 > 
CCR5 > CXCR3 expression. 
Bone marrow CD4+ lymphocytes showed minimal changes with respect to CCR5 
expression during SIV infection while circulating CD4+ lymphocytes displayed significant loss 
of CCR5. CD8+ lymphocytes showed increased expression of CCR5 during SIV infection in BM 
and WB often with significant differences (p<0.05).  Total CCR5 expression on lymphocytes 
was nearly depleted in AIDS except for CD8+ circulating lymphocytes.  Early during SIV 
infection and again in the ASD period, CXCR4 expression rose on CD4+ and CD8+  
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Figure 8.21. Percentages and absolute numbers of CD4 and CD8 lymphocytes expressing 
CCR5 in bone marrow and whole blood during SIV 
Expression of CD45RA and CD195 (CCR5) on lymphocytes during SIV infection by percent 
and absolute numbers in bone marrow and whole blood to detect chemokine receptor CCR5 on 
lymphocytes.  A. Percent CD4+ lymphocytes in bone marrow.  B. Absolute CD3+CD4+ 
lymphocyte numbers in bone marrow.  C. Percent CD4+ lymphocytes in whole blood.  D. 
Absolute CD4+ lymphocyte numbers in whole blood.   E. Percent CD8+ lymphocytes in bone 
marrow.  F. Absolute CD3+CD8+ lymphocyte numbers in bone marrow.  G. Percent CD8+ 
lymphocytes in whole blood.  H. Absolute CD8+ lymphocyte numbers in whole blood. Mann 
Whitney t tests compared populations between control cohort and each infected time period of 
SIV (**p<0.001, ***p<0.01, and ****p<0.05).  Infected time periods were early, ASY was 
chronic asymptomatic group, ASD was advanced SIV disease or chronic symptomatic group, 
and AIDS displayed as mean values + SEM. 
 
Figure on next page. 
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Figure 8.22. Percentages and absolute numbers of CD4 and CD8 lymphocytes expressing 
CXCR4 in bone marrow and whole blood during SIV 
Expression of CD45RA and CD184 (CXCR4) on lymphocytes during SIV infection by percent 
and absolute numbers in bone marrow and whole blood to detect chemokine receptor CXCR4 on 
lymphocytes.  A. Percent CD4+ lymphocytes in bone marrow.  B. Absolute CD3+CD4+ 
lymphocyte numbers in bone marrow.  C. Percent CD4+ lymphocytes in whole blood.  D. 
Absolute CD4+ lymphocyte numbers in whole blood.   E. Percent CD8+ lymphocytes in bone 
marrow.  F. Absolute CD3+CD8+ lymphocyte numbers in bone marrow.  G. Percent CD8+ 
lymphocytes in whole blood.  H. Absolute CD8+ lymphocyte numbers in whole blood. Mann 
Whitney t tests compared populations between control cohort and each infected time period of 
SIV (**p<0.001, ***p<0.01, and ****p<0.05).  Infected time periods were early, ASY was 
chronic asymptomatic group, ASD was advanced SIV disease or chronic symptomatic group, 
and AIDS displayed as mean values + SEM. 
 
Figure on next page. 
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Figure 8.23. Percentages and absolute numbers of CD4 and CD8 lymphocytes expressing 
CXCR3 in bone marrow and whole blood during SIV 
Expression of CD45RA and CD183 (CXCR3) on lymphocytes during SIV infection by percent 
and absolute numbers in bone marrow and whole blood to detect chemokine receptor CXCR3 on 
lymphocytes.  A. Percent CD4+ lymphocytes in bone marrow.  B. Absolute CD3+CD4+ 
lymphocyte numbers in bone marrow.  C. Percent CD4+ lymphocytes in whole blood.  D. 
Absolute CD4+ lymphocyte numbers in whole blood.   E. Percent CD8+ lymphocytes in bone 
marrow.  F. Absolute CD3+CD8+ lymphocyte numbers in bone marrow.  G. Percent CD8+ 
lymphocytes in whole blood.  H. Absolute CD8+ lymphocyte numbers in whole blood. Mann 
Whitney t tests compared populations between control cohort and each infected time period of 
SIV (***p<0.01, and ****p<0.05).  Infected time periods were early, ASY was chronic 
asymptomatic group, ASD was advanced SIV disease or chronic symptomatic group, and AIDS 
displayed as mean values + SEM. 
 
Figure on next page. 
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lymphocytes in BM and WB mostly noted on CD45RA+CD184+ lymphocytes.  However, CD8+ 
circulating lymphocytes showed higher expression on CD45RA-CD184+ memory lymphocytes.  
Additionally CXCR4 total expression was lowest in AIDS except for CD8+ WB cells.  For 
CXCR3 lymphocyte expression, decreases were observed post-infection with depression in 
AIDS except for CD8+ BM cells. 
Plasma Viral Load and the Bone Marrow Lymphocyte Phenotype 
 
 Plasma viral load was high during progressive SIV infection (Figure 8.24).  Significant 
differences were observed between the early and ASY period (p=0.0029) also the early and 
AIDS period (p= 0.0367).   The pattern of changes in viral load during progressive infection was 
similar to the BM compartment changes in patterns of lymphocytes for the following: BM 
CD4:CD8 lymphocyte ratio, CD3+CD8+ BM lymphocytes, BrdU+CD3+CD8+ BM 
lymphocytes, Ki67+CD3+CD8+ BM lymphocytes, central memory CD3+CD8+CD95+CD28+ 
BM lymphocytes, naïve CD3+CD8+CD45RA+HLA-DR- BM lymphocytes, late activation 
CD3+CD8+CD25-CD69+ BM lymphocytes, and CD3+CD8+ BM lymphocytes expressing the 
CXCR4 and CCR5 chemokine receptors.  A correlation was noted between the mean BM 
lymphocyte population and to viral load for only total CXCR4 on CD3+CD8+ BM lymphocytes 
as a moderate negative correlation (Spearman r= -0.5852, p value=0.0021).   
DISCUSSION 
 
Our prior analysis of BM revealed the lymphoid gate by FSC vs. SSC plot encompassed 
lymphocytes of varying CD45 intensity or higher percentages when strictly using the  CD45
Bright
 
gate of mature lymphocytes from CD45 vs. SSC plots (Chapter 5 and Chapter 6).  Therefore we 
chose to utilize the multilineage gate for determination of BM lymphocytes.   Our prior 
phenotypic study  40% lymphocytes consisting of 20% T cells and 20% B cells, 2 % NK cells,  
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Figure 8.24. Plasma viral load during SIV 
SIV plasma viral RNA copies during various phases of SIV disease.  Mann Whitney t tests 
compared populations between control cohort and each infected time period of SIV (***p<0.01, 
and ****p<0.05).  Infected time periods were early, ASY was chronic asymptomatic group, 
ASD was advanced SIV disease or chronic symptomatic group, and AIDS displayed as mean 
values + SEM. 
 
<1% plasma cells and immature B cells as well as 20% erythroid lineage including lineage 
negative immature hematopoietic cells and 5% immature hematopoietic cells (Chapter 5 and 
Chapter 6).  In our earlier WB study, we found the lymphocyte gate of FSC vs. SSC was equally 
representative of CD45
Bright
  circulating lymphocyte population and that the blood lymphocyte 
gate consist of ( >90%) with few immature hematopoietic cells and metarubricytes (when 
present) (Chapter 5 and Chapter 6).   
Important differences were detected between marrow and blood in control macaques.  
CD4:CD8 ratios greater than 1 for WB and less than 1 for BM were detected in the control 
group.  Further, the BM T lymphocytes comprised nearly 3X higher CD8+ lymphocytes than 
CD4+ lymphocytes whereas WB lymphocytes were conversely represented higher CD4+ 
lymphocytes ~1.5X higher than CD8+ lymphocytes in control macaques as previously reported 
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(Mattapallil 2004; Paiardini 2009; Veazey 2000a).  Our finding of increased BM CD8+ T cells 
compared to CD4+ T cells with a lower BM T cell CD4:CD8 ratio compared to peripheral blood 
was supported by similar findings in humans (Palendira 2008) and RM (Paiardini 2009; Sopper 
2003).   
Studies in mice, macaques, and humans revealed CD8+ memory T cells in BM were 
represented in higher percentages than naïve phenotype (Mazo 2005; Paiardini 2009; Palendira 
2008).  Further, Paiardini et al. observed the proliferation in BM of T cells resulted in a larger 
pool of memory lymphocytes in non-SIV infected RM which supports our data (Paiardini 2009).  
Studies of mice revealed post-immunization CD4+ and CD8+ T cells increased in BM (Di Rosa 
2003).  Human studies of BM CD8+ T cell responsiveness to viruses revealed Epstein Barr virus 
(EBV)-specific cells were found in higher levels than cytomegalovirus (CMV)-specific cells 
(Palendira 2008).  Also, studies in mice have revealed adoptive transfer of memory phenotype T 
results in higher seeding of BM compared to lymph node (Di Rosa 2003).  Prior mouse and 
human studies suggest BM is important for trafficking of memory cells suggesting T cell 
recruitment to BM may be involved in the host response to certain viruses (Di Rosa 2003; 
Palendira 2008).  Selective depletion of either CD4+ or CD8+ T cells in BM of non-SIV infected 
RM resulted in rapid proliferation of the lost lymphocytes and return to pre-depletion levels 
respectively indicating BM is involved in T cell homeostasis (Paiardini 2009).  Paiardini et al. 
referred to BM as the „preferred site for proliferation of T cells in NHP‟ (Paiardini 2009).  
Murine studies have identified memory CD4+ T cells home to bone marrow within 3-8 weeks 
post-inoculation with LPS (Tokoyoda 2009).   
Our study found high CCR5 expression on BM CD8+ T cells, of control macaques, at 
about twice levels in blood supported by human findings (Palendira 2008).  However, CXCR3 
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expression of control macaque CD8+ T cells was disparate compared to humans, with control 
macaques having higher expression on BM compared to higher expression on blood CD8+ 
lymphocytes in humans (Palendira 2008).    
We hypothesized absolute numbers of T lymphocytes in BM would decrease during SIV 
infection and our study revealed CD3+BM lymphocytes were increased at all stages during SIV 
infection similar to our prior findings of increased percentage (Chapter 4-6) and reported by 
Sopper et al. (Sopper 2003).  In fact, macrophages were also increased at all stages of SIV 
infection as opposed to minimal increases of monocyte lineage cells observed in our earlier 
studies (Chapter 4-6).  Circulating CD3+ T cells were decreased during SIV infection as 
previously reported (Sopper 2003).  Absolute CD3 lymphocytes negatively correlated between 
the WB and BM compartments as circulating lymphocytes were decreased and BM lymphocytes 
were increased during progressive SIV disease.  Absolute numbers of circulating lymphocytes 
declined in WB during SIV which was also detected in our earlier studies (Chapter 3-4) and 
opposite from BM lymphocyte observations (Chapter 5-6).  Of note, WB percentage loss in this 
study was observed for the later stages of SIV.  In spite of CD3 correlation, total CD4 and CD8 
lymphocytes in whole blood and bone marrow compartments were rarely correlated during SIV 
disease.   
 We hypothesized decreases during all phases of infection for BM CD3+CD8+ 
lymphocytes and CD3+CD4+ lymphocytes, yet this was demonstrated only for the ASD and 
AIDS periods for CD4+ T cells.  Post-infection, total BM T cells were increased, mainly 
attributed to increases in CD8+ cells and maintenance or minimal increases in CD4+ cells.   
Post-infection within BM, proliferation of CD8+ T cells increased as proliferation of CD4+ T 
cells decreased by BrdU, but both subsets shwoed increases by Ki67 staining.  Our findings for 
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BM CD4+ cell Ki67 proliferation was supported by Ki67 staining by Sopper et al. as increased 
for the asymptomatic phase and decline in the AIDS phase toward non-SIV infected rates 
(Sopper 2003).  We observed decreased BM CD4+ T cells in the asymptomatic phase but Sopper 
et al. observed increases during the same phase (Sopper 2003).  We observed minimal loss of 
BM CD4+ T cells in the AIDS phase compared to minimal increases observed by Sopper et al. 
for the AIDS phase (Sopper 2003).  For CD8+ our findings of BM proliferation were in 
agreement with Sopper et al. for BM.  Chronic immune stimulation in the presence of active viral 
replication is one theory for maintenance/proliferation of CD4 lymphocytes during progressive 
SIV infection (Sopper 2003).  Sopper et al. further thought increased proliferation of CD4 
lymphocytes leads to increased destruction of CD4 lymphocytes during SIV infection (Sopper 
2003).  Conversely, increased proliferation of CD8 lymphocytes leads to increased numbers as 
CD8 lymphocytes are spared during SIV infection (Sopper 2003).  Our demonstration of 
maintenance of BM CD4+ lymphocytes during SIV infection by percent and absolute numbers 
rejected our original hypothesis and suggested the WB and BM lymphoid compartments were 
under different homeostatic mechanisms.   
Absolute numbers of CD8+ BM lymphocytes were increased all SIV phases 
characterized by increased proliferation, CM cells, EM cells, TDEM cells, early stage activation 
cells, and chemokine receptor expression.  Further, CD8+ naïve and PLT homing BM 
lymphocytes were increased in early and ASD periods and CD8+ BM ASD and AIDS phases 
increased for GALT homing and chemokine expression.  Absolute numbers of CD8+ circulating 
lymphocytes were increased in early and ASY periods for proliferation, active cell cycle, EM, 
TDEM, and early activation.  Decreases in absolute circulating CD8+ lymphocytes in the ASD 
phase were noted but most examined subsets were increased.  Decreases in absolute numbers of 
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circulating CD8+ lymphocytes in AIDS were observed for proliferation, memory, activation, and 
β7 expression.   
BM CD4+ absolute numbers of naïve cells, EM cells, early activation cells, PeLT 
homing cells, and CXCR4 expressing T lymphocytes were increased in early and ASD periods 
while decreased ASY and AIDS periods.  Absolute CD4+ BM lymphocytes were increased in 
the early phase for CM cells, early to middle stage activation cells, and for CCR5 chemokine 
expression.  Decreased absolute numbers of CD4+ BM lymphocytes were in the ASY phase for 
CM cells, middle stage activation cells, GALT homing cells, and CXCR3 chemokine expression.  
CD4+ BM lymphocytes were increased in the ASD phase for proliferation, cell cycle, CM cells, 
TDEM cells, activation all stages, β7 expression, and  CXCR3 chemokine expression.  Finally, 
CD4+ BM lymphocytes were decreased in AIDS for proliferation, cell cycle, TDEM cells, 
GALT homing cells, CXCR3 and CCR5 expression.  Chemokine receptor expression was 
maintained on CD4+ BM T cells.  WB CD4+ lymphocytes were decreased post-infection with 
few exceptions. 
We examined several subsets of lymphocytes in bone marrow and whole blood.  CD3+ 
circulating lymphocytes declined post-infection as previously reported in RM (Mattapallil 2004).  
SIV infection demonstrated loss of CD4+ circulating cells in all phases but increases in CD8+ 
lymphocytes in the early and ASY periods or asymptomatic groups then dropped in the ASD and 
AIDS periodss or symptomatic groups as supported by Sopper et al. (Sopper 2003). Loss of 
CD4+ WB lymphocytes has been previously reported in SIV (Mattapallil 2004; Nishimura 2007; 
Sopper 2003; Veazey 2000a) as early as 3 DPI and peak at 10-14 DPI (Mattapallil 2005).  WB 
CD8+ lymphocytes were maintained during SIV infection until later in infection (Mattapallil 
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2004).  Absolute numbers of CD4+ circulating lymphocytes were decreased during SIV infection 
for all examined subsets. 
Proliferation of lymphocyte subsets was evaluated.  In our study, lymphocytes were 
mostly in a resting state of the cell cycle in WB and BM control macaques and SIV infected 
macaques supported by findings in peripheral blood lymphocytes of HIV patients (Cannavo 
2001).  In our study, overall percentages of proliferating T cells in control macaques in BM was 
nearly 1/10 less of WB levels.   Proliferating T cells in circulation were predominantly CD8+ 
cells, but proliferating CD4+ cells were noted in low numbers as also previously reported (Kaur 
2000; Sopper 2003).   
We found increased cell cycle activity and proliferation during SIV in CD8+ cells of BM 
and WB as previously reproted (Paiardini 2009; Sopper 2003).  However, we observed decreased 
cell activity and proliferation in CD4+ cells in WB, and depletion in AIDS.  In BM we also 
found depletion in AIDS as reported by by Paiardini et al (Paiardini 2009).  We detected 
increases in WB until AIDS and post-infection in BM as reported by Sopper et al. (Sopper 2003).  
SIVmac251 inoculated RM were reported with proliferating WB CD8+ T cells at 11 DPI and 
CD4+ T cells at 16 DPI (Benlhassan-Chahour 2003).   
Circulating CD4+ and BM CD3+CD4+ lymphocytes showed cell cycle alterations in 
chronic infection notably in AIDS phases, particularly with reference to BrdU:Ki67 and 
CD4:CD8 proliferation ratios. Chaves and Kallas reported HIV patients, without ART, showed 
similar findings including increased CD4+ peripheral blood mononuclear cells (PBMC) in the S 
phase without the ability to proceed normally into G2 and mitosis, or an acquired arrest as 
compared to healthy subjects (Chaves 2004).  Proliferating lymphocytes from SIV infected 
macaques in blood displayed lower absolute numbers of BrdU+CD8+ (S phase)  in the early and 
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ASY periods.  Monceaux et al. reported increased proliferation of circulating CD8+ lymphocytes 
post-infection (Monceaux 2005).  Our results showed similar cell cycle changes in CD4+ 
lymphocytes between the two compartments during chronic infection, suggesting multiple 
lymphoid sites were equally affected, while CD8+ cell cycle function was apparently preserved 
in WB. Also, dysregulation of the cell cycle was observed for BM CD8+ lymphocytes in the 
early and AIDS phases.  
Cell cycle perturbations or cell cycle dysfunction were noted as increased cyclin B1 
levels on peripheral blood lymphocytes of non-ART HIV patients which corrected with ART 
therapy (Cannavo 2001).  However, dysregulation was interrupted based on the the finding of 
G1/S levels of cyclin B and AGNORs in a resting G0 lymphocyte not committed to entering the 
cell cycle (Cannavo 2001).  In vitro studies have shown lack of degradation is the cause of 
Cyclin B overexpression in lymphocytes of HIV patients and not necessarily reflection of an 
increased production (Cannavo 2001).  Thus, dampering of  degradation may be due to a defect 
in protein degradation involving the ubiquitin-proteasome pathway (Cannavo 2001).   In HIV-
infected patients, dysregulated lymphocytes appear to be more susceptible to “cell cycle-related” 
apoptosis versus control lymphocytes in in vitro studies (Cannavo 2001).  HIV-infected patients 
undergoing treatment that reduces viral load and overall immune activation have decreased 
lymphocyte cell turnover and decreased lymphocyte proliferation (Cannavo 2001).  The lower 
proliferation rates allow lymphocytes to regain function of defective protein degradation and thus 
have appropriate levels of cyclin B and AGNORs (Cannavo 2001).  Increased cyclin B1 levels 
from peripheral blood lymphocytes in vitro was also reported in chronically infected SIV RM 
(Paiardini 2006).  
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Naïve and memory lymphocytes were evaluated by different panels.  CD4+ T cells 
usually follow a linear progression from naïve cell to effector memory cell to central memory 
cells, but central memory cells may also be generated from earlier activated T cells (Obhrai 
2006; Sallusto 2004).  Homeostatic or “self-renewal” proliferation of memory cells occurs but is 
mechanistically different from antigenic “pluripotent” memory proliferation (Kaech 2002).  BM 
T cells in control RM were found to be equally represented in naïve and memory populations in 
our study by percentage and absolute number for CD4+ cells but absolute number only for CD8+ 
cells in CD95 versus CD28 strategies.  BM CD3+CD4+ and CD3+CD8+ naïve and CM 
lymphocytes were increased in the early and ASD phase as circulating CD4+ and CD8+ subsets 
were low post-infection at the same period. CD4+ naïve and memory cells in both lymphoid 
compartments were decreased in the ASY period.  Effector memory and TDEM CD8+ 
lymphocytes were increased in BM and circulation, except in AIDS, during progressive SIV 
disease as CD4+ BM cells were maintained and CD4+ circulating lymphocytes were steadily 
depleted.  In AIDS, all subsets were depleted except CD8+ BM memory cells.  CD45RA vs. 
CD62L plots defined CM bone marrow lymphocytes in lower numbers than represented by 
CD95 vs. CD28 plots but patterns were similar. Koopman et al. discovered circulating 
CD4+CD45RA+CD62L+ naïve cells increased as CD4+CD45RA+CD62L- memory or recently 
activate naïve cells decreased which was supported by our findings in percentages, but all were 
decreased by absolute numbers (Koopman 2001). We observed low numbers of BM CD4+ 
central memory CD45RA-CD62L+ in control macaques as reported in mice as an absence of 
CD4+CD62L+ CM BM cells (Tokoyoda 2009). 
In the early and ASD phases, BM CD8+, WB CD8+ and BM CD4+ lymphocytes shared 
increased early and late stage activation markers.  In ASY period of infection, CD8+ early and 
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late stage activated lymphocytes were increased in both compartments.  In AIDS, activated 
CD8+ BM cells increased and WB decreased.  BM CD3+CD4+ lymphocytes displayed 
increased activation in AIDS for early to middle, and late stage activation markers.  Decreased 
CD4+ early and early to middle stage activated cells were noted for both lymphocyte 
compartments.  Activation markers were rarely detected on circulating CD4+ lymphocytes 
consistent with findings of low absolute numbers of CD4+ lymphocytes.   
We observed lymphocytes homing to secondary and tertiary lymphoid tissues in BM.  
Expression of CD4+β7+ circulating lymphocytes decreased post-infection as previously reported 
(Mattapallil 2004; Wang 2009).  In fact, BM CD4+β7+ lymphocytes were decreased post-
infection in parallel to circulating cells.  BM T lymphocytes were increased in the early period 
for CD62L expression while a decline was noted for WB lymphocytes.  BM CD4+ and CD8+ 
homing lymphocytes were decreased in the ASY and increased in the ASD phase.    WB CD4+ 
and CD8+ homing lymphocytes were decreased in the early, ASY and AIDS phases.  BM CD4+ 
homing cells were decreased in the AIDS phases as BM CD8+ lymphocytes were increased in 
AIDS.   
Our study revealed most circulating CD8+ and CD4+ lymphocytes of control macaques 
co-expressed CXCR4 in higher numbers than CCR5, as supported by findings of others 
(Monceaux 2005; Veazey 2000a).  We also noted BM T cells had higher expression of CXCR4 
on cells.  Further we demonstrated CD8+ lymphocytes with CCR5 expression were spared post-
infection including CD45RA+/- phenotype which was supported by findings of others 
(Monceaux 2005; Veazey 2000a).  Numbers of CD4+ circulating lymphocytes with CXCR4 and 
CCR5 expression declined post-infection however, Veazey et al. noted selective decline in 
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CD4+CCR5+ memory populations versus the CXCR4 expressing cells especially early in 
infection (Veazey 2000a).   
We hypothesized the lymphocyte compartments would be differ between BM and WB.  
Divergences between the lymphocyte compartments were observed as were similar patterns in 
infection.  Percentages of BM CD7+ lymphocytes were opposite between CD4+ and CD8+ 
lymphocytes for each phase of SIV infection.  Percentages of CD7+ lymphocytes were decreased 
for circulating CD4+ cells and increased for circulating CD8+ cells post-infection. Our findings 
suggest regulation was preserved during progressive infection for BM CD3+CD8+ lymphocytes 
which responded with increases in total numbers of several subsets post-infection.  Drop in BM 
cells during the ASY and AIDS phases corresponds to loss for CD3+CD4+ lymphocytes but 
decline in CD3+CD8+ from the prior phase.  BM CD3+CD4+ lymphocytes were maintained in 
early and ASD phases indicating regulation was not lost but may have been blunted compared to 
the BM CD3+CD8+ responses.  Circulating CD8+ lymphocytes were increased post-infection 
signifying regulation was also maintained till loss of cells in AIDS but interestingly, cells 
expressing PeLT homing signals were lost during all phases of infection.  As reported 
consistently in SIV, homeostasis was lost for circulating CD4+ lymphocytes in essentially all 
subsets examined.   
The difference between the compartments was more defined for CD4 lymphocytes in all 
periods and in AIDS for CD8+ lymphocytes.  In BM, early and ASD periods had increased 
subsets of lymphocytes  the ASY period had decreased subsets of lymphocytes which was 
similar to the trend post-infection for marrow cellularity and M:E ratio.  Several theories for 
these changes exists including increased virus in BM, increased CD3+ apoptosis, or loss of 
cytokine regulation. AIDS phase showed fairly consistent lower numbers of CD4+ and CD8+ 
210 
 
circulating cells as well as CD3+CD4+ BM lymphocytes, but increased CD3+CD8+ BM 
lymphocytes.  Viral load was not correlated to BM changes during progressive SIV infection.  
Absolute numbers of CD4+ BM T cells were maintained in BM but lost in WB post-infection 
while CD8+ BM T cells were increased in parallel with WB until AIDS which is supported by 
findings of Sopper et al. (Sopper 2003). 
SUMMARY 
 
Progressive SIV infection in Rhesus macaques was studied in both bone marrow and 
whole blood by percent and absolute numbers for several lymphocyte subsets during early and 
chronic phases of SIV infection categorized by day post-inoculation and observance of clinical 
signs and AIDS.  The objective of this study was to evaluate differences in subsets to determine 
if regulation of lymphocytes was disrupted by subset or by lymphocyte compartment, in either 
BM or WB, during SIV infection.  Absolute CD3+ T lymphocytes increased in BM during 
infection characterized by increased CD3+CD8+ lymphocytes, the predominant phenotype in 
control macaques, and maintenance of CD3+CD4+ in early but not late infection.  BM did not 
show loss of lymphocyte regulation, however, the CD3+CD4+ proliferative response was 
blunted compared to the observed increase in cellularity for CD3+CD8+ during all phases of 
SIV.  Overall, BM CD3+CD4+, WB CD4+, and WB CD8+ lymphocytes were decreased in 
AIDS while BM CD3+CD8+ lymphocytes were increased.   
Our study was supported by earlier findings in BM.  BM T lymphocytes are 
predominantly CD8 in control macaques compared to CD4 dominance in WB.  Bone marrow T 
lymphocytes are maintained during SIV infection characterized by increases in CD8+ phenotype 
and preservation of CD4+ phenotypes except in chronic asymptomatic and AIDS phases.  
Blunted response of BM CD3+CD4+ lymphocytes may be due to increased virus in BM, 
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increased apoptosis, or loss of cytokine regulation.  Further studies in BM will aid in defining the 
cause for minimal BM T lymphocyte response of CD4+ T cells and subsets. 
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CHAPTER 9: APOPTOSIS OF T LYMPHOCYTES IN BONE 
MARROW DURING SIV INFECTION IS MINIMAL 
 
INTRODUCTION 
 
Theories of bone marrow hematopoiesis dysfunction include the following: infectious 
disease, anti-microbial therapy, cytokine or chemokine regulated suppression, ART therapy, HIV 
infection of hematopoietic stem cells, HIV protein derived suppression, HIV infection of 
mesenchymal or mononuclear cells involved in hematopoiesis, apoptosis, BM stromal changes, 
and cytokine soluble factors that suppress hematopoiesis (Marandin 1996; Isgro 2005).  SIV 
infection in BM was shown to occur in T cells and macrophages (Chapter 7) and reported to 
occur in dendritic cells (Donaghy 2003).   Bystander apoptosis or direct viral killing of cells 
through apoptosis may occur during SIV and HIV infection (Isgro 2005).   
One theory for increased BM apoptosis may be cell-to-cell interaction in BM between 
SIV infected T cells, macrophages, and dendritic cells  may disrupt cytokine production and lead 
to increased apoptosis of BM cells (Bucur 2000).  Our earlier findings revealed increased T cells, 
macrophages, and plasmacytoid DC but decreased monocytoid dendritic cells during SIV 
infection (Chapter 5, Chapter 6, and Chapter 8).  In vitro evaluation of T cell apoptosis from SIV 
infected macaques has been reportedly due to FAS/CD95 pathway or spontaneous apoptosis 
(Arnoult 2003).  Prior HIV studies reported increased apoptosis of T cells after in vitro 
incubation (Gougeon 1996). 
The objective of this study was to define apoptosis of BM CD4+ T cells in the Rhesus 
macaque and confirm loss during progressive SIV infection.   We hypothesized increased BM T 
cell apoptosis would mirror whole blood during SIV.  Additionally, we hypothesized apoptosis 
would be fueled by increased pro-apoptotic cytokines in bone marrow tissue.  Whole blood was 
analyzed to detect parallel changes in the bone marrow.  Flow cytometry was utilized to 
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determine apoptosis by the activated caspase 3 (AC3) in BM and WB.  Tissue detection of 
apoptosis by AC3 and terminal deoxynucleotidyl transferase (Tdt) deoxyuridine-triphosphatase 
(dUTP) nick end labeling (TUNEL) was performed to visualize bone marrow apoptotic cells.  
Cytokine analysis was performed on plasma and supernatant from stimulated bone marrow 
mononuclear cells. 
MATERIAL AND METHODS 
 
Experimental Database III 
 
Experimental database and definitions are described in Appendix II.   
Hematologic Data and Definitions 
 
Hematologic data and definitions are described in Appendix I. 
Flow Cytometry Analysis 
 
Whole blood and BM tissue collection, flow cytometry preparation, flow cytometry 
acquisition, flow cytometry analysis, and definitions are described in Appendix III.      
Activated Caspase 3  
 
AC3 (PE, clone C92-605) and CD3 (PB, clone SP34-2) antibodies were from BD 
Biosciences (San Jose, CA) and utilized to detect apoptotic T lymphocytes using flow cytometry.  
T lymphocytes were determined by gates in bone marrow (multilineage gate) and whole blood 
(lymphocyte gate) as earlier described (Chapter 5-6).  The gate of interest was defined as 
CD3+AC3+ using the CD3 vs. AC3 plot (Figure 9.1). 
Plasma Viral Load 
 
Plasma viral loads and definitions are described in Appendix IV.   
Apoptosis Detection in Bone Marrow Tissue Sections 
 
BM tissue and appropriate control tissues were analyzed for apoptosis by double labeling 
fluorescent in situ and fluourescent immunohistochemistry.   Tissues were prepared through  
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Figure 9.1. Identification of apoptotic T lymphocytes 
Phenotypic determination of apoptotic T lymphocytes.   CD3+AC3+ T lymphocytes by CD3 
versus AC3 plot.  Cells were identified as described in text. 
 
antigen retrieval for FISH as described in Chapter 7 and FICH was performed as described in 
Chapter 8 using previously described methods (Borda 2004; Kitagawa 1991; Veazey 1998; 
Wang 2008b; Wang 2007).  In situ TUNEL was performed on BM sections per manufacturer 
directions (ApopTag Fluorescein In Situ Apoptosis Detection Kit, Chemicon International; 
Temicula, CA).  Briefly, slides were incubated with equilibration buffer was for 60 minutes at 
room temperature in dark humidified chambers and then incubated with Tdt for 90 minutes in 
dark humidified chambers at 37°C.  The reaction was stopped with stop/wash buffer followed by 
four serial TBS washes.  TUNEL reaction was detected by tissue incubation with anti-
digoxigenin FITC labeled conjugate for 30 minutes at room temperature in a dark humidified 
chamber.   
FIHC was performed after serial TBS washes.  Tissue was incubated in protein block 
(Serum Free Protein Blocker, DAKO; Carpenteria, CA) for 30 minutes at room temperature in 
dark humidified chambers.  First, primary antibody rabbit anti-human polyclonal activated 
caspase 3 (AC3) (Abcam; Cambridge, MA ) was incubated for 60 minutes at room temperature 
CD3 
A
C
3
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on tissues followed by PBS-FSG washes.   A secondary antibody, goat anti-rabbit conjugated to 
fast red Alexa 568 (Invitrogen; Carlsbad, CA ) was incubated on tissues for 30 minutes at room 
temperature for detection of AC3.  Finally, after PBS washes the slides were coverslipped with 
aqueous anti-quenching medium. 
Slides were imaged for fluorescence with flourescent microscopy at the TNPRC 
Confocal Core Microscopy Center.  A Leica DMR microscope was utilized (Leica 
Microsystems; Exton, PA) to view five serial non-touching fields under the 100x objective.  The 
mean number of cells detected for single labeling of TUNEL or AC3 and double labeling with 
TUNEL and AC3 fluorescence was calculated in each of five high power fields (hpf).   
Cytokine Analysis of Plasma and Whole Blood 
 
Plasma for cytokine analysis was separated from heparinized whole blood by 
centrifugation and frozen at -80°C.  Ficoll preparation was used to isolate the mononuclear 
fraction of marrow cells collected during necropsy.  The bone marrow mononuclear cells 
(BMMC) were diluted in enriched RPMI media for a final dilution of 1x10
5
/mL.  Then, 100µL 
of BMMC  from each subject was plated in triplicate into 96 well plates.  Stimulation media was 
prepared from sterile RPMI media with phytohemagluttinin (PHA) (Gibco, Invitrogen; Carlsbad, 
CA) for a desired final concentration of 50ng/mL, phorbol 12-myristate 13-acetate (PMA) 
(Sigma-Aldrich; St. Louis, MO) for a desired final concentration of 100ng/mL, and calcium 
ionophore (Sigma-Aldrich; St. Louis, MO) for a desired final concentration of 250ng/uL then 
frozen in aliquots.  Stimulation media defrosted to room temperature was added at 1:2 ratio per 
well and cells were stimulated for 18 hours in a 37°C incubator with 5% CO2.  Post-incubation, 
plates were centrifuged at 200 x g for 5 minutes and 100 µL of supernatant was retrieved from 
each well and frozen at -80°C.  Supernatants from stimulated cells were utilized for cytokine 
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analysis.  Before and after stimulation of BMMC, monolayer of cells were observed by an 
inverted microscope and nucleated cells were present.   
A magnetic bead array analysis was performed to detect cytokine concentrations as 
previously described (Giavedoni 2005; Ramesh 2009).  Batch analysis of plasma and stimulated 
BMMC supernatant was performed in duplicate.  Cytokines consisted of pre-mixed anti-cytokine 
labelled beads designed to detect 27 cytokines (Table 9.1) (Bio-Plex Human Cytokine 27-Plex 
Panel Group I, Bio-Rad).  Controls for the analysis were RPMI media used as a blank and the 
manufacturer provided low and high standard controls for each cytokine per manufacturer 
instructions  (Bio-Plex Cytokine Assay, Bio-Rad Laboratories; Hercules, CA).  BMMC 
supernatants were diluted 1:100 prior to analysis per manufacturer directions (Bio-Plex Cytokine 
Assay).  The multiplex assay plate was prepared per manufacturer directions (Bio-Plex Cytokine 
Assay).  Detection of cytokines by was performed on the multiplex assay plate analyzer using the 
Bio-Plex 200 Suspension Array Luminex System and Bio-Plex Manager Software (Bio-Rad).  
The low standard was utilized for lower and upper limit detection of cytokines as pg/mL.  
Indeterminate cytokine values were defined as results below the lower limit of the low standard 
for each cytokine.  
Statistical Analysis 
 
For data evaluation, controls were non-SIV infected macaques and SIV infected subjects 
were grouped into periods defined as early and chronic (Appendix II).  Macaques developing 
AIDS were fast and slow progressors. 
Apoptosis and cytokine concentrations for control and SIV infected macaques were 
compared for differences using the Mann Whitney non-parametric unpaired t test and 
correlations were determined using non-parametric Spearman r correlation coefficients in  
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Table 9.1. Cytokine Profile 
 
Cytokine Cytokine Name 
Possible Source for Production  
of Cytokine by these cells: 
IL-1β Interleukin 1β Macrophages, monocytes, dendritic cells 
IL-1ra Interleukin 1ra Macrophages, monocytes, dendritic cells 
IL-2 Interleukin 2 T lymphocytes 
IL-4 Interleukin 4 Basophils 
IL-5 Interleukin 5 T lymphocytes, mast cells, eosinophils 
IL-6 Interleukin 6 
T lymphocytes, macrophages, osteoblasts, smooth muscle 
cells in blood vessels 
IL-7 Interleukin 7 Stromal cells of bone marrow and thymus 
IL-8 Interleukin 8 Macrophages, endothelial cells 
IL-9 Interleukin 9 T lymphocytes 
IL-10 Interleukin 10 Monocytes, T lymphocytes 
IL-12 (p70) Interleukin 12 Dendritic cells, macrophages 
IL-13 Interleukin 13 T lymphocytes 
IL-15 Interleukin 15 Macrophages 
IL-17 Interleukin 17 T lymphocytes 
Eotaxin Eotaxin Macrophages 
FGF basic Basic Fibroblast Growth Factor  
CSF-G Granulocyte Colony Stimulating Factor 
Macrophages, T lymphocytes, mast cells, endothelial cells, 
fibroblasts 
CSF-GM 
Granulocyte-Macrophage Colony 
Stimulating Factor 
Macrophages, T lymphocytes, mast cells, endothelial cells, 
fibroblasts 
IFN-γ Interferon gamma Natural killer cells, lymphocytes, cytotoxic lymphocytes 
IP-10 Interferon Inducible Protein 10 Monocytes, endothelial cells, keratinocytes 
MCP-1 (MCAF) 
Monocyte Chemotactic  Protein 1 or 
CCL2 or Monocyte Chemotactic and 
Activating Factor 
Monocytes, vascular endothelial cells, osteoblasts, smooth 
muscle cells 
MIP-1α 
Macrophage Inflammatory Protein 1 
alpha or CCL3 Macrophages 
MIP-1β 
Macrophage Inflammatory Protein 1 
beta or CCL4 Macrophages, T cells, B cells 
PDGF  
Platelet Derived Growth Factor dimer 
BB Megakaryocytes, stored in platelets 
RANTES 
Regulated upon Activation, normal T 
cell Expressed and Secreted or CCL5 T lymphocytes 
TNF-α Tumor Necrosis Factor alpha 
Macrophages, monocytes, neutrophils, T lymphocytes, NK 
cells 
VEGF Vascular Endothelial Growth Factor Macrophages 
 
 
GraphPad Prism with significance considered as p<0.05 (GraphPad Software; La Jolla, CA).  
Means of data are represented by graphs where error bars represent the SEM.  
Percentages of immunophenotypic populations for control and SIV infected macaques 
were compared using the Mann Whitney non-parametric unpaired t test,  and correlations were 
determined using non-parametric Spearman correlation coefficients GraphPad Prism with 
significance was considered as (GraphPad Software; San Diego, CA).   
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Graphs represent the means and SEM.  Significant differences were defined as  p≤0.05. 
RESULTS 
 
Apoptosis in Bone Marrow Tissue Sections During SIV Infection 
 
Very low numbers of marrow cells were noted to undergo apoptosis in bone marrow 
tissue by evaluation of AC3 and TUNEL staining of BM tissue sections.  Cells were considered 
apoptotic if staining for AC3 and TUNEL was intranuclear, however low numbers of cells 
stained for AC3 within the cytoplasm of infected and non-infected macaques. This 
intracytoplasmic staining for AC3 was often considered phagocytic debris from cells undergoing 
apoptosis.   
Detection of apoptosis by AC3 revealed higher numbers of BM apoptotic cells compared 
to TUNEL or double labeling (Figure 9.2).  In non-infected macaques, the mean of less than 1 
cell per hpf was observed as apoptotic.  During early SIV infection, apoptotic cells were 
significantly decreased in number, but increased during the chronic period.   By double labeling 
for AC3 and TUNEL in BM tissue in the chronic period, less than 1 cell/hpf was apoptotic by 
TUNEL compared to >1 cell/hpf for apoptosis by AC3.   
Apoptosis of T Lymphocytes During SIV Infection 
 
Percentages of CD3+ T lymphocytes undergoing apoptosis were identified by AC3 
staining using flow cytometry.  Few marrow and blood CD3+ T lymphocytes were detected as 
apoptotic (<0.02%) and percentages remained stable during SIV infection for bone marrow and 
whole blood with minimal decrease in the chronic phase (Figure 9.3).  Due to low detection of 
apoptotic T cells, further phenotyping of apoptotic cells was not performed. 
Plasma Cytokines During SIV Infection 
 
Early during SIV infection, rises were detected for the following: IL-1ra (p=0.0035), IL-2 
(p=0.047), IL-4 (p=0.047), IL-15 (0.0239), eotaxin (p=0.0312), MCP-1 (p=0.0078), TNF-α  
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A.                      B.                                              C.     
 
Figure 9.2. Detection of apoptosis in bone marrow tissue 
Fluorescent immunohistochemistry staining for activated caspase 3 (AC3) and fluorescent in situ 
terminal deoxynucleotidyl transferase (Tdt) deoxyuridine-triphosphatase (dUTP) nick end 
labeling (TUNEL) analysis for apoptosis was performed.  Difference between control cohort to 
early and chronic periods of SIV infection were compared by Mann Whitney t tests 
(****p<0.05).  Representation of mean values (grey line) + SEM. 
 
 
 
A.                                                                     B. 
 
Figure 9.3. Apoptosis of T lymphocytes in bone marrow and whole blood 
Percentages of T lymphocytes detected by activated caspase 3 for apoptosis in A. bone marrow 
and B. whole blood.  Difference between control cohort to early and chronic periods of SIV 
infection were compared by Mann Whitney t tests (****p<0.05).  Representation of mean values 
(grey line) + SEM. 
 
 
(p=0.0307), IL-5, Il-7, CSF-G, CSF-GM, INF-γ, IP-10, and RANTES.   During the chronic 
period, increases continued for IL-1ra (p=0.0035), IL-15, MCP-1 (p=0.0099), and TNF-α (Figure 
9.4).  The other cytokines that increased during the early phase were decreased or unchanged  
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Figure 9.4. Plasma cytokine concentrations increased during SIV 
Difference between control cohort to early and chronic periods of SIV infection were compared 
by Mann Whitney t tests (****p<0.05).  Representation of mean values (grey line) + SEM. 
 
 
during the chronic perod (Figure 9.5).   RANTES was increased in the early period, then 
decreased in the chronic phase of SIV infection (Figure 9.6).  PDGF was decreased during the 
early period, and then increased later during infection (Figure 9.6).  IL-6, IL-8, and IL-17 were 
decreased in the chronic period, without any change during early SIV infection (Figure 9.7). 
Bone Marrow Supernatant Cytokine Concentration During SIV Infection 
 
Cytokine concentrations from the supernatant of stimulated bone marrow mononuclear 
cells were detected only for IL-8, and MIP-1β, cytokines secreted by macrophages.  Comparison 
of cytokine concentrations between controls and infected RM did not reveal significance, 
however MIP-1β showed an upward trend post-infection but IL-8 remained unchanged (Figure 
9.8).  BMMC supernatant analysis was indeterminate for IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-
9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-γ, IP-10, 
MCP-1 (MCAF), MIP-1α, PDGF bb, RANTES, TNF-α, and VEGF. 
DISCUSSION 
 
Apoptosis of marrow cells by AC3 was observed to significantly decrease early during 
SIV infection and then increase later during infection within bone marrow.   Even though 
changes in apoptosis were noted in marrow, few cells were detected to be undergoing apoptosis.   
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Figure 9.5. Plasma cytokine concentrations increased early during SIV infection 
Difference between control cohort to early and chronic periods of SIV infection were compared 
by Mann Whitney t tests (****p<0.05).  Representation of mean values (grey line) + SEM. 
 
 
 
 
Figure 9.6. Plasma cytokine concentrations were variable during SIV infection 
Difference between control cohort to early and chronic periods of SIV infection were compared 
by Mann Whitney t tests (****p<0.05).  Representation of mean values (grey line) + SEM. 
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Figure 9.7. Plasma cytokine concentrations decreased during SIV infection 
Difference between control cohort to early and chronic periods of SIV infection were compared 
by Mann Whitney t tests (****p<0.05).  Representation of mean values (grey line) + SEM. 
 
 
 
 
Figure 9.8. Cytokine concentrations in supernatant from stimulated bone marrow cells 
during SIV infection 
Difference between control cohort to early and chronic periods of SIV infection were compared 
by Mann Whitney t tests (no differences).  Representation of mean values (grey line) + SEM. 
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By flow analysis of apoptosis in marrow and blood, the percentages indicated apoptosis of CD3+ 
T lymphocytes to be a rare event that was unchanged during SIV infection.  Our finding was 
consistent with blood lymphocytes from chronically SIV infected RM that had similar levels of 
apoptosis to non-SIV infected RM detected by AC3 (Paiardini 2006).   Paiardini et al. detected 
higher levels of activated caspase 8 (AC8) in SIV infected RM compared to non-infected 
macaques (Paiardini 2006).  AC8 is an initiator caspase upstream from AC3 in the FAS mediated 
apoptosis pathway (Elmore 2007).  Within lamina propria of SIV infected RM, increased 
apoptosis of CD4+ and not CD8+ T cells was identified by TUNEL and AC3 (Li 2005) 
Theile et al. reported AIDS patients were observed with increased apoptosis in BM 
identified by TUNEL compared to non-HIV infected people (Thiele 1997).   In addition Theile et 
al. indetified similar bone marrow changes for non-AIDS patients with myelitis and 
myelodysplasia suggestive of premature cell death or ineffective hematopoiesis (Thiele 1997).  
Theile et al. proposed that detection of apoptosis may be impeded by efficient removal of 
apoptotic cells by tissue macrphages (Thiele 1997).  Further Theile et al. suggested apoptosis 
may result in recruitment of macrophages which in turn could secrete cytokines to enhance 
apoptosis (Thiele 1997).  We observed by apoptosis staining in BM tissue the presence of 
intracytoplasmic fluorescence for AC3 suggestive of phagocytosed debris from apoptotic cells, 
however this was noted in control and infected macaques.   We also found several cytokines 
increase post-infection in BMMC, a fraction of which likely contained macrophages.  However,  
MIP-1β (a chemoattractant for granulocytes) was only increased in early and later periods.  
Moreover, TNF-α in plasma was continually elevated post-infection which can induce apoptosis 
(Thiele 1997). 
Our finding of increased MIP-1β in marrow supernatant was supported by similar 
findings in BMMC from HIV patients receiving ART (Dallalio 1999).  In additon, TNF and 
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RANTES were also found to elevated by Dallalio et al. in HIV patients (Dallalio 1999).  We 
detected increases in plasma TNF early and late during SIV infection but only during the early 
phase for RANTES.  Our study demonstrated BMMC supernatant levels of MIP-1β was higher 
post-infection compared to control macaques supported by reports of significantly higher 
concentrations by ELISA in supernatant from BM aspirates of HIV infected patients than non-
infected (Dallalio 1999).  IL-1β and IFN-γ were not detectable in bone marrow supported by 
minimal detection by ELISA from BM aspirates of HIV patients (Dallalio 1999).  BM aspirate 
supernatant from HIV patients revealed significant increases in TNF-α and MIP-1α from non-
HIV infected patients and minimal changes in RANTES by ELISA determination (Dallalio 
1999). 
Cytokine analysis of supernatant from long term bone marrow culture cells (LTBMC) 
infected with HIV did not reveal differences compared to control cultures for IL-1α, IL-3, IL-6, 
MIP-1α, TGF-β, and TNF-α (Marandin 1995).  In our study, IL-1α, MIP-1α, and TGF-β were 
not detectable in supernatant.  In our study IL-6, MIP-1α, and TNF-α were low in accordance 
with HIV studies (Marandin 1995) but IL-6 was high in HIV studies (Marandin 1995).    Also 
stromal cells in LTBMC from HIV infected cultures were able to support hematopoiesis 
compared to non-infected LTBMC cultures (Marandin 1995).   
IL-7 supports survival of CD8+ naïve cells while IL-7 and IL-15 support expansion of 
memory cells (Koopman 2001).  IL-2 and IL-4 can support proliferation of CD8+ memory cells 
(Koopman 2001).  IL-7 supports survival of CD4+ naïve, memory, and effector cells (Koopman 
2001).  IL-2 inhibits effector cells during priming but prevents apoptosis during the contraction 
phase for CD4+ lymphocytes (Koopman 2001).    
Limitation of this study was BMMC supernatant stimulation performed to determine 
cytokine levels during SIV infection.  Cellular composition of the BMMC may not have 
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supported detection of cytokines.  Monocytes, macrophages, and lymphocytes secrete several of 
the cytokines analyzed and should have been represented in the mononuclear ficoll preparation 
but flow analysis was not performed to confirm the phenotype of BMMC before or after 
stimulation.  It is unknown what concentration or ratio of cells is needed in bone marrow to 
detect cytokine levels, though previous studies have detected concentrations of cytokines in 
marrow supernatant.  The dilution factor may have been a hindrance to detection.  The dilution 
factor for supernatant was chosen at 1:100 per manufacturer recommendations, but several 
cytokines were not recorded because the level of detection was below the lower limit of the 
standard.  Cytokine concentrations in supernatant may be undetectable, even without dilution, 
but optimal for cell-to-cell interface within bone marrow tissue.  Microarray analysis to detect 
upregulation of genes that target cytokine production found with BMMC fractions may reveal 
changes during SIV infection. 
SUMMARY 
 
In vivo apoptosis of T cells is minimally changed during SIV infection in bone marrow 
and whole blood.  Cytokine analysis of supernatant from bone marrow mononuclear cells of 
infected macaques did not reveal increases in pro-apoptotic cytokines.  Plasma cytokine levels 
from the same macaques revealed pro-inflammatory cytokines.  Our hypothesis was rejected for 
increased apoptosis in bone marrow of T cells. 
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CHAPTER 10: CONCLUSION 
 
We hypothesized bone marrow is a site of increased apoptosis for CD4+ T lymphocytes 
during SIV/HIV infection causing depletion of this subset in the marrow.  Potential mechanisms 
of CD4+ T lymphocyte loss in the bone marrow include the following: (1) direct viral infection 
of CD4+ T cells and destruction (Harbol 1994; Paiardini 2009); (2) “bystander apoptosis” of 
CD4+ T cells as an effect from nearby virally infected bone marrow cells (Chen 2002; Li 2005; 
Paiardini 2009); or (3) apoptosis and/or defective lymphopoiesis leading to lack of reconstitution 
secondary to chronic immune stimulation during SIV/HIV infection (Harbol 1994; Paiardini 
2009).  The accelerated apoptosis may be from direct cell infection and loss or the result of 
“bystander apoptosis” from nearby infected cells or viral proteins.  For true bystander apoptosis 
to be a mechanism of destruction, any CD4+ T lymphocytes could potentially undergo 
programmed cell death regardless of chemokine receptor expression, but this could also be 
dependent on cell activation. 
First, we demonstrated the Rhesus macaque model for progressive SIV disease parallels 
HIV disease of humans with regard to hematologic abnormalities detected on a complete blood 
count.  Lymphopenia, neutropenia, anemia, thrombocytopenia, and eosinophilia are common in 
prevalence and distrubtion during progressive SIV disease.  The SIV model of RM was validated 
for study of hematologic abnormalities in HIV disease. 
We then confirmed the Rhesus macaque model for SIV disease mimics HIV disease of 
humans with regard to observable bone marrow changes by an objective detailed morphologic 
assessment.  We documented marrow panhypercellularity (especially in the AIDS phase), BM 
fibrosis, BM lymphoid aggregations, BM iron depletion, and increased BM CD34+ 
hematopoietic stem cells during progressive SIV disease that was similar to findings during  HIV 
disease.  The BM myeloid to erythroid ratio is mostly maintained with minimal loss of myeloid 
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lineage cells and increase of erythroid lineage cells post-infection.  Despite observed changes in 
BM, during progressive infection the marrow was able to respond appropriately to peripheral 
needs by increase production of hematopoietic cells especially noted in AIDS.  The SIV model 
of RM was validated for study of bone marrow changes in HIV disease. 
We established a percent increase in the erythroid and lymphoid lineages, maintenance of 
the monocytic lineage, and drop in the granulocytic lineage during progressive SIV disease in 
macaques by phenotypic analysis of marrow hematopoeitic cell lineages by flow cytometry.  Our 
phenotypic analysis of BM was similar to our morphologic analysis of BM during SIV with 
respect to increased T lymphocytes and erythroid cells,  lack of change in monocytes, and loss of 
granulocytes.  Further, we determined the increase in marrow lymphocytes was due to CD3+ T 
lymphocytes while B lymphocytes, plasma cells, NK cells, and DC cells decreased in the 
marrow during progressive SIV disease.  As T lymphocytes increased in BM, antigen presenting 
dendritic cells in BM and WB decreased suggestive of a loss and not redistribution of cells. 
We quantified viral copies of RNA in BM during progressive SIV infection in macaques 
with minimal observable detection of infective cells except in chronic phases.  Viral DNA 
wasdetected by polymerase chain reaction during progressive SIV infection also with rare 
observable productively infected cells in BM.  Hematopoietic cells infected with SIV were 
macrophages, CD3+ T lymphocytes, and other mononuclear cells in BM.  
We demonstrated the percentage increase in BM T cells post-SIV infection in macaques 
translated to increased absolute numbers of CD3+ T lymphocytes during SIV infection 
predominantly by CD8+ T cells.  Suprisingly, unlike WB, BM CD4+ T lymphocytes were 
maintained during progressive SIV infection with evidence of proliferation.  Our hypothesis of 
loss of CD4+ T lymphocytes during progressive SIV infection was rejected based on this 
unexpected finding.    
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We observed few apoptotic cells were present in bone marrow for control and SIV 
infected RM.  Flow cytometry analysis of apoptosis of CD3+ cells revealed low percentages of 
cells were undergoing apoptosis as determined by detection of activated caspase 3 expression 
during SIV.  Bone marrow cytokine concentrations from supernatant of stimulated marrow 
mononuclear cells detected rare cytokines while plasma detected pro-inflammatory cytokines 
during progressive SIV infection. 
Theories for loss of CD4+ T lymphocytes in marrow were rejected in this study due to 
lack of loss of these cells in bone marrow during various periods of SIV infection in the RM.  
Few productively SIV infected cells were detected in marrow though RNA and DNA viral copies 
were detected by PCR so direct viral destruction or bystander apoptosis of CD4+ T lymphocytes 
is unlikely.  Low numbers of marrow cells were undergoing apoptosis so virally induced 
apoptosis of CD4+ T lymphocytes is unlikely.  Cytokine expression was minimally detected in 
stimulated BM mononuclear cells so chronic immune stimulation affecting marrow cytokine 
production was not detected to halt or prevent lymphopoiesis of T lymphocytes.   
Neutropenia was a consistent finding in SIV infected RM especially in progressive 
disease.  Myeloid loss of granulocytic cells and not monocytic cells was noted in the BM during 
SIV infection though the BM cellularity increased.  Maintenance of CD4+ T lymphocytes in BM 
was detected during progressive SIV infection.  Future studies are needed to determine relevance 
of these factors during SIV and HIV. 
Our findings suggest bone marrow and whole blood are under different homeostatic 
mechanisms.  CD8+ T lymphocytes were able to respond during progressive SIV infection 
though CD4+ T lymphocytes were maintained but did not increase.  Proliferation in BM of 
CD4+ and CD8+ T lymphocytes indicates bone marrow tissue can support lymphopoiesis during 
SIV infection but cell cycle dysfunction was evident for CD4 cells.   
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Our study of marrow raises the question that bone marrow may be a de novo site of 
CD4+ T lymphocyte production and provide CD4+ T lymphocytes to enter circulation and may 
be the “tap” in the purported  “tap and drain” mechanism of CD4+ T lymphocyte loss and 
turnover (Chen 2002).  Lymphocyte numbers may be increased in bone marrow following 
infection because of redistribution or increased migration from or decreased emigration to 
peripheral blood and lymphoid tissues.  HIV infected patients demonstrated significant increases 
of CD4+ T lymphocytes migrating from peripheral blood to bone marrow compared to 
uninfected people by in vivo CD4 lymphocyte autologous nuclear labeling studies (Chen 2002). 
Future studies in bone marrow lymphocyte homeostasis may provide clues to changes 
identified during SIV and HIV infection. 
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APPENDIX I: HEMATOLOGIC DATA AND DEFINITIONS 
 
All hematologic values were generated from a single ethylenediaminetetraacetic acid 
(EDTA) anti-coagulated sample of whole blood processed the same day and analyzed on a 
hematology analyzer at the TNPRC Clinical Pathology Core Laboratory.  EDTA blood for CBCs 
collected on day of sacrifice was obtained immediately prior to humane euthanasia.  EDTA 
blood was maintained at room temperature on a rocker until CBC analysis was performed.  CBC 
data with values outside of the reference ranges/intervals or those flagged for any reason were 
always evaluated microscopically by review of a modified Wright stained blood smear.  
CBCs were evaluated from day 0 of SIV inoculation serially over time till day of 
sacrifice for SIV infected subjects in ED I (Appendix II).  Control subjects in ED I had one CBC 
evaluated.   Subjects in ED II, ED III, and ED IV (Appendix II) had one CBC evaluated on the 
day of sacrifice.   
Samples collected prior to Sept 1, 2001 were analyzed using a Coulter T540 hematology 
analyzer (Beckman Coulter; Fullerton, CA) and samples collected after 2001 were generated 
using an ADVIA 120 hematology analyzer (Bayer; Tarrytown, NY).  However, prior to this 
transition, extensive quality control testing was performed to ensure consistency of data 
collection and analysis between the two instruments (data not shown).  Subjects included in ED I 
utilized both hematologic analyzers.  Subjects included in ED II -IV utilized only the ADVIA 
120 hematologic analyzer. 
Hematologic conditions were interpreted by observed laboratory parameters.  
Abnormalities were defined based upon CBC reference intervals for the Rhesus macaque.  
Cytopenia or decreased values were defined as the following: leukopenia (white blood cell 
(WBC) count <6,600 cells/µL); lymphopenia (absolute lymphocyte count <2,600 cells/µL); 
monocytopenia (absolute monocyte count <100 cells/µL); neutropenia (absolute neutrophil count 
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<2,200 cells/µL); and TCP without gross or microscopic evidence of platelet clumping (platelet 
count < 193,000 cells/µL).  Cytosis or cytophilia were defined as the following: leukocytosis 
(total WBC count >15,500 cells/µL); basophilia (absolute basophil count >100 cells/µL); 
eosinophilia (absolute eosinophil count >400cells/µL); lymphocytosis (absolute lymphocyte 
count >8,600 cells/µL); monocytosis (absolute monocyte count >600 cells/µL); and neutrophilia 
(absolute neutrophil count >5,600 cells/µL; and reticulocytosis (reticulocyte count >212x10
9
 
cells/µL).  
Anemia was defined as a low hematocrit value (hematocrit <34.8%).  Anemia was further 
characterized by MCV and MCHC values.  Microcytosis was defined as a decreased MCV value 
(<63.7 fL), normocytosis was defined as a MCV value within the reference interval (63.7-86.9 
fL) and macrocytosis was defined as an increased MCV value (>86.9 fL).  Anemia was also 
classified as hypochromic or normochromic by the MCHC value.   Hypochromia was defined as 
a decreased MCHC value (<28.9 g/dL) and normochromia was defined as a MCHC value within 
the reference interval (28.9-35.4 g/dL).  Reticulocytosis was defined as regenerative during an 
anemic condition.  Reticulocyte count was performed for ED II and III. 
Mean platelet volume (reference interval 7.0-12.0 fL) was evaluated for ED II and III. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
237 
 
APPENDIX II: EXPERIMENTAL DATABASE 
 
RESEARCH SUBJECTS 
 
Four experimental databases were utilized that consisted of different control and SIV 
infected RM and different designations of stages during SIV infection defined as periods.  ED I 
was utilized in Chapter 3.  ED II was utilized in Chapter 4, Chapter 7, and Chapter 8.  ED III was 
utilized in Chapter 5, Chapter 6, Chapter 7, and Chapter 9.  ED IV was utilized in Chapter 7.   
Controls were uninfected or non-inoculated for SIV and changed for each ED.  Asian RM 
were chosed for the SIV animal model of HIV disease at the TNRPC.  Rhesus macaques were 
inoculated by once by  either intravenous (IV), intra-vaginal (INVG), or intra-rectal (IR) route 
with either of SIVmac239, SIVmac251, or SIVB670.   
IV administration was performed according to TNPRC SOP 3.18.2 Intraveous 
Inoculation of Nonhuman Primates.  INVG administration was performed according to TNPRC 
SOP 3.19.2 Intravaginal Inoculation of Nonhuman Primates.  IR administration was performed 
according to TNPRC SOP 3.49.2 Intra-rectal inoculation of Nonhuman Primates.  Subjects were 
at least 1.75 years of age at time of inoculation.  Control subjects were naïve for SIV inoculation 
and age-matched.  Further, all animals were devoid of SIV-related experimental treatment, 
therapy, or vaccination throughout the study.   
All RM subjects were sedated for examinations, procedures, and/or transport to the 
necropsy suite per TNPRC SOP 3.1.2 Chemical Restraint of Nonhuman Primates for 
Examination and Minor Procedures by TNPRC veterinarians. Venipuncture was performed 
according to TNPRC SOP 3.10.3 Blood Collection by Venipuncture in Nonhuman Primates.  
Select RM were intra-peritoneally injected with bromodeoxyuridine (BrdU) 24 hours prior to 
humane sacrifice.   
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Control macaques in ED I were not sacrificed after sample collection.  Control macaques 
in ED II-III were humanely euthanized at the termination of their study protocol as were SIV 
infected macaques.  Additionally, SIV infected RM were humanely euthanized for intractable 
illness prior to termination of their study protocol. Throughout the study, clinical signs were 
monitored and recorded by TNPRC veterinarians.  Euthanasia was performed according to 
TNPRC SOP 3.23.2 Euthanasia Procedures in Nonhuman Primates.  Necropsy included gross 
evaluation of multiple organs and tissues for each subject along with sample collection obtained 
by a necropsy prosector and/or veterinary pathologist. Multiple samples from organs/tissues were 
taken from each subject for histopathologic review by a TNPRC veterinary pathologist.  Either 
absence of significant lesions, no significant lesions found (NSF), or presence of disease 
processes were confirmed by histopathological examination of multiple organs/tissues obtained 
from necropsy.  Samples were obtained at necropsy and disease was confirmed by gross and 
histopathological examination of multiple organs/tissues.   
DEFINITIONS OF PERIODS DURING SIV INFECTION 
 
For data evaluation, inoculated subjects were grouped based on progression of infection 
as control, early, and chronic periods of SIV infection.  Early, chronic, and AIDS periods 
consisted of SIV inoculated macaques.  Early subjects were 1-42 days post-inoculation (DPI) at 
humane sacrifice.  The chronic subjects were >42 DPI.  AIDS subjects were chronically infected 
with clinical signs and disease consistent with AIDS criteria.  
The chronic time period was subdivided for ED II and ED IV by clinical signs and 
disease process, based on the 2008 World Health Organization (WHO) and CDC classification 
for HIV.  The chronic group was subdivided into 3 phases based on clinical signs ascertained by 
TNPRC laboratory animal veterinarians and necropsy diagnosis of disease as asymptomatic SIV 
disease (ASY), advanced SIV disease (ASD), and acquired immune deficiency syndrome 
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(AIDS).  ASY subjects were without clinical signs of disease at humane sacrifice and without 
necropsy diagnosis of disease.  ASD subjects or “sick” macaques displayed clinical signs of 
disease with confirmed necropsy diagnosis of disease but lacking AIDS defined diseases at 
humane sacrifice.  AIDS was defined based on the 1993 Centers for Disease Control (CDC) 
guidelines of encephalitis, lymphoid tumors, or opportunistic infections (OI).  AIDS subjects had 
classic clinical signs and disease consistent with AIDS criteria.  The progression to AIDS was 
defined as fast or slow progressors. 
EXPERIMENTAL DATABASE I-IV 
 
Experimental Database I 
 
 The 21 infected subjects ranged in age from 1.77-12.2 years of age at inoculation (mean 
4.98 years) as defined in Table II.1.  Three male and two female RM were examined in the 
SIVmac239 group with an average of 691 DPI (range 359-1113 DPI), six males were examined 
in the SIVmac251 group with an average of 814 DPI (range 536-1071 DPI), and five male and 
five females were examined in the SIVB670 group with an average of 454 DPI (range 278-776 
DPI). Criteria for diagnosis of AIDS remained fairly consistent between groups except for 
animal BE53, inoculated with SIVmac251, diagnosed with multi-organ lymphoma.  Each 
infected RM had at least one CBC drawn during each successive stage of infection.  Thirty-one 
control RM consisted of twenty-two male and nine female macaques whose ages ranged from 
2.24 to 9.72 years (mean of 5.10 years).  Controls are defined in Table II.2. 
Experimental Database II 
 
Thirty-nine Indian RM were included in this study (Table II.1).  Control subjects 
consisted of eight RM, 3 male and 5 female with an average age of 7.6 years at sacrifice (range 
3-10 years).  Ten early subjects, within 8-22 DPI, were all inoculated IV with SIVmac251, 8 
male and 2 female with an average of 7.2 years at sacrifice (range 3-20 years).  At 63-181 DPI  
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Table II.1. SIV Inoculated Rhesus Macaque Experimental Database I 
 
 
Subject 
ID
a
 Sex 
Age at 
Inoculation, 
Years 
SIV 
Inoculum 
Days Post- 
Inoculation  
at Sacrifice AIDS Diagnosis 
BR20 Mb 6.35 mac239 389 Pneumocystis pneumonia 
EE54 Fc 2.75 mac239 359 Pneumocystis pneumonia 
I553 F 12.20 mac239 646 Pneumocystis pneumonia 
P045 M 8.46 mac239 1113 Pneumocystis pneumonia 
T798 M 6.22 mac239 949 Intestinal mycobacteriosis 
AE55 M 5.10 mac251 658 Pneumocystis pneumonia 
BE53 M 3.33 mac251 536 Lymphoma, multi-organ 
BE65 M 3.33 mac251 1071 Intestinal mycobacteriosis 
BI33 M 5.17 mac251 899 Pneumocystis pneumonia 
BT51 M 4.03 mac251 990 Intestinal mycobacteriosis 
P503 M 10.31 mac251 730 Pneumocystis pneumonia 
G010 F 1.95 B670 390 Meningoencephalitis 
G055 F 2.31 B670 343 Meningoencephalitis 
G143 M 1.93 B670 445 Cryptospordiosis 
G164 M 1.87 B670 776 Meningoencephalitis 
 J714 M 2.02 B670 317 Pneumocystis pneumonia 
N073 M 3.88 B670 510 Intestinal mycobacteriosis 
N217 F 9.91 B670 546 Intestinal mycobacteriosis 
P337 M 2.04 B670 517 Intestinal mycobacteriosis 
R544 F 7.87 B670 414 Meningoencephalitis 
T270 F 1.77 B670 278 Cryptospordiosis 
a) ID= identification; b) M = male; c) F = female 
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Table II.2. Controls in Experimental Database I 
 
Subject ID
a
 Sex Age, Years 
CE04 Fb 9.72 
CF18 F 8.55 
CT13 Mc 6.47 
DF51 M 6.41 
DF99 M 6.38 
DJ11 M 6.16 
DN57 M 5.46 
DR15 F 5.91 
DR48 F 5.89 
DV24 F 5.84 
DV66 M 5.38 
EA27 M 5.90 
EB45 M 5.31 
EB50 M 5.28 
EF56 F 5.87 
EL18 M 4.92 
EL50 M 4.36 
EL52 F 4.81 
EM96 F 4.76 
EP43 M 4.29 
ER34 F 4.48 
FG52 M 3.35 
FH22 M 3.33 
FH43 M 3.33 
FH71 M 3.31 
FJ20 M 3.14 
FJ65 M 3.14 
FJ68 M 3.13 
FP79 M 2.28 
FT10 M 2.24 
FT46 M 2.23 
a) ID= identification; b) F = female; c) M = male 
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were seven ASY subjects inoculated with SIVmac251, 5 male by IR route and 2 female by 
INVG route with an average age of 5.8 years at sacrifice (range 4-10 years).  The ASD subjects 
were two male and three female subjects inoculated IV with SIVmac251 and one female was 
inoculated INVG with SIVB670 that ranged 63-959 DPI with an average age of 7.4 years at 
sacrifice (range 4-13).  Finally, AIDS subjects were 414-1071 DPI and consisted of three male 
and one female subject inoculated IV with SIVmac251, three males inoculated with SIVmac239, 
and one female inoculated INVG with SIVB670 with an average of 9.4 years at sacrifice (range 
6-14).  AIDS subjects were slow progressors or >260 DPI at humane sacrifice. 
Experimental Database III 
 
Twenty-four Asian RM were included in this study (Table II.2).  Control subjects 
consisted of twelve female Indian RM with an average age of 9.9 years at sacrifice (4-16 years).  
All experimental subjects were infected with SIVmac251.  Eight early subjects, within 8-13 DPI, 
were all inoculated IV with SIVmac251, 1 male and 7 females with an average age of 10.3 years 
at sacrifice (range 5-14 years).  Eight chronic subjects, within 71-1068 DPI, were all inoculated 
with SIVmac251, 5 females by INVG route, 2 females by IV route, and 1 male by IR route with 
an average of 8.7 years at sacrifice (range 3-11).  Chronic RM included 1 asymptomatic, 2 
symptomatic, and 5 AIDS subjects.  AIDS subjects were fast progressors with clinical signs and 
disease consistent with AIDS criteria for ED II. AIDS diagnoses were all different including OIs, 
lymphoma, and encephalitis.  All RM were of Indian origin except 1 female in AIDS. 
Experimental Database IV 
 
Experimental database II and III were combined to form a single cohort of only SIV 
infected macaques divided into early (18 RM), ASY (8 RM), ASD (8 RM), and AIDS (13 RM) 
periods based on definitions for ED II including forty-seven subjects.  The AIDS group included 
fast and slow progressors.   
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Table II.3. Experimental Database II 
 
 
Subject  
ID
a
 Sex 
 Age at 
Sacrifice
, years 
DPI
b
 at 
Sacrifice 
SIV Inoculum, 
Route 
 
 
Period of Infection, Necropsy Diagnosis 
BrdU
c
 
Administration 
CONTROL 
 
 
  
  
AJ79 Fd 7.19   
 
Control, NSFe +f 
BB05 Mg 6.91   
 
Control, NSF -h 
EH70 F 3.01   
 
Control, NSF + 
EH80 F 3.01   
 
Control, NSF + 
EH95 F 3.00   
 
Control, NSF + 
H741 M 15.73   
 
Control, NSF + 
L750 M 12.12   
 
Control, NSF + 
R534 F 10.21   
 
Control, NSF + 
EARLY 
 
 
  
  
AV63 F 4.37 
 
mac251, IVi Early, NSF + 
AV85 F 8.16 21 mac251, IV Early, LHj + 
BA17 M 8.28 12 mac251, IV Early, LH + 
BI58 M 3.19 22 mac251, IV Early, LH - 
BN37 M 2.53 21 mac251, IV Early, LH - 
BV13 M 3.33 8 mac251, IV Early, LH + 
C419 M 20.27 9 mac251, IV Early, NSF + 
CB74 M 3.25 21 mac251, IV Early, LH + 
L880 M 11.33 10 mac251, IV Early, LH + 
T139 M 7.26 13 mac251, IV Early, LH + 
CHRONIC 
 
 
  
  
BV74 M 4.73 63 mac251, IRk ASYl, LH + 
CF35 M 4.51 91 mac251, IR ASY, LH + 
DB53 M 5.12 77 mac251, IR ASY, LH - 
DE09 M 3.59 76 mac251, IR ASY, LH - 
DI28 M 3.53 80 mac251, IR ASY, LH - 
N998 F 10.13 180 mac251, INVGm ASY, LH + 
R908 F 8.91 181 mac251, INVG ASY, LH - 
AP53 F 6.44 63 mac251, IV ASDn, Septicemia, Bacterial pneumonia - 
BD78 M 3.93 205 mac251, IV ASD, Pulmonary infarct, Thrombosis + 
BE64 F 5.30 742 mac251, IV ASD, Right heart failure + 
CD95 F 7.73 924 mac251, IV ASD, Advanced colitis + 
L164 F 12.93 195 B670, INVG ASD Pericardial and abdominal effusion + 
V205 M 8.11 959 mac251, IV ASD, Intestinal amyloidosis  + 
AE55 M 6.93 658 mac251, IV AIDSo, Pneumocystosis and Cryptosporidiosis + 
BA25 M 10.71 544 mac239, IV AIDS, Pneumocystosis  - 
BE65 M 6.31 1071 mac251, IV AIDS, Mycobacterium avium pneumonia + 
BI33 M 7.67 899 mac251, IV AIDS, Pneumocystosis  - 
I553 F 14.00 646 mac251, IV AIDS, Pneumocystosis  - 
P045 M 11.56 809 mac239, IV AIDS, Pneumocystosis + 
R544 F 9.03 414 B670, INVG AIDS, Meningoencephalitis + 
T798 M 8.86 949 mac239, IV AIDS, Mycobacterium avium pneumonia  + 
a) ID = identification; b) DPI = days post-inoculation; c) BrdU = bromodeoxyuridine; d) F = female; e) NSF = no significant 
lesions found;  f) + = positive for BrdU administration; g) M = male; h) - = negative for BrdU administration; i) IV = 
intravenous; j) LH = Lymphoid hyperplasia;  k) IR = intra-rectal; l) ASY = asymptomatic disease; m) INVG = intra-vaginal; n) 
ASD = advanced SIV disease; o) AIDS = acquired immune deficiency syndrome  
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Table II.4. Experimental Database III 
 
 
Subject  
ID
a
 Sex 
 Age at 
Sacrifice
, years 
DPI
b
 at 
Sacrifice 
SIV Inoculum, 
Route 
 
 
Period of Infection, Necropsy Diagnosis 
 
BrdU
c 
Administration 
CONTROL 
 
 
  
  
AG71 Fd 11.07   
 
Control, NSFe +f 
BB01 F 13.03   
 
Control, NSF + 
CC10 F 8.93   
 
Control, NSF + 
GN70 F 10.11   
 
Control, NSF + 
HI54 F 5.39   
 
Control, NSF + 
HI55 F 4.44   
 
Control, NSF + 
HI56 F 4.43   
 
Control, NSF + 
HI57 F 4.59   
 
Control, NSF + 
EARLY 
 
 
  
 + 
AV91 Mg 14.08 10 mac251, IVh Early, LHi + 
BA57 F 14.01 8 mac251, IV Early, LH + 
HI52 F 5.43 7 mac251, IV Early, LH + 
HI53 F 6.60 8 mac251, IV Early, LH + 
HI58 F 6.64 12 mac251, IV Early, LH + 
HI63 F 6.54 12 mac251, IV Early, LH + 
M992 F 16.06 13 mac251, IV Early, LH + 
T108 F 13.12 8 mac251, IV Early, LH + 
CHRONIC 
 
 
  
 + 
HG49 F 11.25 145 mac251, INVGj ASYk, Lymphoid hyperplasia + 
FE53 M 4.11 140 mac251, IRl ASDm, Pulmonary infarct, Vasculopathy + 
FT46 M 3.04 71 mac251, IR ASD, Severe gastroenteritis + 
AL07 F 11.43 195 mac251, INVG AIDSn, Mycobacterium avium  + 
FA14 F 9.50 1068 mac251, IV AIDS, Pneumocystosis pneumonia + 
HG56 F 10.67 152 mac251, INVG AIDS, Gastric lymphoma + 
HG58 F 9.97 283 mac251, INVG AIDS, Encephalitis + 
HI68  F 9.83 155 mac251, INVG AIDS, Cytomegalovirus, Vasculitis + 
a) ID = identification; b) DPI = days post-inoculation; c) BrdU = bromodeoxyuridine;  d) F = female; e) NSF = no significant 
lesions found;  f) + = positive for BrdU administration; g) M = male; h) IV = intravenous; i) LH = Lymphoid hyperplasia;  j) 
INVG = intra-vaginal; k) ASY = asymptomatic disease;  l) ;  IR = intra-rectal;    m) ASD = advanced SIV disease;   n) AIDS = 
acquired immune deficiency syndrome  
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Table II.5. Experimental Database IV 
 
 
Subject  
ID
a
 Sex 
 Age at 
Sacrifice
, years 
DPI
b
 at 
Sacrifice 
SIV Inoculum, 
Route 
 
 
Period of Infection, Necropsy Diagnosis 
Early 
 
 
  
 
AV63 Fc 4.37   mac251, IVd Early, NSFe 
AV85 F 8.16 21 mac251, IV Early, LHf 
AV91 Mg 14.08 10 mac251, IV Early, LH 
BA17 M 8.28 12 mac251, IV Early, LH 
BA57 F 14.01 8 mac251, IV Early, LH 
BI58 M 3.19 22 mac251, IV Early, LH 
BN37 M 2.53 21 mac251, IV Early, LH 
BV13 M 3.33 8 mac251, IV Early, LH 
C419 M 20.27 9 mac251, IV Early, NSF 
CB74 M 3.25 21 mac251, IV Early, LH 
HI52 F 5.43 7 mac251, IV Early, LH 
HI53 F 6.6 8 mac251, IV Early, LH 
HI58 F 6.64 12 mac251, IV Early, LH 
HI63 F 6.54 12 mac251, IV Early, LH 
L880 M 11.33 10 mac251, IV Early, LH 
M992 F 16.06 13 mac251, IV Early, LH 
T108 F 13.12 8 mac251, IV Early, LH 
T139 M 7.26 13 mac251, IV Early, LH 
ASYh           
BV74 M 4.73 63 mac251, IRi ASY, LH 
CF35 M 4.51 91 mac251, IR ASY, LH 
DB53 M 5.12 77 mac251, IR ASY, LH 
DE09 M 3.59 76 mac251, IR ASY, LH 
DI28 M 3.53 80 mac251, IR ASY, LH 
HG49 F 11.25 145 mac251, INVGj ASY, Lymphoid hyperplasia 
N998 F 10.13 180 mac251, INVG ASY, LH 
R908 F 8.91 181 mac251, INVG ASY, LH 
ASDk           
AP53 F 6.44 63 mac251, IV ASD, Septicemia, Bacterial pneumonia 
BD78 M 3.93 205 mac251, IV ASD, Pulmonary infarct, Thrombosis 
BE64 F 5.3 742 mac251, IV ASD, Right heart failure 
CD95 F 7.73 924 mac251, IV ASD, Advanced colitis 
FE53 M 4.11 140 mac251, IRl ASD, Pulmonary infarct, Vasculopathy 
FT46 M 3.04 71 mac251, IR ASD, Severe gastroenteritis 
L164 F 12.93 195 B670, INVG ASD Pericardial and abdominal effusion 
V205 M 8.11 959 mac251, IV ASD, Intestinal amyloidosis  
 
Table II.5 continued on next page 
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AIDSl           
AE55 M 6.93 658 mac251, IV AIDS, Pneumocystosis and Cryptosporidiosis 
AL07 F 11.43 195 mac251, INVG AIDS, Mycobacterium avium  
BA25 M 10.71 544 mac239, IV AIDS, Pneumocystosis  
BE65 M 6.31 1071 mac251, IV AIDS, Mycobacterium avium pneumonia 
BI33 M 7.67 899 mac251, IV AIDS, Pneumocystosis  
FA14 F 9.5 1068 mac251, IV AIDS, Pneumocystosis pneumonia 
HG56 F 10.67 152 mac251, INVG AIDS, Gastric lymphoma 
HG58 F 9.97 283 mac251, INVG AIDS, Encephalitis 
HI68  F 9.83 155 mac251, INVG AIDS, Cytomegalovirus, Vasculitis 
I553 F 14 646 mac251, IV AIDS, Pneumocystosis  
P045 M 11.56 809 mac239, IV AIDS, Pneumocystosis 
R544 F 9.03 414 B670, INVG AIDS, Meningoencephalitis 
T798 M 8.86 949 mac239, IV AIDS, Mycobacterium avium pneumonia  
a) ID = identification; b) DPI = days post-inoculation; c) F = female; d) IV = intravenous; e) NSF = no significant lesions found;  
f) LH = Lymphoid hyperplasia; g) M = male; h) ASY = asymptomatic; i) IR = intra-rectal; j) INVG = intra-vaginal; k) ASD = 
advanced SIV disease;  l) AIDS = acquired immune deficiency syndrome  
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APPENDIX III: FLOW CYTOMETRY ANALYSIS 
 
WHOLE BLOOD COLLECTION 
 
Whole blood was obtained immediately prior to euthanasia into EDTA tubes.  All WB 
samples were maintained at room temperature on a blood rocker till processed.   
BONE MARROW TISSUE COLLECTION 
 
Bone marrow necropsy collection from the femur was obtained within 30 minutes post-
sacrifice.  Bone marrow examination by ante-mortem and post-mortem has been reported to be 
comparable (Switzer 1967).  Marrow tissue was harvested for formalin fixation and fresh tissue 
was suspended in 10mL of an enriched RPMI media solution. The enriched media solution 
consisted of 500mL RPMI 1640 IX without glutamine (Mediatech; Herndon, VA); 25mL 
Standard Fetal Bovine Serum (HyClone; Logan, UT); 5mL BioWhittaker™ Penicillin 
Streptomycin with 10,000 U Pen/mL and 10,000 µg Strep/mL (Cambrex; Walkersville, MD); 
5mL BioWhittaker™ L-glutamine 200mM solution is 0.85% NaCl solution (Cambrex; 
Walkersville, MD); and 5mL HyQ® Hepes 1M solution (HyClone; Logan, UT).   
The BM sample in media was thoroughly mixed by vortex then centrifuged at 400 x g for 
7 minutes (Beckman Coulter Allegra™ 6R Centrifuge; Beckman Coulter, Inc.; Fullerton, CA).  
The supernatant and fat was discarded.  The bone marrow cell pellet was resuspended in 2 mL of 
the enriched media and thoroughly vortexed.  Resuspended bone marrow was filtered through 
nylon mesh and placed into a clean tube.  Prior to flow cytometry staining, 20µL of processed 
bone marrow sample and 180µL of trypan blue were mixed and live cells counted using a 
hemocytometer.  Final dilution of 1x10
7
/mL live cells was performed with the enriched RPMI 
media solution.  Processed bone marrow tissue was maintained on ice until flow cytometry 
staining.  
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FLOW CYTOMETRY STAINING OF WHOLE BLOOD AND  
BONE MARROW TISSUE 
 
 Human or non-human primate antibodies from commercial distributors or NIH were 
optimized for flow cytometric analysis in the Rhesus macaque for whole blood and bone marrow 
tissue.   Antibody panels were prepared for detection of specific cell populations as detailed in 
each chapter.  Single antibodies or an antibody cocktail composed of multiple single 
fluorochrome antibodies were applied to each tube based upon the pre-determined panel.   
Appropriate volume and dilution of antibodies were added for each tube.  Each subject had 
multiple tubes included in a batch to determine phenotypic characteristics of specific cell 
populations. Appropriate compensation tubes were included within each batch of subject 
samples.  Surface staining was performed for each sample.  Intracellular staining for detection of 
proliferation and apoptosis was performed after surface staining.  
Antibodies were directly conjugated to the following fluorochromes: Allophycocyanin 
(APC), Allophycocyanin Cyanine 7 (APC-Cy7),  Anemonia mojona Cyanine (AmCyan), 
Fluorescein isothiocyanate (FITC), Pacific Blue (PacBlue or PacBl), Peridinin Chlorophyll 
Protein (PerCP), Peridinin Chlorophyll Protein Cyanine 5.5 (PerCP-Cy5.5), Phycoerythrin (PE), 
Phycoerythrin Texas Red (PE-Tx RED or PE-TxR), Phycoerythrin Cyanine 5 (PE-Cy5), 
Phycoerythrin Cyanine 7 (PE-Cy7), and Quantom dots 655 (QDOT 655). 
Flow Cytometry Compensation Tubes 
 
 Compensation sample tubes utilized whole blood samples from a RM subject.  One 
compensation tube was unstained blood cells.  Other compensation tubes comprised an 
individual antibody for each fluorochrome used in the pre-determined panels.  Each 
fluorochrome was represented in the compensation panel.  Compensation antibody tubes were 
dictated by the fluorochromes analyzed and defined lymphocyte populations.   
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Flow Cytometry Surface Staining 
 
Surface staining was performed with appropriately diluted antibodies and compensation 
tubes as previously described (Veazey 2000b).  Briefly, monoclonal antibody for surface staining 
was incubated with 10
6
 cells of WB or BM samples in100µL aliquots for 30 minutes in the dark 
at 4°C.  Red blood cell lysis was performed with a 1X BD FACS Lysing Solution 1X as directed 
by the manufacturer and incubated for 10 minutes at room temperature in the dark (BD 
Biosciences; San Jose, CA).  A short wash in 3mL of phosphate buffered saline (PBS) at 400 x g 
for 7 minutes followed.  The supernatant was discarded leaving a cell pellet.  Samples to be 
analyzed for surface staining only were fixed as detailed below.  Samples to be analyzed for 
intracellular markers were fixed and processed as described later. 
The cell pellet was fixed.  For four color flow cytometry, fixation was in 300 µL per 
sample of 2% paraformaldehyde.   For multi-color flow cytometry, fixation was in 300 µL per 
sample of BD Stabilizing Fixative as directed by the manufacturer (BD Biosciences).  All fixed 
samples were maintained at 4°C until analysis.   
Flow Cytometry Intracellular Staining 
 
After surface staining, flow cytometry samples processed for intracellular staining to 
detect proliferation by Ki67 and bromodeoxyuridine (BrdU) or apoptosis by activated caspase 3 
(AC3).  Samples were maintained at 4°C in the dark after intracellular staining till analysis. 
Intracellular staining for detection of proliferation during G1, S, G2 and mitosis phases of 
the cell cycle by Ki67 was performed after surface staining as previously described (Kaur 2000).  
Cells were fixed with 600µL of 4% paraformaldehyde for 30 minutes in the dark at room 
temperature.  Cells were permeabilized by a wash in 2mL of a 0.1% saponin-PBS solution.  The 
sample was decanted and the pellet was incubated with 20µL of Ki67 antibody for 30 minutes at 
room temperature in the dark.  A final wash in 0.1% saponin-PBS solution with supernatant 
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discard was performed and cells were fixed with 300µL of 2% paraformaldehyde and stored 
overnight. 
Intracellular staining for detection of proliferation during the S phase or DNA synthesis 
of the cell cycle by BrdU staining was performed as previously described (Wang 2008a).  RM 
had been inoculated intra-peritoneal with BrdU 24 hours prior to sacrifice.   BrdU was 
administered at 60mg/kg of body weight diluted in sterile PBS to a final dilution of 20mg 
BrdU/mL of PBS.  After surface staining, cells in the sample were fixed and permeabilized with 
100µL of BD Cytofix/Cytoperm Fixation and Permeabilization buffer (BD Biosciences)  for 15 
minutes on ice in the dark.  A wash with 3mL of 1X BD Perm Wash buffer (BD Biosciences), at 
400 x g for 7 minutes followed by discard of the supernatant formed a cell pellet.  The pellet was 
incubated with 100µL of deoxyribonuclease (DNAse) (Sigma-Aldrich; St. Louis, MO) for 60 
minutes at 37°C in a humidified incubator with 5% CO2.  Another wash followed by incubation 
with 20µL of anti-BrdU antibody for 30 minutes at room temperature in the dark.  A final wash 
with supernatant discard was performed and cells were fixed with 300µL of 2% 
paraformaldehyde and ready for analysis. 
Intracellular staining for detection of apoptosis by activated caspase 3 was performed 
after surface staining.  Cells in the sample were permeabilized with 250µL of BD 
Cytofix/Cytoperm (BD Biosciences) fixation and permeabilization buffer for 20 minutes at 4°C 
in the dark. A wash with 1X BD Perm Wash buffer (BD Biosciences), diluted per manufacturer 
instructions from 10X, at 400 x g for 7 minutes followed by discard of the supernatant.  The 
pellet was incubated with 15µL of activated caspase 3 antibody and 50µL of 1X BD Perm Wash 
buffer (BD Biosciences), per tube, for 60 minutes at room temperature in the dark.  A final wash 
with supernatant discard was performed and cells were fixed with 300µL of 1% 
paraformaldehyde. 
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FLOW CYTOMETRY ACQUISTION  
 
Flow cytometry evaluation of samples, surface and intracellular staining, was performed 
within 24 hours of cell preparation as a batch including compensation tubes. Flow cytometry 
analysis by a flow cytometer was performed in the TNPRC Flow Cytometry Core Laboratory.   
Four color flow cytometry analysis was performed on the BD FACSCalibur Flow 
Cytometer (BD Biosciences) with Macintosh Operating System 10.4.1 (Apple Software; 
Cupertino, CA).  Data acquisition was obtained by Cell Quest Pro 5.2.1 (BD Biosciences).  A 
minimum of 20,000 events was recorded for each sample.   
Multi-color flow cytometry analysis was performed when samples contained five or more 
fluorochromes. Multi-color flow cytometry analysis was performed on the BD LSRII (BD 
Biosciences) with BD FACSDiva operating system and acquisition software (BD Biosciences).  
A minimum of 10,000 events was recorded for each sample.   
FLOW CYTOMETRY DATA ANALYSIS  
 
Flow cytometry data acquired from the TNPRC flow cytometry core laboratory was 
analyzed by using FlowJo for Windows (Tree Star, Inc.; Ashland, OR).  Basic gating is depicted 
in Figure III.1.  Gating strategies to identify specific populations of interest are defined by 
chapter.  Immunophenotype of cells was reported in percentages. 
Flow Cytometry Compensation Tubes 
 
 Fluorescence identified as negative or positive signal for each fluorochrome served as 
controls for gating of panels in a compensation tube panel as described by Walker et al (Walker 
2004b).  Selection for absence or presence of fluoruescence for a selected fluorochrome tagged 
to a single specific antibody established negative and positive signals respectively (Figure 2.1).  
Compensation tubes allowed setting of flow cytometry analyzers to properly detect antibodies 
within ranges of fluorescence and minimized spectral overlap.   
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WHOLE BLOOD ABSOLUTE CD4+ LYMPHOCYTE COUNT 
 
The whole blood absolute CD4+ lymphocyte count for each Rhesus macaques infected 
with SIV was determined for experimental database II (Table III.1) and experimental database III 
(Table III.1).   The whole blood lymphocyte phenotypic population was identified by the parent 
gate of forward scatter versus side scatter plot (Figure III.1).  The gate of interest was identified 
from the parent gate as CD4 versus side scatter plot to reveal CD4+ lymphocytes as percentages 
of total lymphocytes.  The immunophenotype percentage of CD4+ lymphocytes was multiplied 
by the absolute lymphocyte and the final number was the whole blood absolute CD4+ 
lymphocyte count of cells/µL.   
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Table III.1. Whole Blood Absolute CD4 Lymphocyte Count for Experimental Database II 
 
ED IIa 
Subject  
IDb 
Absolute CD4 Lymphocyte Count  
cells/µL 
AV63 463 
AV85 670 
BA17 416 
BI58 558 
BN37 542 
BV13 752 
C419 383 
CB74 992 
L880 212 
T139 355 
BV74 775 
CF35 546 
DB53 277 
DE09 1192 
DI28 810 
N998 584 
R908 653 
AP53 1127 
BD78 729 
BE64 258 
CD95 543 
L164 317 
V205 195 
AE55 150 
BA25 169 
BE65 288 
BI33 150 
I553 21 
P045 2 
R544 190 
T798 43 
a) ED II = experimental database II 
b) ID = identification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ED IIIa 
Subject  
IDb 
 
Absolute CD4 Lymphocyte Count  
cells/µL 
AV91 472 
BA57 246 
HI52 664 
HI53 325 
HI58 651 
HI63 438 
M992 227 
T108 653 
AL07 56 
FA14 244 
FE53 469 
FT46 279 
HG49 184 
HG56 339 
HG58 341 
HI68  22 
a) ED III = experimental database III 
b) ID = identification
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APPENDIX IV: PLASMA VIRAL LOAD 
 
VIRAL LOAD 
 
Plasma samples were processed from EDTA whole blood collected at necropsy and 
frozen at -80°C.  Thawed plasma samples were analyzed for quantitative analysis of SIV.  
Plasma viral load was determined by bDNA assay (Siemens Clinical Laboratory; Berkeley, CA) 
as previously described (Smith S. M. 1999) from frozen plasma samples.  Nucleic acid 
hybridization technique for the quantitation of SIVmac or SIVsm in RM plasma by detection of 
genomic RNA SIV was performed.  The hybridization probe detects the pol gene in an SIV RNA 
4.0 branched DNA (bDNA) assay.   Viral load was reported as RNA copies/mL of plasma.   
Experimental Database Plasma Viral Load 
 
For ED II, thirty-nine Indian RM were included in this study but only Rhesus macaques 
inoculated with SIV had viral loads determined (Table IV.1).   
For ED III, twenty-four Asian RM were included in this study but only Rhesus macaques 
inoculated with SIV had viral loads determined (Table IV.1).   
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Table IV.1. Experimental Database Plasma Viral Load 
 
ED II
a
 
Subject  
ID
b
 
Plasma Viral Load 
x 10
4 
copies/mL 
AJ79  
BB05  
EH70  
EH80  
EH95  
H741  
L750  
R534  
AV63 190.00 
AV85 23.00 
BA17 1100.00 
BI58 1200.00 
BN37 34.00 
BV13 1600.00 
C419 1100.00 
CB74 210.00 
L880 700.00 
T139 320.00 
BV74 0.08 
CF35 12.17 
DB53 2.86 
DE09 0.97 
DI28 82.02 
N998 42.76 
R908 0.47 
AP53 410.00 
BD78 8.60 
BE64 79.00 
CD95 15.65 
L164 770.00 
V205 18.24 
AE55 75.00 
BA25 67.26 
BE65 8.55 
BI33 36.13 
I553 189.54 
P045 714.89 
R544 170.00 
T798 0.37 
b) a) ED II = experimental database II 
c) b) ID = identification 
d)  
e)  
 
 
 
 
ED III
a
 
Subject  
ID
b
 
 
Plasma Viral Load 
x 10
4 
copies/mL 
AG71  
BB01  
CC10  
GN70  
HI54  
HI55  
HI56  
HI57  
AV91 15719.00 
BA57 1428.82 
HI52 370.06 
HI53 355.57 
HI58 849.60 
HI63 2431.09 
M992 3494.98 
T108 5.73 
AL07 37.46 
FA14 14.90 
FE53 34.35 
FT46 17079.80 
HG49 10.49 
HG56 1952.27 
HG58 0.71 
HI68  807.62 
ED III = experimental database III 
ID = identification
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APPENDIX V: COPYRIGHT PERMISSION 
 
Permission was granted from the publisher (Figure V.1) and author (Figure V.2) to use 
the schematic found in Chapter 2 (Gupta 2007). 
 
 
 
 
Figure V.1. Copyright permission from publisher 
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